

66th ASH® Annual Meeting and Exposition

December 7-10, 2024 • San Diego, CA

















PROGRAM-AT-A-GLANCE



CHECK OUT DATA FOR OUR NEWLY APPROVED INDICATION

Explore the evidence at the

2024 ASH Annual Meeting:
December 7-10,
Booth 2129,
or visit
PERSEUSQUAD.com



PROGRAM OF THE 66TH ANNUAL MEETING OF

AMERICAN SOCIETY OF HEMATOLOGY



-

December 7 - 10, 2024

lanalumab (VAY736)








VAYHIT1 (Phase 3 Randomized Study of Ianalumab and CS in Adults With ITP [NCT05653349])1-3

Key Inclusion Criteria^a

- Aged ≥18 years with
- Primary ITP diagnosed within 3 months before 1L CS ± IVIG treatment
- Platelet count <30 g/L before
 1L CS ± IVIG treatment
- Response (platelet count ≥50 g/L) to CS ± IVIG at any time prior to randomization




- Primary endpoint: Time from randomization to TF
- Select secondary endpoints: Response and CR rate at each time point, time from randomization to first CR, duration of CR, frequency of adverse events, and other safety parameters

VAYHIT2 (Phase 3 Randomized Study of Ianalumab and Eltrombopag in Adults With ITP [NCT05653219])1.4.5

Key Inclusion Criteria^a

- Aged ≥18 years with
- Primary ITP with insufficient response to, or relapse after 1L CS ± IVIG treatment
- Platelet count <30 g/L and assessed need for treatment per physician's discretion




- Primary endpoint: Time from randomization to TF
- Select secondary endpoints: Response and CR rate at each time point, time from randomization to first CR, duration of CR, frequency of adverse events, and other safety parameters

VAYHIA (Phase 3 Randomized Study of Adults With wAIHA [NCT05648968])1.6.7

Key Inclusion Criteria^a

- Aged ≥18 years with
- Primary or secondary wAIHA who had an insufficient response to, or relapsed after
 ≥1 line of treatment, including patients with CS resistance, dependence, or intolerance
- Hb concentration at screening ≥5 g/dL and <10 g/dL, associated with symptoms related to anemia
- Stable dose of supportive care for ≥4 weeks prior to randomization



- Primary endpoint: Binary variable indicating whether a participant achieves a DR for at least 8 consecutive weeks, between Week 9 and Week 25, in the absence of rescue or prohibited treatment
- Select secondary endpoints: Duration of response; time from randomization to DR, first response, and first CR; frequency of adverse events and other safety parameters

Abbreviations: 1L, first line; CR, complete response; CS, corticosteroids; DR, durable response; EOT, end of treatment; Hb, hemoglobin; ITP, immune thrombocytopenia; IV, intravenous; IVIG, intravenous immunoglobulin; PBO, placebo; Q4W, every 4 weeks; R, randomization; TF, treatment failure; wAIHA, warm autoimmune hemolytic anemia.

^a For complete eligibility criteria, please see ClinicalTrials.gov. ^b If platelet count ≥50 g/L at the end of combination treatment period for ≥2 consecutive assessments, will start tapering eltrombopag for a maximum of 8 weeks until discontinuation if platelet counts remain ≥30 g/L.

References: 1. Al-Samkari H, et al. Blood. 2023;142(suppl 1):5456. 2. ClinicalTrials.gov. NCT05653349. Accessed June 14, 2024. https://clinicaltrials.gov/ct2/show/NCT05653349 3. Data on file. VAYHIT1 protocol amendment 4. Novartis; December 14, 2023. 4. ClinicalTrials.gov. NCT05653219. Accessed June 14, 2024. https://clinicaltrials.gov/ct2/show/NCT05653219 5. Data on file. VAYHIT2 protocol amendment 4. Novartis; November 3, 2023. 6. ClinicalTrials.gov. NCT05648968. Accessed June 14, 2024. https://clinicaltrials.gov/ct2/show/NCT05648968 7. Data on file. VAYHIA protocol amendment 4. Novartis; January 17, 2024.

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

Please visit us at booth #2529



Table of Contents

SCHOOL OF LIFTH WAY OF CO.	About ASH	
	ASH Executive and Program Committees	5
	Reviewers of Abstracts and Hematology 2024	8
	Corporate Acknowledgements	11
	Recipients of Awards	14

Guide to Navigating the Meeting	
General Information	21
Diversity, Equity, and Inclusion at ASH	33
Non-CME Sessions	36

Meeting Schedule	
Schedule-At-A-Glance	37

Browse by Session Type	
Marquee Sessions	59
Scientific Sessions	63
Education Sessions	75
Special Interest Sessions and Studios	87
Trainee Activities	99
Scientific Catagories	107
Oral and Poster Abstract Sessions	109

continued on next page

Table of Contents

Table of Contents

Interact with Industry	
Satellite Symposia	123
Product Theaters	135
Industry Theaters	139
Industry Forums	141
Company Showcases	142
Clinical Trials Showcase	143
Exhibitor Directory	145
Browse by Disease	
Browse By Disease Introduction	153
Bleeding and Clotting	155
Bone Marrow Failure Syndrome	159
Genetic Disorders	161
Hemoglobinopathies	163
Immune Disorders	165
Lymphoid Malignancies	167
Metabolic Disorders	175

Table of Contents

AMERICAN SOCIETY OF HEMATOLOGY EXECUTIVE COMMITTEE

STAFF LIAISONS:

Martha Liggett, Esq., mliggett@hematology.org
Matthew Gertzog, MBA, CAE, mgertzog@hematology.org
LaFaundra Neville Ingram, CAP, Ineville@hematology.org

OFFICERS:

President: Mohandas Narla, DSc President-Elect: Belinda Avalos, MD Vice President: Robert Negrin, MD Secretary: Cynthia E. Dunbar, MD Treasurer: Joseph R. Mikhael, MD

COUNCILLORS:

Christopher R. Flowers, MD, MSc ('26)
H. Leighton Grimes, PhD ('27)
Mary M. Horowitz, MD ('27)
Charlotte Marie Niemeyer, MD ('26)
Sarah H. O'Brien, MD ('25)
Betty Pace, MD ('24)
Jamile M. Shammo, MD ('24)
Wendy Stock, MD ('25)

Leaders 5

PROGRAM COMMITTEE

STAFF LIAISON:

Ana Velarde E-mail: avelarde@hematology.org

Mohandas Narla, DSc ('24) - Chairperson, President

Belinda Avalos, MD ('24) - Ex-Officio: President-Elect Joseph R. Mikhael, MD ('26) - Ex-Officio: Treasurer Cynthia E. Dunbar, MD ('24) - Ex-Officio: Secretary Robert Negrin, MD ('25) - Ex-Officio: Vice President Nancy Berliner, MD ('24) - Liaison, Editor-in-Chief, *Blood*

Catherine M. Bollard, MD ('26) - Liaison, Editor-in-Chief, *Blood Advances*Jennifer R. Brown, MD, PhD ('24) - Liaison, Chair, Committee on Educational Affairs
Hetty Carraway, MD, MBA ('26) - Liaison, Chair, Committee on Training
Jorge Cortes, MD ('24) - Liaison, Editor Designee, *Blood Global Hematology*Adam Cuker, MD ('25) - Liaison, Chair, Committee on Quality

Willem E. Fibbe, MD ('24) - Liaison, Editor Designee, *Blood Immunology & Cellular Therapy*Patrick G. Gallagher, MD ('24) - Liaison, Editor Designee, *Blood Red Cells & Iron*Aaron T. Gerds, MD, MS ('25) - Liaison, Editor-in-Chief, *ASH Clinical News*Phoebe Joy Ho, MBBS ('25) - Liaison, Chair, International Members Committee
Judith Kleinerman, MD ('25) - Liaison, Chair, CME Accreditation Committee
Jonathan D. Licht, MD ('28) - Liaison, Editor-in-Chief, *Blood Neoplasia*

Keith R. McCrae, MD ('28) - Liaison, Editor-in-Chief, *Blood Vessels, Thrombosis & Hemostasis*Mary-Elizabeth M. Percival, MD ('25) - Liaison, Chair, Committee on Practice
Andrew W. Roberts, MBBS, PhD ('24) - Liaison, Deputy Editor, *Blood*Mikkael A. Sekeres, MD ('24) - Liaison, Chair, Committee on Communications

Alison R. Walker, MD, MBA, MPH ('24) - Liaison, Chair, Committee on Diversity, Equity and Inclusion
Andrew S. Weyrich, PhD ('26) - Liaison, Deputy Editor, *Blood Advances*Alisa Wolberg, PhD ('26) - Liaison, Chair, Committee on Scientific Affairs

6 Leaders

ANNUAL MEETING ACCREDITED EDUCATION COMMITTEE

STAFF LIAISON:

Ana Velarde
E-mail: avelarde@hematology.org

John Koreth MD, MBBS, PhD, DPhil ('24) - 2024 Education Program Co-Chair Rakhi P. Naik, MD ('24) - 2024 Education Program Co-Chair Sant-Rayn Pasricha, MD, PhD ('24) - 2024 Scientific Program Co-Chair Jennifer J. Trowbridge, PhD ('24) - 2024 Scientific Program Co-Chair

Payal C. Desai, MD ('25) - 2025 Education Program Co-Chair Esther A. Obeng, MD, PhD ('25) - 2025 Scientific Program Co-Chair Betty Pace, MD ('25) - 2025 Scientific Program Co-Chair Rayne H. Rouce, MD ('25) - 2025 Education Program Co-Chair Hanny Al-Samkari, MD ('24) - Executive Editor, Hematology Rajesh Behl, MD ('24) - Appointed Member Patricia A. R. Brunker, MD ('24) - Appointed Member Shannon A. Carty, MD ('24) - Appointed Member Maria Monica Gramatges, MD, PhD ('24) - Appointed Member Alex Francisco Herrera, MD ('24) - Appointed Member Shernan G. Holtan ('24) - Appointed Member Judith Kleinerman, MD ('25) - Appointed Member, Chair, CME Accreditation Committee Shaji Kunnathu Kumar, MD ('24) - Appointed Member Kevin Kuo, MD, MSc, FRCPC ('24) - Appointed Member Michele Lambert, MD ('24) - Appointed Member Ang Li, MD, MS ('24) - Appointed Member Zhuoyan Li, MD ('24) - Appointed Member Frederick Locke, MD ('24) - Appointed Member Luca Malcovati, MD ('24) - Appointed Member Ann Mullally, MD ('24) - Appointed Member Deborah M. Siegal, MD, MSc ('24) - Appointed Member Michelle P. Zeller, MD ('24) - Appointed Member

Leaders

2024 REVIEWERS

The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of *Hematology* 2024, the ASH Education Program.

ASH ABSTRACTS COORDINATING REVIEWERS

Alvaro Alencar Jane Apperley Caroline Arber Alberto Arribas Pere Barba Meral Beksac Pavan Bendapudi N. Nora Bennani Neha Bhasin Robert Bowman Marc Braunstein Jennifer Brudno Andrew Brunner Barbara Buldini Shruti Chaturvedi Lynette Chee Matthew Cheung Nora Chokr Joselle Cook Luciano Costa Francesca Cottini Erich De Paula

Richard Dillon

Karen Effinger

Carlo Dufour

Firas El Chaer Patrick Ellsworth Henrik Frederiksen Sylvain Garciaz Eva Gine Andres Gomez-De Leon

Nicole Grieselhuber Carmelo Gurnari

Fernanda Gutierrez-Rodrigues

Betty Hamilton Eliza Hawkes Gabriela Hobbs Matthew Hsieh Raphael Itzykson Shai Izraeli

Patrick Connor Johnson Malgorzata Kasztan Colm Keane Nandita Khera Jean-Jacques Kiladjian

Kevin Kuo Catherine Lai

Ming Y Lim Cheryl Lobo Meng Lv Kami Maddocks Kris Mahadeo Johnny Mahlangu Ajay Major Ariela Marshall Laura Michaelis Kenichi Miharada Lekha Mikkilineni

Mohamad Mohty Kerry Morrone Niroshan Nadarajah Bertrand Nadel Laura Newell

Diu Nguyen Alexander Oeser Jad Othman Neil Palmisiano Anna Parks Erin Parry Robert Paulson Jerlym Porter Barbara Pro

Hang Quach Antonio Risitano Harvey Roweth Russell Ryan Kristen Sanfilippo Juerg Schwaller Noha Sharafeldin Geoffrey Shouse Tanya Siddiqi Laura Silvestri Melody Smith Kimberly Stegmaier Christopher Su Owen Tamplin Yvette Tanhehco Antiopi Varelias Aman Wadhwa

Johannes Waldschmidt Roland Walter Lachelle Weeks Adrian Wiestner Lindsay Wilde Chuanfeng Wu Andrew Yee Jonathan Yen

Charles De Bock

Neil Zakai

ASH ABSTRACTS REVIEWERS

Hussein Abbas
Maya Abdallah
Hisham Abdel Azim
Mouhamed Yazan Abou-Ismail
Ingerid Abrahamsen
Suchitra Acharya
Diego Adrianzen Herrera
Anjali Advani
Shreya Agarwal
Inhye Ahn
Sanjay Ahuja
Imo Akpan
MHD Monzr Al Malki
Haifa Al-Ali
David Allan

Alberto Alvarez-Larran Maria Amaya Emmanuela Ambrose Mathew Angelos Shaniqua Anum Andrew Artz Sarit Assouline Holger Auner Sharl Azar Constance Baer

Carl Allen

Rahul Banerjee Darko Barisic Michal Bar-Natan Betsy Barnes Benjamin Barwick Rafet Basar Glaivy Batsuli

Steven Bair

Linda Baughn Lisa Baumann Kreuziger Silvia Bea

Jennifer Belsky Lina Benajiba M. Bender Rusha Bhandari Shruti Bhatt Giulia Biancon Poorva Bindal James Blachly Bradley Blaser Piers Blombery David Bond Martin Bornhäuser Brian Branchford Danielle Brander Joshua Brandstadter Susan Branford

Megane Brusson Francesco Buccisano Sani Bukari Naresh Bumma Birgit Burkhardt Kelly Bush Ja Min Byun Gregory Calip

Carlos Bravo-Perez

Tim H. Brummendorf

Valentine Brousse

Maria Domenica Cappellini Beatrice Casadei Sharon Castellino Michele Cea Wing Chan Andres Chang Dai Chihara David Chiron Hannah Choe Satheesh Chonat Elise Chong Stephen Chung Alfred Chung Sabino Ciavarella Shashank Cingam Jean-Sébastien Claveau Jacqueline Cloos Thomas Cluzeau Jacob Cogan Alexander Coltoff Perla Colunga-Pedraza Annarita Conconi Nathan Connell Laura Connelly-Smith

Paul Coppo Francis Coyne John Crispino Jennifer Crombie Nicholas Cross Susanna Curtis Monica Cusan Melissa Cushing

Catherine Coombs

May Daher, MD Naval Daver Jennifer Davila Pavel Davizon-Castillo Ghadeer Dawwas Stephane De Botton Masia De Haas Zachariah Defilipp Roberta Demichelis Selami Demirci Marta Derecka Srinivas Devarakonda Tejaswini Dhawale Akiva Diamond Laura Dillon Shira Dinner Pilar Dominguez Bhavya Doshi Genevieve Douglas Matthieu Duchmann Andrew Dunbar Kieron Dunleavy Urshila Durani Cihangir Duy

Cinangir Duy
Dimitar Efremov
Karin Ekstroem Smedby
James England
Anoop Enjeti
Narendranath Epperla
Raquel Espin Palazon
Laura Evgin
Mark Ewalt

Mark Ewalt
Titilope Fasipe
Pierre Fenaux
Timothy Ferng
Francesca Ferraro
Alejandro Ferrer
Adele Fielding

8 Reviewers

2024 REVIEWERS

Warren Fingrut Ross Firestone Jamie Flerlage James Ford Stephanie Forte Thomas Fox Haydar Frangoul Jason Freed Sebastian Galeano Nicolas Gallastegui Crestani Paolo Gallipoli

Maher Gandhi Arpita Gandhi Saravanan Ganesan Guillermo Garcia-Manero Laurent Garderet

Oluwabukola Gbotosho Gloria Gerber Aaron Gerds Gabriel Ghiaur Andrew Gillis-Smith Yelena Ginzburg

Merlin Nithya Gnanapragasam

Lucy Godley Ivana Gojo Mendel Goldfinger David Gomez-Almaguer George Goshua Gaurav Goyal Hildegard Greinix Amanda Grimes Steven Grover Natalie Grover Zhaohui Gu Ashish Gupta

Guru Subramanian Guru Murthy

Konstantine Halkidis Mehdi Hamadani Muhammad Saad Hamid

Walter Hanel Patrick Hanley Claire Harrison Monique Hartley-Brown Daigo Hashimoto

Sascha Haubner Erika Haydu Fan He

Caroline Heckman Merja Heinäniemi Vignir Helgason Johannes Hellmuth Peiman Hematti

Tobias Herold Daniel Herranz Nobuko Hijiya Brian Hill Kirsty Hillier Laura Hilton Alexandre Hirayama

Ian Hitchcock

Phoebe Joy Ho Andreas Hochhaus Hanno Hock Gregor Hoermann Mitchell Horwitz Chi-Joan How Myo Htut Bei Hu Li-Wen Huang Malin Hultcrantz Ibrahim Ibrahim Kazusa Ishii Seethal Jacob

Preetesh Jain

Andrew Jallouk Ashley Jenkins

Xu Ji Debbie Jiang Nisha Joseph

Radoslaw Kaczmarek Tapan Kadia Elizabeth Kang Prashant Kapoor Margaret Kasner Dickran Kazandjian Sioban Keel Saad Kenderian

Michael Keng Vanessa Kennedy Bryce Kerlin Rachel Kesse-Adu Niloufer Khan Irum Khan Rami Khoriaty Taylor Kim Allison King Adam Kittai Marina Konopleva

Divya Koura Taxiarchis Kourelis Kamil Kranc Colin Kretz Matthew Kudek Shekhar Kumar Anita Kumar Andrea Kündgen James LaBelle Madhavi Lakkaraja

Kentson Lam Barbara Lam Arielle Langer Alessandra Larocca Thomas Larsen Jeffrey Lebensburger Richard Leblanc Sung-Eun Lee Holly Lee Suzanne Lentzsch

Hannah Levavi John Levine Mark Levis Graham Lieschke Jane Little Hongtao Liu

Alexander Lesokhin

Armando Lopez-Guillermo

Selina Luger Thomas Lund Kathryn Lurain Marlise Luskin Jaroslaw Maciejewski Nicola Maciocia Harinad Maganti Subramaniam Malarkannan

Sami Malek Maria Elisa Mancuso Giovanni Marconi Karlyn Martin Lucia Masarova John Mascarenhas Camila Masias Sara Mastaglio Matthew Matasar Marshall Mazepa Christine McMahon Shannon Meeks Manja Meggendorfer

Christopher Melani

Avital Mendelson Francois Mercier Sara Meyer Syed Mian Annarita Miccio Wolfgang Miesbach Linde Miles

Jordan Milner Alice Mims Meera Mohan Riccardo Moia Daniel Molin Molly Mollica

Guillermo Montalban-Bravo

Lee Mozessohn Pashna Munshi Khaled Musallam Markus Müschen Moaath Mustafa Ali Mikko Myllymäki Omar Nadeem Rupa Narayan Mariam Nawas Steffan Nawrocki Natalia Neparidze Richard Newcomb

Samuel Ng Dang Nguyen Charlotte Niemeyer

Cesar Nombela-Arrieta Panagiotis Ntziachristos Chijioke Nze **Christopher Oakes** Elizabeth O'Donnell Hideyuki Oguro Jessica Okosun Ana Oliver Sin Tiong Ong

Udo Oppermann Folashade Otegbeye Muhit Ozcan Simona Pagliuca Giovanni Palladini Helen Papadaki Christopher Park Oren Pasvolsky Bhavisha Patel **Anand Patel** Shyam Patel Rafal Pawlinski Jason Payne Laurie Pearson

Xuying Pei Marie-Claude Pelland-Marcotte

Usha Perepu Alexander Perl Michael Pfeffer Sheetal Phadnis Eric Pietras Allyson Pishko Uwe Platzbecker Mortimer Poncz Kimmo Porkka Jacqueline Poston . Alexandra Power-Hays Ashvind Prabahran Claude Preudhomme Alexandre Puissant Vinod Pullarkat Dianne Pulte John Quigley Brittany Ragon Dristhi Ragoonanan

Parul Rai

Sandeep Raj Madhvi Rajpurkar Ron Ram Emilio Ramos Leo Rasche Farhad Ravandi John Reagan Michaela Reagan Daniel Reed Lindsay Rein

Ruben Rhoades

Guillaume Richard-Carpentier

Marta Riva Mary Riwes Nathan Roberts Rachel Rodenbach Sæmundur Rögnvaldsson Ashley Rosko

Tracey Rouault Kevin Rouault-Pierre **Daniel Royston** David Russler-Germain

Roberta Russo Christine Ryan Sushree Sahoo

Shella Saint Fleur-Lominy

David Sallman

Gabriela Sanchez-Petitto

Jennifer Saultz Yazeed Sawalha Caner Saygin Phillip Scheinberg Heinrich Schlums Alec Schmaier Kelly Schoenbeck Anna Schuh Michael Scordo Fernanda Seguro Tarsheen Sethi Katie Seu Brian Shaffer Gunjan Shah Surbhi Shah Nishi Shah Rory Shallis Akshay Sharma Aditi Shastri

Sruti Shiva Warren Shlomchik William Shomali Nicholas Short Tanaya Shree Surbhi Sidana Ariosto Siqueira Silva

Shai Shimony

Sarah Skuli Tobias S. Slørdahl Meray Socolovsky Eric Solary Jacob Soumerai

Andrew Srisuwananukorn

Maximilian Stahl Michele Stanchina Joseph Stanek Eytan Stein Kristy Stengel Deborah Stephens Brigitte Strahm Prithu Sundd Dipti Talaulikar Carlyn Tan Sarah Tasian Elisa Ten Hacken

Seitaro Terakura

Reviewers

2024 REVIEWERS

Deirdra Terrell
Sarah Tettamanti
Gita Thanarajasingam
Swee Lay Thein
Ing Tiong
Erika Tissino
Joshua Tobin
Daisuke Tomizawa
Pallawi Torka
Tomomi Toubai
Benjamin Tourdot
Claudio Tripodo
Judith Trotman
Alvaro Urbano-Ispizua

Saad Usmani

Mounica Vallurupalli

Layla Van Doren Karin Vanderkerken Santosha Vardhana Rahul Vedula Elvira Velloso Abi Vijenthira Aaron Viny Valeria Visconte Evangelia Vlachodimtropoulou Koumoutsea

Evangelia Vlachodir Koumoutsea Phuong Vo Peter Voorhees Sebastian Vosberg Elvin Wagenblast Matthew Walter Wencke Walter Tzu-Fei Wang Eunice Wang Lili Wang Julia Warren Oliver Weigert Jason Westin Allison Wheeler Hilary Whitworth William Wierda Shaina Willen Basem William Samuel Wilson Nina Worel Jennifer Woyach

Zhijie Wu

Min Xia

Yang Xu Lucrecia Yanez San Segundo Moua Yang Albert Yeh Joanna Yi Jennifer Yu Adam Zayac Xiaotian Zhang Xiangyu Zhao Daniel Zheng Jan Zuna

ASH ABSTRACTS TRAINEE REVIEWERS

Nowah Afangbedji Luis E. Aguirre Adekunle Alagbe Waleed Alduaij Anand Bhagwat Siobhan Branfield Henna Butt Virginia Camacho Oladipo Cole Kaitlyn Dykes Annamaria Gulla Cynthia Hahn Xu Han Zalaya Ivy Johann-Christoph Jann Nikeshan Jeyakumar Edward Kwarteng

Emmanuel J. Favaloro

Audrey Lasry

Jerry Lee
Pengfei Liang
Emily Liang
Cecile Lopez
Xinjian Mao
Kylee Martens
Ronak Mistry
William Nicol
Madeline Niederkorn

Miriam Osei Helen Reed Lakshmi Sandhow Johannes Schmoellerl Jessica Stempel Zanshe Thompson Natthakan Thongon Bryan Valcarcel

HEMATOLOGY 2024 REVIEWERS

Nowah Afangbedji Mouhamed Yazan Abou-Ismail Denise M. Adams Adekunle Adekile Hanny Al-Samkari Ashley Allen Ash B. Alpert Richard F. Ambinder Lauren E. Amos Michael Andreeff Donald M. Arnold Eugenia Vicky Asare Shannon Bates Michael R. Bishop Alexandra J. Borst Jonathan F. Brammer Natalie S. Callander Jonathan C.T. Carlson Marc Carrier C. Patrick Carroll Corey Casper Jorge J. Castillo Spero R. Cataland Yves Chalandon Luke Y.C. Chen Hannah Cohen Raymond L. Comenzo Shelley E. Crary Susan E. Creary Mark Andrew Crowther Adam Cuker Anita D'Souza Akiva Diamond

Laura W. Dillon

Lorenzo Falchi

Titilope Fasipe

Amir T. Fathi

Courtney D. DiNardo

Angela Ďispenzieri

Timothy S. Fenske Kleber Yotsumoto Fertrin Steven Fishbane Veronica H. Flood Robin Foà Gian Luca Luca Forni Francine M. Foss Svlvie D. Freeman David A. Garcia Norbert Gattermann Francesca Gav Sergio A. Giralt Aaron D. Goldberg Rachael F. Grace Maria Monica Gramatges Michael R. Grunwald Sumit Gupta Mehdi Hamadani Claire N. Harrison Joshua A. Hill Eric J. Huselton Seethal A. Jacob Julie Jaffray Nitin Jain Partow Kebriaei Sioban B. Keel Adam S. Kittai Ashwin Kotwal Elizabeth F. Krakow John Kuruvilla Abdullah Kutlar Michele P. Lambert Marco Lanzillotta Daniel C. Link Mark R. Litzow Frederick L. Locke Kah Poh Loh Marlise R. Luskin

Kami J. Maddocks Michael Makris Peter Martin Camila Masias Julia F. Maxson Keith R. McCrae Vickie McDonald Patrick T. McGann Neha Mehta-Shah Matthew G. Mei Saskia Middeldorp Narla Mohandas Peter Mollee Franck Morschhauser Alison J. Moskowitz Craig H. Moskowitz Guillaume Moulis Ann Mullally Taizo A. Nakano Robert S. Nearin Enrico M. Novelli Chiiioke Nze Elizabeth O'Donnell Kristen M. O'Dwyer Isaac Odame Oreofe O. Odeiide Olatovosi Odenike Oluwatoyosi Onwuemene Thomas Ortel Menaka Pai Anna L. Parks Rushad Patell Naveen Pemmaraju Juliana Perez Botero Kristen M. Pettit Tycel J. Phillips

Margaret V. Ragni V. Koneti Rao Patrick M. Reagan Sarah C. Rutherford Bethany T. Samuelson Bannow Kristen Sanfilippo Santosh L. Saraf Kerry J. Savage Farzana Savani Jordan K. Schaefer Nirav N. Shah Nirmish Shah Joseph J. Shatzel Alexa J. Siddon Deborah M Siegal Robert J. Soiffer Andrew B. Song Pieter Sonneveld Adam S. Sperling Matthias Stellies Deborah M Stephens Paolo Strati Δli T Taher Mehrnoosh Tashakori **David Trent Teachev** Takanori Teshima Philip A. Thompson Keri Toner Fabien Touzot Judith Trotman Luca Vago Tzu-Fei Wang Tanya Wildes Jennifer A. Woyach Robin Yabroff Renato Zambello Amer M. Zeidan

Andrew D. Zelenetz

10 Reviewers

Allyson Pishko

Barbara Pro

Daniel A. Pollvea

CORPORATE ACKNOWLEDGMENTS

2024 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 23, 2024.

2024 ASH Annual Meeting Foundation Run/Walk Supporters

PREMIER

Acrotech Biopharma Inc AstraZeneca Editas Medicine Gilead and Kite Oncology GSK

LEAD

AbbVie Medidata, a Dassault Systèmes company

2024 ASH Annual Meeting Education Supporters

ASH would like to acknowledge the following companies for the educational grants provided in support of the 2024 ASH Annual Meeting:

General Education Grant

AbbVie

AstraZeneca GlaxoSmithKline

Incyte Corporation

Lilly USA, LLC

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Hematology 2024: The Education Program

AstraZeneca

GlaxoSmithKline

Novartis Pharmaceuticals Corporation

2024 ASH Independent Medical Education Supporters

ASH would like to acknowledge the following companies for their support:

Agios Pharmaceuticals Inc.

bluebird bio, Inc.

Novartis Pharmaceuticals Corporation

Novo Nordisk

Pfizer Inc.

Vertex Pharmaceuticals Incorporated

Corporate Acknowledgments 11

2024 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 23, 2024.

2024 ASH Award Supporters

ASH would like to acknowledge and thank the following companies for supporting the ASH Bridge Grant, Hematology Inclusion Pathway and Scholar Award programs:

AstraZeneca

Novartis Pharmaceuticals Corporation

2024 Annual Meeting Corporate Supporters

ASH would like to acknowledge the following companies for their support of the 2024 ASH Annual Meeting:

AbbVie

Pedicabs

AstraZeneca

Exhibit Hall Aisle Signs
Pedicabs

Daiichi Sankyo, Inc.

PosterCast

Eli Lilly and Company

Photo Zone and Social Media Walls

European School of Haematoloy (ESH)

ASH-a-Palooza - Gold Level Supporter

FWGBD & HTRS

ASH-a-Palooza - Gold Level Supporter

GSK

ASH Hotel Door Drop Bag

Mobile Device Charging Stations

Pedicabs

Johnson & Johnson

Headshot Alley

Mobile Device Charging Stations

NMDP

ASH-a-Palooza - Platinum Level Supporter

Novartis Pharmaceuticals Corporation

Mobile Device Charging Stations

Pierre Fabre Pharmaceuticals Inc.

ASH Park @ The Plaza - Jenga

SOBI, Inc.

Hand Sanitizing Stations

Spark Therapeutics

Hand Sanitizing Stations

Syndax

Mobile App

12 Corporate Acknowledgments

CORPORATE ACKNOWLEDGMENTS

2024 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 23, 2024.

2024 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy throughout the year is sincerely appreciated.

ASH is grateful for the generous support of the following companies:

Premier Circle	Partner Circle	Advocate Circle	Insider Circle
GSK	AbbVie	Agios	Autolus
Novartis	AstraZeneca	Amgen	Bluebird Bio
Pfizer	BMS	Astellas	Geron
Regeneron	Daiichi-Sankyo Int'l	BeiGene	Kura Oncology
	J&J Innovative Medicine	Genentech	Orca Bio
	Kite/Gilead	Genmab	
	Lilly/Loxo	Merck & Co.	
	Vertex	Sanofi	
		Syndax	
		Takeda	

2024 ASH Health Equity Collective

The Health Equity Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH's work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the inaugural members for their laudable work:

Genentech	Merck
GSK	Novartis
J&J Innovative Medicine	Pfizer
Lilly	Vertex

RECIPIENTS OF AWARDS

WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

2024	Éliane Gluckman	2018	Victor Hoffbrand	2012	James George
2023	Blanche P. Alter	2017	Marshall A. Lichtman	2011	David G. Nathan
2022	Irving Weissman	2016	Thalia Papayannopoulou	2010	Volker Diehl
2021	Harvey Lodish	2015	Aaron Marcus	2009	H. Franklin Bunn
2020	Mohandas Narla	2014	Kanti Rai	2008	Robert Kyle
2019	Richard H. Aster	2013	Sir David John Weatherall	2007	Ernest Beutler

ERNEST BEUTLER LECTURE AND PRIZE

2024	Stuart Orkin and John Tisdale	2018	Alan D'Andrea and Neal Young	2012	Bruce R. Blazar and Carl H. June
2023	Takehisa Kitazawa and	2017	Luigi Naldini and Marina Cavazzana	2011	Janet D. Rowley and Brian J. Druker
	Johnny Mahlangu	2016	Hugues de Thé and Zhu Chen	2010	Barry S. Coller and Joel S. Bennett
2022	John Atkinson and Peter Hillmen	2015	Alfred Goldberg and Paul Richardson	2009	Yuet Wai Kan and Thomas Maniatis
2021	Margaret Shipp and Stephen Ansell	2014	Michael R. DeBaun and		
2020	Courtney DiNardo and Ari Melnick		Robert P. Hebbel		
2019	Sriram Krishnaswamy and	2013	Kenneth Kaushansky and		
	Jeffrey I. Weitz		David J. Kuter		

E. DONNALL THOMAS LECTURE AND PRIZE

WILLIAM DAMESHEK PRIZE

2024	Sean J. Morrison	2012	Timothy J. Ley	2000	David Ginsburg
2024	Scar 6. Morrison	2012	Timothy o. Ley	2000	-
2023	Katy Rezvani	2011	George Q. Daley	1999	Irving Weissman
2022	Bruce Blazar	2010	Leonard I. Zon	1998	Stuart H. Orkin
2021	Connie Westhoff	2009	John E. Dick	1997	Robert Rosenberg
2020	Toshio Suda	2008	Neal S. Young	1996	Stanley Korsmeyer
2019	Philip D. Greenberg	2007	Hal Broxmeyer	1995	Charles Esmon
2018	Connie J. Eaves	2006	E. Richard Stanley	1994	Thomas P. Maniatis
2017	James R. Downing	2005	Rainer Storb	1993	Thomas P. Stossel
2016	David Scadden	2004	Donald Metcalf	1992	Stuart Kornfeld
2015	Barbara C. Furie and Bruce Furie	2003	Ernest Beutler		
2014	Tomas Ganz	2002	Kenneth Mann		

2013 Katherine A. High 2001 Samuel E. Lux, IV

2006 Riccardo Dalla-Favera

2024	Ami Bhatt	2005	John Dick	1989	Samuel E. Lux IV
2023	Omar Abdel-Wahab	2004	Ronald Levy	1988	Theodore S. Zimmerman
2022	Irene Ghobrial	2003	Gary Gilliland	1987	Charles Sherr
2021	Elizabeta Nemeth	2002	Catherine Verfaillie	1986	Stuart Orkin
2020	Adolfo Ferrando	2001	Brian Druker	1985	Thomas F. Deuel
2019	Emmanuelle Passegué	2000	David A. Williams	1984	Barbara C. and Bruce Furie
2018	Ross L. Levine	1999	Salvador Moncada	1983	Thomas P. Stossel
2017	Benjamin L. Ebert	1998	J. Evan Sadler	1982	Janet D. Rowley
2016	Charles Mullighan	1997	Björn Dahlbäck	1981	Philip W. Majerus
2015	John Byrd	1996	Kenneth Kaushansky	1979	Yuet Wai Kan
2014	Scott Armstrong	1995	James Ihle	1978	Robert D. Rosenberg
2013	Andrew Weyrich	1994	George J. Broze, Jr.	1977	Yale Nemerson
2012	Margaret A. Goodell	1993	Owen Witte	1976	Robert I. Weed
2011	Christoph Klein	1992	Richard D. Klausner	1975	Charlotte Friend
2010	David T. Scadden	1991	Makio Ogawa	1974	Robert C. Gallo
2009	Louis M. Staudt	1990	Thalia Papayannopoulou and George		
2008	Kenneth Anderson		Stamatoyannopoulos		
2007	William Vainchenker				

ASH AWARD FOR LEADERSHIP IN PROMOTING DIVERSITY

2024	James George	2021	Deepika Darbari	2018	Cage S. Johnson and José A. López
2023	Alexis A. Thompson	2020	Edward J. Benz Jr.	2017	Betty Pace
2022	James Gavin and David Wilkes	2019	Griffin P. Rodgers		

HENRY M. STRATTON MEDAL

2	2024	Douglas Cines and Katherine High	2015	Nancy Speck and Karl Welte	2003	Janet Rowley
2	2023	Rodger McEver and James B. Bussel	2014	Geraldine Schechter and Timothy	2002	George Stamatoyannopoulos
2	2022	Timothy Ley and Robert Montgomery		Springer	2001	Harold R. Roberts
2	2021	Kwaku Ohene-Frempong and	2013	Nancy Andrews and Elaine Jaffe	2000	H. Franklin Bunn
		Denisa Wagner	2012	Richard Aster and David Ginsburg	1999	Helen Ranney
2	2020	Maria Domenica Cappellini and	2011	Ching-Hon Pui	1998	Arthur W. Nienhuis
		Michelle Le Beau	2010	Sanford Shattil	1997	Rainer Storb
2	2019	William Allen Eaton and Richard A.	2009	Connie Eaves	1996	Bernard Forget
		Larson	2008	Clara Bloomfield	1995	David Nathan
2	2018	Brunangelo Falini and Freda K.	2007	Carlo Croce	1994	Titus H.J. Huisman
		Stevenson	2006	Jack Hirsh	1993	Earl W. Davie
2	2017	Josef Tomas Prchal and Sherrill J.	2005	Barry Coller	1992	Kenneth G. Mann
		Slichter	2004	Stanley Korsmeyer		
2	2016	J. Evan Sadler and Avalew Tefferi				

HENRY M. STRATTON LECTURE (1970-1991)

1991	Ralph L. Nachman	1983	Eugene P. Cronkite	1975	E. Donnall Thomas
1990	Malcolm Moore	1982	Ernest A. McCulloch	1974	Ernest Beutler
1989	Aaron J. Marcus	1981	Clement A. Finch	1973	Albert S. Gordon
1988	Robert S. Schwartz	1980	Yuet Wai Kan	1972	Oscar D. Ratnoff
1987	Robert C. Gallo	1979	Henry S. Kaplan	1971	H.G. Kunkel
1986	Bernard Babior	1978	William N. Valentine	1970	W.R. Bruce
1985	Vincent DeVita	1977	Thomas A. Waldmann		
1984	Samuel Rapaport	1976	Wendell F. Rosse		

ASH MENTOR AWARD

2024	Stephen D. Nimer and Charles A.	2017	Ronald Hoffman and Oliver W. Press	2010	Mary M. Horowitz and Harvey F. Lodish
	Schiffer	2016	Laurence Boxer and Ralph L. Nachman	2009	Arthur Nienhuis and Stuart H. Orkin
2023	Stephen Sallan and Helen Heslop	2015	Curt Civin and Craig Kitchens	2008	George R. Buchanan and Timothy J.
2022	Michael Caligiuri and Christopher	2014	Grover C. Bagby Jr. and John F.		Ley
	Flowers		DiPersio	2007	Edward J. Benz Jr and Harold R.
2021	Anthony Goldstone and Jonathan Licht	2013	John Adamson and Stanley Schrier		Roberts
2020	Judith Gasson and Wendy Stock	2012	Beverly S. Mitchell and Rainer F. Storb		
2019	Michael R. DeBaun and Leonard I. Zon	2011	Nancy C. Andrews and Malcolm K.	2006	Samuel E. Lux and Deane F. Mosher
2018	John E. Dick and Reed E. Drews		Brenner		

ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

UNDERGRADUATE STUDENT

Joshua Wischmeyer

University of Colorado Anschutz Medical Campus

MEDICAL STUDENT

Shan Liu

University of Pennsylvania

GRADUATE STUDENT

Travis Fleming

Boston Children's Hospital, Harvard Medical School

RESIDENT PHYSICIAN

Amelia Haj, MD, PhD

Massachusetts General Hospital

POST-DOCTORAL FELLOW

Jenny Paredes, PhDCity of Hope

ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Hematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

Aneta Mikulasova, PhD

Faculty of Medical Sciences, Newcastle University

Alexandros Rampotas, MBBS, MRCP

University College London

Xuesen Zheng, PhD King's College London

ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

Adrian Minson, MBBS

University of Melbourne

ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan

Yu Akahoshi, MD, PhD

Icahn School of Medicine at Mount Sinai

Toru Miyajima, MD

Hokkaido University Faculty of Medicine and Graduate School of Medicine

Ruka Shimura, MSc

The University of Tokyo

ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to Italian two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

Enrica Federti

Luca Lanino, MD

University of Verona

IRCCS Humanitas Research Hospital

ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.

Hussein Awada

Fernanda Gutierrez-Rodrigues, PhD

Taussig Cancer Institute, Cleveland Clinic

National Institutes of Health

JOANNE LEVY, MD. MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Natalie Grover, MD

University of North Carolina

MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand's disease.

Amelia Haj, MD, PhD

Massachusetts General Hospital

ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Samuel Urrutia, MD

University of Texas MD Anderson Cancer Center

HEMATOLOGY INCLUSION PATHWAY (HIP) GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology, offers merit-based HIP Graduate Student Abstract Achievement Awards to select graduate students to acknowledge their accomplishments in the field of hematology.

Francesca Cendali Colorado University, Anschutz	NaShea Kendrick Case Western Reserve University	Alicia Matthews Case Western Reserve University	Suruchi Salgar Baylor College of Medicine
Alejandro De Janon	Kristopher Knight	Daniel Navarrete	Casey Wong
Emory University	Emory University	Stanford University School of Medicine	Queen's University
Daisy Diaz Rohena	Olivia Lightfuss		
University of Texas MD Anderson	University of Tampa	Maria Feliz Norberto	
Cancer Center		Albert Einstein College of	
	Paola Manara	Medicine	
Mike Fernandez The City of Hope	University of Miami		

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology, offers merit-based Abstract Achievement Awards (formerly Travel Awards) to select individuals to acknowledge the accomplishments of hematologists-in-training. This year's Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Hazim Ababneh	Theodora Alese	Naszrin Arani	Jie Bai
Salma Abdelbaky	Abdulrahman Alhajahjeh	Ferran Araujo-Ayala	Nora Balas
Chathuri Abeyakoon	Majd Al-Hamaly	Donovan Argueta	Nithya Balasundaram
Marina Able	Fatemeh Alikarami	Ivan Arnaud-Borboa	Tommaso Balestra
Nicholas Aboreden	Sabine Allam	Isabell Arnhardt	Suraj Bansal
Salma Abosabie	Jessica Allen	Sankalp Arora	Yu-Cheng Bao
Abdulaziz Abu Haimed	Adrian Almodovar Diaz	Frida Bugge Askeland	Mei Bao
Vera Adema	Ali Al-Mousawi	Enrico Attardi	Hafiza Sidra Bashir
Michael Agius	Shaikha Alqahtani	Zachary Avigan	Heya Batah
Luis E. Aguirre	Mark Althoff	Inci Aydemir	Francis Baumgartner
Jaehyun Ahn	Sarah Aminov	Edward Ayoub	Samantha Beck
Inemesit Akpan	Felicia Andresen	Roberta Azevedo	Isabelle Becker
Jean-Baptiste Alberge	Zhiwei Ang	Amro Baassiri	Nathan Becker
Manuela Albuquerque De Melo	Charles Antony	Aban Bahabri	Maddalena Benetton

Camelia Benlabiod Luca Bertamini Kalay Bertulfo Vanthana Bharathi Nayda Bidikian Kavita Bisht Hassan Bjeije Stefan Bjelosevic Joanna Blocka Veronica Bochenek

Geethika Bodanapu Prajwal Boddu Anna Bode Dennis Bonal Elizabeth Bonner

Natalia Alejandra Borbaran Bravo

Austin Boucher Jonas Bouhlal Wallace Bourgeois Leora Boussi Ava Boutilier Molly Brakhane Franziska Brauneck Zachary Braunstein Carlos Bravo-Perez Charlotte Brierley Cameron Brown Heiko Bruns Maura Bueno Richard Buka

Henna Butt Lilia Cabrera-Cosme

Xuan Cai

Virginia Camacho Ana Cantillo Garcia Janick Caron-L'Ecuyer Alberto Carturan Vinicius Carvalho Gabriele Casirati Eva Castellano Lucas Catelli Luiz Catto Alexis Caulier Okan Cetin

Lyam Carlo Chacon Rangel Jean-Nicolas Champagne Ophelie Champion Chrystelle Charles

Floris Chabrun

Thomas Chatzikonstantinou

Sharieel Chaudhry Selina Chavda Robert Chavez Mimi Chen Fang Chen Zhaozhao Chen Yu-Han Chen **Zhangliang Cheng** Qiao Cheng Karthik Chetlapalli Cho Han Chiang Nikhil Chilakapati Daniel Choi

Nicholas Chornenki Yasmeen Choudhri

Saifur R. Chowdhury Fabliha Chowdhury Vitida Chuenqviroj Nicoletta Cieri **Edward Cliff** Steven Coyne J. Philip Creamer Nataly Cruz-Rodriguez Samuel Cutler

Steve Dagenais-Bellefeuille Benjamin Dannenmann Janneke de Boer Amna De Bolos Marco De Dominici Romy De Laat-Kremers

Anne de Vaan Marouscha De Vries Philippe Decruvenaere Abdullah Deen Marie Demmerle Nihar Desai

Xavier Deschenes-Simard Sara-Maude Desforges Marie-Pier Desjardins Nivedhitha Devaraju Adit Dharia Vikram Dhillon Sandhya Dhiman Arjun Dhir

Aintzane Diaz-Mazkiaran

Deepika Dilip Danai Dima Thi Huong Lan Do

Venkatasai Rahul Dogiparthi

Nadezda Dolgikh **Edward Dominguez** Ruochen Dong Peiyuan Dong Tim Dreier Claire Drysdale Hanna Duan Manisha Dubev Marygrace Duggar Alasdair Duguid William Dunn Munevver Duran Debasmita Dutta Rudra Dutta

Alexandra Elias Habib El-Khoury Brandon Ellsworth Estela Emiliano Maximilian Englert Carolin Escherich Elliot Eton Laura Eurelings Ton Falques David Fandrei Rochelle Fayngor Erin Feliciano Dan Feng

Gaelen Dwyer

Jan-Niklas Eckardt

Justin Ferdinandus Conroy Field

Byron Figueroa Ross Firestone Rodrigo Fonseca Josie Ford Alexandra Forman Jayanne Forrest Dominic Fowler-Shorten

Emily Franco Pablo Freire Katie Frenis Jan Frenking Mirco Friedrich Benjamin Frost Takeshi Fuiino Takanori Fukuta Moritz Furstenau Thomas Fusillo Maria Gabarros-Subira Greeshma Gaddipati

Nico Gagelmann

Wael Gamal

Zhen Gao Camila Garcia Juan Esteban Garcia-Robledo

Boula Gattas Phalica Georges Ian Ghezzi Nora Gibson Kellen Gil Victoria Gill

Samira Glaeser-Khan

Lewis Go **Utkarsh Goel** Marti Goldenberg Shakirat Gold-Olufadi Jordan Goldstein Inna Gong Alexia Gonzalez Carmen Gonzalez Britten Gordon Ayaka Goto Sascha Gottert Adrian Gottschlich Karan Gowda Selene Grano Graeme Greenfield Caitlin Gribbin Luca Guarnera Amaliris Guerra Ruwan Gunaratne Qiuyu Guo Chengcai Guo Gopila Gupta Gamze Gursoy Lucas Gushiken

Joshua Gustine Christian Hackenbroch Christopher Haddad Cynthia Hahn Trent Hall

Karina Hamamoto Matthew Hamby Mark Hamilton

Alessandra Hartke Jessica Frade-Guanaes Alina Hartmann Khalil Hassan Fan He Amanda Henderson

Xu Han Tianxiao Han

Xu Han

Lauren Harmon

Sara Harrysson

Fthan Harris

Samantha Hershenfeld Shigeki Hirabayashi Tatsuro Hirao Semegne Hiruy Carrie Ho Angus Hodder Fieke Hoff Gordon Hoffmann Joseph Hong

Ziyi Hu Qiusha Huang Yun Huang Cameron Hunter Tiana Huynh Soo Yeon Hwang Anastasia latrou Shuntaro Ikegawa Makoto Iwasaki Bruna Jacintho Gohul Jalajakumari Sophie James Billy Jebaraj Jacob Jendro Madeline Jenkin Chen Jia Dongxu Jiang Dylan Jochum

Maxime Jullien David Juna Mabel Jung Bailee Kain Mariam Kalds Josette Kamel Tomasz Kaminski Jyoti Kandarp Karl Kapahnke Peter Kaplinsky Nilesh Kapoor Negin Karisani Monisha Kashyap Shobhita Katiyar Afroditi Katsarou

Nikolaos Katsivelos Lukas Kazianka Lei Ke Colleen Kelly Michael Kern Taria Kewan Mohamed Khalil Aalia Khan Shreyas Khanna Somya Khare

Wannakorn Khopanlert Jahanzaib Khwaja

Awards

Lin Han

Won Jun Kim Johannes Luebke Quentin Kimmerlin Wenjing Luo Malte Knoll Xiurui Lv Min Jung Koh Liemei Lv Ran Kong Charlotte Korst Julie Ma Anne Marijn Kramer Sirui Ma Benjamin Kroger Walid Macaron Julia Kuehn Mikaela Magtoto Marius Kulp Palani Kumar Abdula Maher Mariia Kumskova Alisa Maier Domenico Maisano Emil Kyvsgaard Monica Labrano Elias

Kartik Lakhotiya Mithra Lakshmi Narasimhan

Barbara Lam Stephen Lam Calvin Lam Maria Latacz Dona Le Yonatan Lean

Hannah Lebensburger Dasom (Caroline) Lee Nicholas Lee

Kevin Lee Kevin Jan Legscha

Ying Lei

Orly Leiva Lennart Lenk Stefania Leone Etienne Leveille

Ruonan Li Jiazhuo Li Qiaoli Li Haiou Li Yang Li

Ang Li Menglin Li Jingmei Li Jue Li

Xiaoli Li Yingying Li Ruiqi Liao Bram Lim

Keli Lima

Xiangjie Lin Karena Lin Rebecca Ling Anath Lionel Jinakun Liu

Fuauo Liu Yu Liu Wenbing Liu Meng Liu Zhenyu Liu Ting Liu

Marissa Locastro Justin Loke Waseem Lone

Edouard Long

Yadith Karina Lopez-Garcia

Eleni Louka Zhe Lu Danny Luan Mona M.Hosseini

Samuel Magaziner

Jasmine Makker Arushana Maknojia Panagiotis Malandrakis Aashray Mandala **Anthony Mansour**

Xinjian Mao Qiangian Mao Ludovica Marando Alfredo Marchetti Francisco Marchi Maya Mardini Amira Marouf Shannon Martin Claudio Martines Juan Martinez Jennifer Marvin-Peek

Sanne Massaar Thibault Masse Ramon Massoni-Badosa

Kosuke Matsuzaki Nazia Matto Markus Maulhardt Priyanshi Maurya Resham Mawalkar Christina Mayerhofer Stefania Mazzi Rabea Mecklenbrauck

Karnika Mehrotra Rushabh Mehta Yihan Mei George Mellgard Chloe Merrion

Sophie-Luise Mersiowsky

Lauren Merz Thomas Mever Markus Meyerhofer Daigo Michimata Nicole Michmerhuizen **Taylor Mills**

Carolina Mireles Satoshi Mitsuyuki Bhavesh Mohan Lal Alfonso Molina Paritosh Mondal **Analy Mora** Marisa Morakis Yenny Moreno Vanegas

Mary Morgan Ibrahim Muhsen Vaibhavi Mukhtiar Roger Mulet-Lazaro Carea Mullin

Umair Munawar Josiah Murray Sooho Myoung Maria N. Barrachina Pinanong Na Phatthalung

Neha Nagpal Nour Naji **Udit Nangia** Siena Nason Ahmad Nassar

Anna Navarro Figueredo Zi Yun Ng

Ka Lam Nelson Ng Daniel Nguyen

Hoang Thao Giang Nguyen Clare Nimura

Imran Nizamuddin Kingsley Nnawuba James Nolan Abdelrahman Noureldin Andres Novola-Perez Ellen Nuttall Musson Modesty Obasohan

Ivan Odak Lorenz Oelschlager Rurika Okuda Jose Oliveira Lucas Oliveira Souza

Paul Olson Rubi Alejandra Orta-Martinez

Cesar Alexander Ortiz Rojas Jon Thorir Oskarsson Naoual Ouazzani Chahdi Mitsuaki Oura

Edward Owusu Kwarteng

Dakshin Padmanabhan Aswin Pai **Andrew Palmer** Nilesh Pandey Arjun Pandey

Marios Papadimitriou Julien Papoin

Makayla Pardo Alyssa Parker Tyler Parsons Helene Pasquer Victor Pastre Evani Patel Mihir Patel Shaun Patterson Akshay Patwardhan Aline Pavan Aishwarya Pawar

Charles Pei Livius Penter Diego Pereira-Martins Tommaso Perini Luiza Perruso **Daniel Peters Daniel Petersheim** Verena Pfister Jonah Pierce Lucio Pinheiro

Ted Piorczynski

Vincenzo Pizzuti

Boadan Popescu **Kunal Potnis Olivier Pouliot** Camilla Poulsen **Edward Poynton** Parash Prasad **Betsy Pray** Alexandra Prosser Andrew Pucka

Carlos Quintero Hernandez Nabil Rahman

Shinya Rai Vincenzo Raimondi

Vinothkumar Rajan Jahanara Raiwani Sai Prasad Ramachandran

Hari Raman Rahul Ramaswamy Nikhil Ranian Michael Rassner Kristin Rathje Upasana Ray Suravi Raychaudhuri

Lauren Reiman Kai Reieski Kehan Ren Erika Ren Simon Renders Johanna Richter Oona Rinkinen Fausto Rios-Olais Elena Riva

Carola Riva Joshua Rivenbark Alexandra Rizaldi Mark Robinson Yara Rodriguez

Alfonso Rodriguez Espada Juan Jose Rodriguez Sevilla Antonio Rodriguez-Romera Alanis Rodriguez-Rosario Maximilian Alexander Rohnert

Alexandra Rojek Benjamin Rolles Ilaria Romano Carolina Romero Alexis Romero Marco Roncador Cedric Rossi Pier Rovatti Fernanda Roversi Pooia Rov Rahul Roy Gillian Rush Anna Rydstrom **Christine Saber**

Kelsey Sack Borhan R. Saeed Dipanjali Saha Yumika Saito Sahitya Saka Sophiya Sami Eleanor Sams Sohani Sandhu Caroline Sands

Roberta Santos Azevedo Christopher M. Sauer Anais Schavgoulidze Inga Schimansky Roman R. Schimmer Constanze Schneider Christopher Schorr Freya Schulze Alexandra Schurer Robert Schwab Alix Schwarz Lauren Scott David Sedloev Tro Sekayan

Tahereh Setayesh
Maiko Sezaki
Haya Shaalan
Rushil Shah
Sayyam Shah
Xinhe Shan
Ke Shang
Yang-Liu Shao
Vanessa Shao
Balkrishan Sharma
Malini Sharma
Mengzhu Shen
Kexin Shen

Justin Senecal

Evgenii Shumilov Rodrigo Silva-Aguiar Luise Araujo De Albuquerque

Kathryn Shimamoto

Simoes Natalie Smith Febe Smits Cinnie Soekojo Eli Soyfer

Shuvu Shi

Karan Srisurapanont David Stahl

Robert Stanley Maximilian Steinhardt Til Steinicke Patrick Stelmach

Victoria Stepanyants Dominique Sternadt Jonathan St-Onge

Jessica Stempel

Shan Su Shengqin Su Yani Suber

Rajagopalan Subramaniam Varun Sudunagunta Takeshi Sugio Adam Suleman Ruifeng Sun Hao Sun Shu Sun Lee-Kai Sun

Venkatasubramaniam Sundaramurthy

Arvind Suresh

Shruthi Suryaprakash

Fiona Swain Samantha Swenson Bartosz Szmyd Ravina Taak Michelle MH Tan Jia Yi Tan

Xinjie Jonathan Tang Jingwen Tang Matthew Tanner Mohammad Tarek Paniz Tavakoli

Ana Cristina Tejada Vasquez

Ivan Tesakov Zanshe Thompson Yuanyuan Tian Natalia Timofeeva Rosa Toenges Lauren Tokessy Sara Torres-Esquius Elizabeth Traxler James Troyer Sven Turkali Alex Tward Priyanka Ugale Emma Uible Ejike Ujoatu Masahiro Uni Caitlin Unkenholz Serhan Unlu Kristi Upadhyaya

Federica Valigi Yannis Valtis Konrad Van Der Zwet Nikita Vantsev Victoria Vardell Angelica Varesi Ashley Varkey Loic Vasseur

Amog Urs

Jule Ussmann

Margarita Vazquez Almonte Antonio Vega Mateos

Junia Vieira
Lucas Wadley
Isaac Wakiro
Janek Walker
Bo Wan
Xueping Wan
Xueer Wang
Boya Wang
Daniel Wang
Zhe WANG
Chenguang Wang

Ke Wang Yu-Hung Wang Rouxing Wang Guo-Ling Wang Lu-Lu Wang Xingchen Wang Zhenkun Wang Gauri Wechalekar Ruowen Wei

Samuel Weinschenk Jackson Weir Ethan Whipp Laura Wiegand

Thomas Wiseman

Emily Wolf Jasper Wong Gordon Wong Hengwei Wu Zhijie Wu

Xia Wu Ioanna Xagoraris Infencia Xavier Raj Mengfang Xia Alexander Xiang Shiyu Xiao Xuegin Xie Tingting Xie Chang Xu Yuxi Xu Yongfang Xu Jane Xu Miao Xu Jason Xu Changwen Xue Yuting Yan Hao Yan Zhe Yang Jiayu Yang

Ruimeng Yang Tingting Yang Yu Yang Yuan Yao Yanki Yarman Samuel Yates Zhi Han Yeoh Tiankai Yin Taishi Yonezawa Jihye Yoon James Yoon

Tetsuichi Yoshizato Helena Yu Dandan Yu Jinglei Yu Heye Yu Mengyao Yuan Kun Yun Matteo Zampini

Mengtong Zang

Saurabh Zanwar
Sen Zhang
Ellen Zhang
Pu Zhang
Yu Zhang
Xinyan Zhang
Zijun Zhang
Jingliao Zhang
Xiaoshuai Zhang
Jing Zhang
Yinqiang Zhang
Zhong Zhang
Haiqiong Zheng
Xiang Zhou
Jialin Zhou

Bachisio Ziccheddu David Zihala

Michelle Zhu

Natalia Zing Cristina Zucchinetti Ines Zugasti Melissa Zwick

Yin Yuan
Saurabh Zanwar
Clare Zarka
Martha Zarou
Chi Zhang
Ellen Zhang
Jingliao Zhang
Lei Zhang
Menglu Zhang
Michelle Zhang
Ningning Zhang
Xiao-shuai Zhang
Yaping Zhang
Yi Zhang
Peng Zhao

Yi Zhang
Peng Zhao
Peng Zhao
Hao Zheng
Xinhui Zheng
Chen Zhou
Jianying Zhou
Xiang Zhou
Xinyue Zhou
Yichao Zhou
Yifan Zhou
Hongming Zhu
Xinyu Zhu
Katherine Zhuo
Bachisio Ziccheddu

Fu Ziyu Becky Zon Adi Zoref-Lorenz Luciana Zuccherato Ines Zugasti

AMERICAN SOCIETY OF HEMATOLOGY 66TH ASH® ANNUAL MEETING AND EXPOSITION

MEETING DATES: DECEMBER 7-10, 2024

GENERAL INFORMATION

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society's annual meeting, is to facilitate the global exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing

and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

At this year's annual meeting, ASH will continue to offer an inclusive environment for all participants, including a focus on making the in-person meeting in San Diego and the virtual meeting platform as accessible as possible for attendees with disabilities. ASH will offer mobility, vision, hearing, and other resources as needed. For more information or for questions regarding these services, please contact <code>disabilities@hematology.org</code>.

TWO WAYS TO ATTEND THE 66TH ASH ANNUAL MEETING

ASH is pleased to continue to offer the 66th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in San Diego or participate using ASH's virtual meeting platform. All participants, regardless of location, will have access to the virtual meeting platform built for

learning, collaboration, and networking. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual meeting platform, and attendees will have the ability to ask questions and participate in real time.

REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual meeting platform through January 1, 2025.

Registration is available now at hematology.org/meetings/annual-meeting/registration-information. Those who have previously registered may upgrade their subscription to extend their access to the meeting's virtual platform at any time by contacting the Registration Center.

IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual meeting platform through January 1, 2025. In-person registrants have the option to extend their access to the virtual meeting platform for an additional fee.

VIRTUAL ACCESS REGISTRATION PACKAGE OPTIONS

The virtual meeting packages were designed to give attendees maximum flexibility. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate

in real time. The platform will also include on-demand recordings of all sessions (unless otherwise noted), as well as access to networking opportunities, exhibits, and more.

Real-Time Experience: Access through January 1, 2025

Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC credits can be claimed through April 11, 2025 by viewing the qualifying sessions on the virtual meeting platform.

Extended Flexibility: Access through February 1, 2025

Provides ongoing access to continue watching on-demand sessions after the meeting ends. CME/MOC credits can be claimed through April 11, 2025 by viewing qualifying sessions on the virtual meeting platform.

• Best Value: Access through March 1, 2025

Provides maximum flexibility to continue accessing on-demand sessions at the best price per day of access. CME/ MOC credits can be claimed through April 11, 2025 by viewing qualifying sessions on the virtual meeting platform.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 26)

Registration Category	In-Person or Real-Time Experience (Virtual access through January 1, 2025)	In-Person or Virtual Extended Flexibility: (Virtual access through February 1, 2025)	In-Person or Virtual Best Value: (Virtual access through March 1, 2025)
Member (Active and International)	\$950	\$1,050	\$1,150
Non-Member	\$1,600	\$1,700	\$1,800
Associate or International Member	\$175	\$200	\$225
Medical Student, Graduate Student, or Resident Member	\$175	\$200	\$225
Non-Member in Training*	\$275	\$300	\$325
Allied Health Professional	\$850	\$950	\$1,050
Spouse/Guest (in person only)	\$175	NA	NA
Honorary/Emeritus (before 1/1/15)	\$0	\$50	\$100
Honorary/Emeritus (after 1/1/15)	\$175	\$200	\$200
Non-Profit Patient Advocacy Organization Representative (Application for approval is required in advance)	\$0	\$0	\$0

^{*} Advance registration rates for Non-Members in Training are available through December 1, 2024.

BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

Member
Non-MemberGreen
Associate MemberBlue
International Associate MemberBlue
Non-Member in TrainingBlue
Graduate/Medical Student Member Blue
Resident MemberBlue
Honorary/Emeritus MemberWhite
Allied Health Professional Purple
Exhibitor Booth PersonnelBlack
Spouses/GuestYellow
MediaOrange

BADGES

Badges will be mailed in advance of the meeting to North American attendees who have registered by October 31. International attendees may pick up their badge at one of several registration locations in San Diego, including at the San Diego International Airport, Marriott Marquis San Diego Marina, Manchester Grand Hyatt, and the San Diego Convention Center. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

OVERVIEW OF THE MEETING SCHEDULE PREVIEW DAYS: DECEMBER 4-5, 2024

Beginning December 4, 2024, the ASH annual meeting virtual platform will be available to all registered participants at annualmeeting.hematology.org

All registered attendees are encouraged to log in early to get acquainted with the site's navigation. To log into the platform, you will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the meeting's virtual platform, please contact the ASH Customer Service department by emailing customerservice@hematology.org or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for International callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time. Over the dates of the meeting, extended customer

service hours will be offered; please visit www.hematology.org/contact-us for specific hours.

If you have successfully accessed the meeting's virtual platform but are having difficulty with one of its features, please use the online support form feature within the platform for technical assistance.

FRIDAY-ONLY PROGRAMMING: December 6, 2024

There are pre-meeting activities scheduled on Friday, December 6, 2024.

• Friday Satellite Symposia

• ASH-a-Palooza

Scientific Workshops

Refer to schedule at-a-glance or the mobile app for specific session times.

OFFICIAL MEETING DAYS: December 7-10, 2024

The 66th ASH Annual Meeting and Exposition will take place December 7-10, 2024 in San Diego, California, and on the meeting's virtual platform. All times listed reflect the Pacific time zone.

Saturday, December 7 Refer to schedule-at-a-glance or the mobile app for specific session times

Refer to schedule-at-a-glance or the mobile app for specific session times

Monday, December 9 Refer to schedule-at-a-glance or the mobile app for specific session times

Refer to schedule-at-a-glance or the mobile app for specific session times

Refer to schedule-at-a-glance or the mobile app for specific session times

All sessions will occur in the mobile app for specific session times

All sessions will occur in the mobile app for specific session times

All sessions will occur in the mobile app for specific session times

The meeting concludes at 1:00 p.m.

All sessions will be presented at the in-person meeting in San Diego, and unless otherwise noted all events will stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform for the duration of your registration package. Scientific Workshops will be available until December 14, 2024.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CATCH UP DAYS: December 11-13, 2024

After the official dates of the annual meeting, ASH Poster Walks will be held on Wednesday, December 11, on the meeting's virtual platform.

BINGE WATCHING—CATCH UP ON CONTENT

Participants will also be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting from December 11 through the end of their virtual meeting registration package.

NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. In San Diego, small gathering and seating areas will be available indoors and outdoors to informally meet with colleagues.

ASH's virtual meeting platform makes connecting with colleagues in San Diego and all around the world easy. On the meeting's virtual platform click on Networking to connect with your peers.

ASH SOCIAL MEDIA WALLS

Take a break from the science and visit the ASH Social Media Walls located on the meeting's virtual platform and throughout the convention center to view and contribute to a real-time scientific conversation and engage with colleagues on a variety of topics. This year, the Walls will feature a daily leaderboard

ranking of the top 10 most prolific tweeters who use the featured annual meeting hashtags (#ASH24, #ASHRunWalk, #ASHKudos, and #ASHaiku). The leaderboard will reset each day, giving you ample opportunity to join the online discourse.

SPEAKER INFORMATION

SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in the Sails Pavilion at the San Diego Convention Center. All times are in Pacific time.

Speaker Ready Room Hours

Thursday, December 5 3:00 p.m. – 6:00 p.m.
Friday, December 6 7:00 a.m. – 6:00 p.m.
Saturday, December 7 7:00 a.m. – 6:00 p.m.
Sunday, December 8 7:00 a.m. – 6:00 p.m.
Monday, December 9 7:00 a.m. – 6:00 p.m.
Tuesday, December 10 7:00 a.m. – 11:00 a.m.

All speakers should bring a copy of their presentation to the Speaker Ready Room on a CD-R, DVD-R, or USB flash drive (memory stick, jump drive, etc.). A professional audio-visual (AV) technician will be available to consult with you on any of the guidelines and to make certain your slides are properly identified

for your specific session. Please turn in your presentation to the Speaker Ready Room according to the following guidelines:

24 hours before your presentation if you would like the AV technician to assist you in formatting your presentation to ensure clear and readable images.

6 hours before your presentation, if your PowerPoint presentation was prepared on an Apple computer.

At least 6 hours before your presentation if your presentation contains movies or other videos.

At least 4 hours before your presentation if your presentation is final and requires no modifications.

CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), all meeting session chairs, speakers, and moderators are required to disclose in writing any financial relationships they may have prior to the meeting. All poster presenters are required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. If bias, actual or perceived, occurs during the presentations,

session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including chairs, speakers, and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity's Board of Directors or advisory committee, and any other financial relationship.

Any questions about this policy or concerns regarding disclosures should be directed to CME@hematology.org.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES

- Upon completion of this educational activity, participants should be able to:
- Employ the knowledge gained regarding the diagnosis and treatment of classical and malignant hematologic disorders to improve patient care;
- Discuss state-of-the-art research in hematology; and
- Analyze the potential contribution of novel, not-yetapproved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of **70 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with their participation in the live activity.

CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide **AMA PRA Category 1 Credits**™ to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for *AMA PRA Category 1 Credits*™.

HOW TO OBTAIN A CME CERTIFICATE

A processing fee of \$30 will be charged for CME certificates. Attendees must complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (www.hematology.org) by clicking the CME link on the homepage. The online process for claiming CME credits and printing a CME certificate for the 66th ASH Annual Meeting must be completed no later than April 11, 2025.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 70 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. In addition to completing the evaluation survey, attendees must submit a reflective statement on how they intend to change their practice based on the knowledge gained from participation in the meeting. Attendees must also provide their ABIM number and date of birth. Upon review and approval of the reflective statement, points will be submitted to the ACCME by ASH and will appear in the ABIM Physician Portal within 48 hours. Points will only be submitted if all the steps are completed. To receive ABIM MOC points for the 66th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 11, 2025.

CERTIFICATE OF PARTICIPATION

Non-physicians and other health-care professionals attending the meeting may print a Certificate of Participation after completing the Annual Meeting Evaluation Surveys through the ASH website (www.hematology.org) beginning Saturday, December 7, 2024. The online process of filling out the annual meeting survey and printing the certificate must be completed no later than April 11, 2025. There is no charge to meeting registrants for this service.

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website (http://ebah.org). For information about claiming EBAH CME for the 66th ASH Annual Meeting email cme@hematology.org.

QUALIFYING ACCREDITED SESSIONS

Attendees can claim CME for viewing qualifying sessions as they are broadcast in-person and on the virtual platform. Credit can also be claimed for viewing qualifying sessions on the platform after they have concluded.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

ATTENDEE SERVICES

ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in the Sails Pavilion at the San Diego Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or make a donation to the ASH Foundation. The following resources are also offered at ASH Central: the ASH Health Equity Studio, fASHion boutique for the hematologist with style, smASH Pickleball, ASH Live: Remote Session Viewing, ASH Store, ASH Foundation Run/Walk Registration and Bib Pick Up, Collaboration Rooms, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio.

ASH Health Equity Studio

As part of ASH's commitment to promoting and nurturing a diverse and inclusive hematology community, the ASH Health Equity Studio will once again be located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include short presentations by an inperson speaker followed by an interactive discussion co-led by the speaker and an ASH member. These micro-sessions will also be available on the virtual meeting platform.

ASH Live: Remote Session Viewing Area

A designated seating area that will enable attendees to experience select sessions in progress elsewhere without having to navigate through the building. This viewing area will have television monitors/screens displaying the slides from a selection of sessions. Participants will be provided with a set of headphones so they may listen to the selected session's speakers. Note: Not all sessions will be broadcast into the remote session viewing area. Check the annual meeting mobile app or ASH News Daily for more information on which sessions are available remotely.

ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at (www.hematology.org/Store).

ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness.

Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the

top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple, back-to-back reservations cannot be accommodated. Outside food and beverage and/or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website (www.hematology.org) via the mobile application or the Collaboration Room Help Desk in the Sails Pavilion to reserve a Collaboration Room.

Collaboration Room Hours

Friday, December 6 7:00 a.m. – 5:45 p.m. Saturday, December 7 . . . 7:00 a.m. – 5:45 p.m. Sunday, December 8 7:00 a.m. – 5:45 p.m. Monday, December 9 7:00 a.m. – 5:45 p.m. Tuesday, December 10 . . . 7:00 a.m. – 12:45 p.m.

fASHion

For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, ranging from outerwear, athletic wear, golf polos, hematology specialty socks, bow ties, neck ties, scarves, and kids' apparel, too. Items will be available for purchase in an array of sizes while supplies last.

Headshot Alley

Need a new professional headshot? Get one for free at Headshot Alley in ASH Central. Your headshot will be sent to you via email for immediate downloading.

Photo Zone

Capture the excitement of the annual meeting with your friends and colleagues by taking a photo in the ASH photo zone, located in ASH Central. Various props and backdrops will be available and will change daily.

Trainee Lounge

Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Mobile App

ASH's mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2024 annual meeting. The application includes the full text of the abstracts and the articles available in Hematology 2024 (the ASH Education Program). The application will allow users to add a session to their device's calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

Personal Device Viewing Technology

Second screen technology through the meeting's virtual platform enables attendees to view session slides in real time from most personal devices, including smartphones, tablets, and laptop computers. Viewing sessions on personal devices

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

allows for better viewing of images that can be difficult to see from the back of the session room and allows the audience to submit questions to the moderators virtually. Some sessions will also use this technology for audience polls.

To view a session on your personal device you can navigate to your session via the annual meeting mobile app or through the meeting's virtual platform.

PosterCast

While you are in the poster hall, use PosterCast to view five-minute video presentations by the author. This tool is especially useful when viewing posters while the author is not present in the in-person poster hall.

You can view the PosterCasts on your device by visiting the PosterCast website at https://postercast.com/ash and signing in with your ASH credentials.

To view a poster's recording, search the PosterCast website for the poster number. You will then be able to watch a five-minute video describing the poster's content while you view the poster. A link to the PosterCast recording will also appear within the poster description on the ASH meeting mobile app.

ASH FOUNDATION DONOR LOUNGE

Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of \$250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit hematology.org/foundation for more information. The Donor Lounge will be located in the Tides Restaurant on Level 1 of the San Diego Convention Center. The Tides Restaurant is located adjacent to Hall A and can be accessed from the Hall A Lobby.

ASH MANAGEMENT OFFICE

The ASH Staff Office is located in Room 15A on the Mezzanine level of the San Diego Convention Center.

ASH PARK @ THE PLAZA

ASH Park @ the Plaza will be located in Park Plaza at the San Diego Convention Center. This area will feature early morning yoga, life-sized games, and lounge furniture. There will also be ample seating and tables outdoors for those who wish to take a break and enjoy the San Diego sunshine.

BUSINESS CENTER

The San Diego Convention Center has a FedEx Office that provides full-service business needs for your convenience located on the ground level across from Hall D. FedEx Office provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM

ASH has, once again, made arrangements with KiddieCorp to provide child-care services for children ranging in age from six months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for 24 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained childcare specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for

nursing mothers to store milk after using the lactation room. The deadline for reserving space for your child is November 15.

The cost for child-care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 15 preregistration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 6, through Tuesday, December 10.

The child-care room is located in Room 16 on the Mezzanine Level at the San Diego Convention Center.

Child Care Room Hours

Friday, December 6 6:30 a.m. – 7:30 p.m. Saturday, December 7 6:30 a.m. – 7:30 p.m. Sunday, December 8 6:30 a.m. – 8:00 p.m. Monday, December 9 6:30 a.m. – 8:00 p.m. Tuesday, December 10 . . . 7:30 a.m. – 1:30 p.m.

COAT/BAG CHECK

Complimentary coat and bag check is available on the Ground Level of the San Diego Convention Center in Box Office A and Hall H Lobby as well as in the East Lobby Lounge of the Marriott Marquis San Diego Marina and the Seaport Foyer at the Manchester Grand Hyatt. Electronic items will not be accepted.

Coat/Bag Check Hours

Friday, December 6 7:00 a.m. – 6:30 p.m. Saturday, December 7 . . . 7:00 a.m. – 8:00 p.m. Sunday, December 8 7:00 a.m. – 8:30 p.m. Monday, December 9 7:00 a.m. – 8:30 p.m. Tuesday, December 10 . . . 7:00 a.m. – 2:00 p.m.

FRIENDS OF BILL W.

A meeting room for the Friends of Bill W. is located in Conference Room 2 at the Marriott Marquis San Diego Marina in South Tower Level 3.

HEMATOLOGY MEETUPS

To encourage interaction among attendees, "Hematology Meet Up" areas consisting of public meeting spaces with couches, chairs, and tables will be placed in the convention center. Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that attendees can coordinate meeting up with each other at a specific location.

INTERNET STATIONS

Internet Stations are placed throughout the San Diego Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

LOST AND FOUND

Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 14A on the Mezzanine Level of the San Diego Convention Center.

NURSING MOTHERS' LOUNGES

Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the San Diego Convention Center, Hilton San Diego Bayfront, Marriott Marquis San Diego Marina, and Manchester Grand Hyatt. Each nursing mothers' lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is also a complimentary refrigerator located in the Child Care Room, Room 16 at the San Diego Convention Center.

Nursing Mothers' Lounges Locations

San Diego Convention Center:

- Hall E Lobby
- Hall B1 Lobby
- Mezzanine Level

Manchester Grand Hyatt

• Show Office 3

Hilton San Diego Bayfront

Agua Level

Marriott Marquis San Diego Marina

• Pacific Ballroom West Registration Desk

QUIET ROOMS

Two quiet rooms are located in San Diego Convention Center. Show Office G is designated as the Female Quiet Room and Show Office H is designated as the Male Quiet Room.

PRESS COMPLEX

The Press Complex, open to registered members of the media, is located on the third Level of the Seaport Tower at the Manchester Grand Hyatt.

Press Room Hours

Friday, December 69:00 a.m. – 5:00 p.m.
Saturday, December 77:00 a.m. – 6:00 p.m.
Sunday, December 87:00 a.m. – 6:00 p.m.
Monday, December 97:00 a.m. – 6:00 p.m.
Tuesday, December 107:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS

New this year: consult the ASH Campus Map and ASH Food Guide for detailed information regarding concessions and dining options throughout the San Diego Convention Center, Marriott Marquis San Diego Marina, Manchester Grand Hyatt, and Hilton San Diego Bayfront. The map will provide information on what type of food is available where so that you can easily find meals and snacks throughout the ASH campus.

Should you wish to dine off campus, a variety of restaurants are also located near the San Diego Convention Center.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY

To stay safe during your visit to San Diego, please follow the tips provided below:

Never hand your phone to someone else (i.e. handing to an Uber or Taxi driver to show them directions or asking a stranger to take your photo).

Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.

Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.

Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.

When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

When driving, keep all car doors locked.

SHUTTLE SERVICE

ASH will provide complimentary shuttle service between most hotels in the ASH housing block and the San Diego Convention Center; additionally, 15 hotels are within walking distance of the San Diego Convention Center.

Shuttle Boarding Locations

Routes 1-2 Marriott Marquis Pacific Ballroom

Routes 3-8 SDCC Halls A-C Routes 9-12 SDCC Halls F-H

Routes 13-16 Park Blvd. (Near ASH Park @ the Plaza)

Shuttle Hours

Thursday, December 5 No shuttle service
Friday, December 6 6:30 a.m. – 10:30 p.m.
Saturday, December 7 6:30 a.m. – 9:30 p.m.
Sunday, December 8 6:30 a.m. – 9:30 p.m.
Monday, December 9 6:30 a.m. – 9:30 p.m.
Tuesday, December 10 6:30 a.m. – 2:00 p.m.
Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the San Diego Convention Center:

- Courtyard San Diego Gaslamp/Convention Center
- · Embassy Suites San Diego Bay Downtown
- · Hard Rock Hotel San Diego
- · Hilton San Diego Bayfront
- Hilton San Diego Gaslamp Quarter
- · Horton Grand Hotel
- Hotel Indigo San Diego Gaslamp Quarter
- Hotel Z
- · Manchester Grand Hyatt

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

- Margaritaville Hotel San Diego Gaslamp Quarter
- · Marriott Marguis San Diego Marina
- · Marriott San Diego Gaslamp Quarter
- · Omni San Diego
- · Pendry San Diego
- · Residence Inn San Diego Downtown/Gaslamp Quarter

AIRPORT SHUTTLE INFORMATION

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes from the San Diego Convention Center to the San Diego International Airport during the days and times indicated below.

Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall C Lobby, Ground Level of the San Diego Convention Center. Tickets cost \$20 (credit card only)

Tickets Sales Hours

Monday, December 99:00 a.m. - 7:00 p.m. Tuesday, December 107:00 a.m. - 1:45 p.m.

Shuttle Hours

Monday, December 912:00 noon - 6:00 p.m. Tuesday, December 109:00 a.m. - 2:00 p.m.

Departure Location: San Diego Convention Center, Buses load outside curbside in front of Hall C Lobby, Level 1

PARKING

On-site private vehicle parking is available at the San Diego Convention Center as well as nearby parking options that serve the Downtown San Diego area. For detailed parking information, visit https://www.visitsandiego.com/parking.

GETTING AROUND

The area's public transportation system - MTS - has routes servicing the San Diego Convention Center with connections to the San Diego International Airport and downtown San Diego. To plan your journey and obtain the latest fares, visit https://www.sdmts.com/.

Taking the MTS Trolley is one of the most convenient and least expensive ways to explore the downtown area and the San Diego Convention Center. For maps and fare information, visit the MTS Trolley website, **sdmts.com/transit-services/trolley**.

FRED: Free Ride Everywhere Downtown is a unique form of transport in San Diego. These electric, open-air vehicles offer completely free rides within their service area throughout downtown San Diego. Service works through a mobile app and can be a great option if the pick-up times align with your schedule. Download the Ride Circuit app to request a ride. Hours of operation can be found at ridecircuit.com/fred.

Taxis in San Diego are billed using a base fare of \$3 with a charge of \$3.30 per mile.

EXPOSITION

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 66th ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls C-F in the San Diego Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, NO ONE under the age of 18 will be permitted within the exhibit areas.

Exhibit Hours

Saturday, December 7...... 11:00 a.m. – 5:00 p.m. Sunday, December 8...... 10:00 a.m. – 5:00 p.m. Monday, December 9...... 10:00 a.m. – 2:00 p.m.

LUNCH AVAILABLE SUNDAY AND MONDAY

Your "ticket" for lunch is encoded in your badge, which will be scanned for entry into the "ticketed" event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Exhibit Hall or on the Sails Pavilion Terrace. Lunch will be served from the ASH Café areas located in the back of the exhibit hall and on the Sails Terrace.

Lunch Hours

ASH BOOTH (#1215) – YOUR GATEWAY TO ALL ASH HAS TO OFFER

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1215). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of Blood, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

CORPORATE PRESENTATIONS

Corporate Presentations include Product Theaters, Industry Theaters, Industry Forums, and Company and Clinical Trials Showcases, which feature new research findings, company overviews, and products presented to small groups of annual meeting attendees (no more than 150). All corporate presentations will take place on the Upper Level of the San Diego Convention Center (Rooms 1-5). Check the mobile app for the specific room number of the presentation you wish to attend. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Corporate Presentation Theater Hours

Saturday, December 7 8:00 a.m. - 9:00 a.m.

11:30 a.m. – 12:30 p.m.

1:30 p.m. – 2:00 p.m.

3:30 p.m. - 4:00 p.m.

Sunday, December 8 8:00 a.m. – 9:00 a.m.,

11:30 a.m. - 12:30 p.m.

Monday, December 9 8:00 a.m. – 9:00 a.m.,

12:15 p.m. – 1:15 p.m.

Please see pages 135-143 for detailed Corporate

Presentation program information.

POSTER SESSIONS

Poster sessions are held in Halls G-H of the San Diego Convention Center. Receptions are scheduled for Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

Saturday, December 7

9:00 a.m. – 7:30 p.m. Poster Session I – Viewing 5:30 p.m. – 7:30 p.m. Poster Session I – Presentations

Sunday, December 8

9:00 a.m. – 8:00 p.m. Poster Session II – Viewing 6:00 p.m. – 8:00 p.m. Poster Session II – Presentations

Monday, December 9

9:00 a.m. – 8:00 p.m. Poster Session III – Viewing 6:00 p.m. – 8:00 p.m. Poster Session III – Presentations

SOCIAL EVENTS

POSTER HALL RECEPTIONS

Saturday, December 7 5:30 p.m. – 7:30 p.m. Sunday, December 8 6:00 p.m. – 8:00 p.m. Monday, December 9 6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2024 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

ASH FOUNDATION RUN/WALK

Sunday, December 8, 2024, 7:00 a.m. - 9:00 a.m.

Fifth Avenue Landing (on the Embarcadero and marina side of the convention center toward the Hilton San Diego Bayfront Hotel)

Begin your day in a fun, healthy, and philanthropic way by participating in the 11th annual ASH Foundation Run/Walk before attending the sessions on Sunday, December 8. Participants may run or walk through the designated event course in scenic San Diego, choosing either a 3K or 5K route. Not attending in person this year? Don't worry! You can still support the Foundation by choosing your own virtual 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Greatest Needs Fund. ASH and the ASH Foundation may opt to designate a portion of, or all corporate sponsorship revenues associated with the run/walk to help support the cost of administering the event. Learn more and register at hematology.org/foundation/run-walk.

MEETING RULES AND REGULATIONS

CODE OF CONDUCT

ASH is committed to providing a welcoming meeting environment for all attendees. This Code of Conduct applies to all in-person and virtual participants, including members, volunteers, guests, exhibitors, vendors, staff, and any other attendee.

All attendees will conduct themselves in a collegial and respectful manner, free from any form of discrimination, harassment, or retaliation. Attendees will commit to creating a safe, inclusive, and professional atmosphere. Inappropriate conduct, including but not limited to harassment; threatening

physical or verbal actions; or disorderly or disruptive conduct, will not be tolerated.

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact customerservice@hematology.org as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

MEETING AND SESSION PARTICIPATION

Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct, including but not limited to harassment, threatening physical or verbal actions, or disorderly or disruptive conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual meeting platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the San Diego Convention Center:

- I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE SAN DIEGO **CONVENTION CENTER FROM ANY AND ALL SUCH** LIABILITY. I agree, for myself and any heirs, not to sue ASH or the San Diego Convention Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.
- I agree that I will not pass my registration badge to another individual, or otherwise allow anyone else to use my badge. I understand that violation will result in immediate revocation of my access to the meeting, and possibly future meetings.

PARTICIPATION OF FINANCIAL PROFESSIONALS

Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priority. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

ANNUAL MEETING DATA COLLECTION

As a participant of the meeting, you have read and agreed to the following privacy policies and/or terms of service:

American Society of Hematology

Privacy Policy (hematology.org/about/privacy-policy)

Terms of Service (hematology.org/about/terms-of-service)

SPARGO (ASH Registration and Housing provider)

Privacy Policy (https://spargoinc.com/privacy-statement)

Freeman (Virtual Meeting Platform provider)

Privacy Policy (https://www.freeman.com/privacy-policy/)

Terms of Service (https://www.freeman.com/terms/)

Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

PROHIBITED SESSION ROOM BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshal.

CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants in the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH's ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. No identifying personal information will be stored in the RFID badge, only an ID number. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact ashregistration@spargoinc.com.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Materials presented at the American Society of Hematology ("ASH") annual meeting, including all slides, written and oral presentations, posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Meeting Materials"), are protected by copyright and may not be publicly displayed or republished (including social media) without the express written consent of the copyright owner, ASH, or (in the case of the slides and posters) the presenter or author except as expressly provided in this Policy.

B. Photographs and Audio Recording

Limited Right to Share: Except as provided in Sections A and B.2 of this Policy (hematology.org/meetings/annual-meeting/attendee-resources/photography-and-recording#b2), attendees of the ASH annual meeting may take photographs and make audio recordings (but no video recordings or live-streaming) of Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

Attribution: an attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or his or her use;

Non-Commercial: an attendee may not use the Meeting Materials for commercial purposes; and

No Derivatives: if an attendee remixes, transforms, or builds upon the Meeting Material, he or she may not distribute or publish the modified material.

Poster and Exhibit Hall Presentations: Attendees of the ASH annual meeting may take photographs and make recordings of Meeting Materials associated with Poster and Exhibit Hall presentations and displays for personal, non-commercial, use only. Attendees are strictly prohibited from sharing Meeting Materials associated with Poster Presentations or exhibit hall displays without the express consent of the presenter or exhibitor, respectively, and the copyright owner of such Meeting Materials.

C. No Disruptive Recordings or Photos

Attendees taking photos or audio recording of meeting materials must do so in a non-disruptive manner so as not to disturb the presenter and other attendees. Flash photography is strictly prohibited.

D. No Video Recording, Live Audio, or Video Streaming

Sharing any recordings of meeting materials, including live streaming audio or video recordings, is strictly prohibited.

E. Violators

Violators of this Policy may be asked to leave the room or session and may be escorted and barred from the ASH meeting. Repeat violators may have their ASH meeting badges and/or virtual meeting access revoked and not be allowed to return to attend the remainder of the ASH meeting.

F. Disclaimer

ASH will have professional photographers present at the meeting, and portions of the meeting will be recorded. Any photographs or recordings taken during the meeting may be used in future ASH publications, online, or in other ASH materials. Attendance or participation in the meeting constitutes an agreement with ASH by the registrant for the Society to use and distribute the registrant's image or voice in photographs, videotapes, audiotapes, or other electronic media pertaining to the ASH annual meeting events and activities.

DIVERSITY, EQUITY, AND INCLUSION AT ASH®

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care

communities. ASH's efforts in diversity, equity, and inclusion apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 65th ASH Annual Meeting to help improve diversity, equity, and inclusion in medical research on hematologic diseases and disorders and in the practice of hematology.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

ASH HEALTH EQUITY STUDIO GOD-CME

Saturday, Sunday, Monday

Sails Pavilion

As part of our commitment to promoting and nurturing a diverse and inclusive hematology community, the American Society of Hematology (ASH) is offering the ASH Health Equity Studio, located in ASH Central. This brave space is designed to help attendees recognize inequities in health care and provide tools to make change in their institutions. Plan to attend these sessions to learn more about the root causes of health inequities, strategies to overcome disparities in patient care and career development, and ways to improve diversity and inclusion in hematology. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to address health inequities at your institution.

ANNUAL MEETING SESSIONS THAT HIGHLIGHT DIVERSITY, EQUITY, AND INCLUSION

Day	Time	Session Title	Program	Location	CME
Friday	7:00-10:00 AM	Satellite Symposia: Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape	Interact with Industry	Room 6B	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Next Up: Conversations On Optimizing CD38 Antibody-Based Triplet Regimens For Early-Relapse Multiple Myeloma	Interact with Industry	Room 6B	CME
Friday	12:00-5:00 PM	ASH-a-Palooza	Trainee Activities	Gaslamp Quarter	
Friday	2:00-5:00 PM	Scientific Workshop on Aging and Hematology	Scientific Program	Room 7	
Friday	3:00-6:00 PM	Satellite Symposia: A Step-By-Step Approach to CAR T-cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management	Interact with Industry	Room 6B	CME
Saturday	9:30-10:45 AM	A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma	Education Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME
Saturday	9:30-10:45 AM	The Expanding Landscape of Treatment for ITP	Education Program	Room 28 A-D	CME
Saturday	9:30-11:00 AM	908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	

DIVERSITY, EQUITY, AND INCLUSION AT ASH

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Saturday	12:00-1:30 PM	322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations	Oral Abstract Sessions	Room 29	
Saturday	12:30-1:30 PM	2024 Ham-Wasserman Lecture: Sickle Cell Disease in Developing Countries	Marquee Sessions	Hall B	CME
Saturday	2:00-3:15 PM	Hematologic Management of the Patient with Heavy Menstrual Bleeding	Education Program	Room 28 A-D	CME
Saturday	2:00-3:30 PM	Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities	Special-Interest Sessions	Room 11	CME
Saturday	4:00-5:30 PM	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Saturday	4:00-5:30 PM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Sessions	Room 6DE	
Saturday	6:30-9:00 PM	Hematology Inclusion Pathway	Special- Interest Sessions	Marriott Marquis San Diego Marina, Marina Ballroom E	
Sunday	7:30-9:30 AM	Medical Educators Symposium	Special- Interest Sessions	Marriott Marquis San Diego Marina, Marina Ballroom FG	CME
Sunday	9:30-11:00 AM	908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Sunday	9:30-11:00 AM	Health Equity Symposium: Race, Structural Racism and the Social Determinants of Health in Hematology	Special- Interest Sessions	Room 6DE	
Sunday	9:30-11:00 AM	Sickle Cell Disease Centers Session	Special- Interest Sessions	Room 33	CME
Sunday	11:00 AM-12:30 PM	LGBTQIA+ Community Networking Brunch (for in-person participants)	Special- Interest Sessions	Manchester Grand Hyatt San Diego, Coronado DE	
Sunday	11:30 AM-12:30 PM	Health Equity Rounds Lunch	Special- Interest Sessions	Manchester Grand Hyatt San Diego, Coronado Ballroom AB	
Sunday	12:00-1:30 PM	909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients	Oral Abstract Sessions	Room 6A	
Sunday	4:30-5:45 PM	Spotlight Sessions: Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All	Education Program	Room 30	CME

DIVERSITY, EQUITY, AND INCLUSION AT ASH

 $All\ events\ take\ place\ in\ the\ San\ Diego\ Convention\ Center\ unless\ indicated\ otherwise.\ All\ times\ are\ in\ Pacific\ time.\ Duplication/recording\ is\ prohibited.$

Day	Time	Session Title	Program	Location	CME
Sunday	4:30-5:45 PM	Spotlight Sessions: Biology Underlying Disparities in Lymphoid Malignancies	Scientific Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	CME
Sunday	4:30-5:45 PM	Race and Ancestry in Precision Medicine	Special- Interest Sessions	Room 6DE	CME
Monday	10:30-11:45 AM	Spotlight Sessions: Making a Match: Optimal Donor HLA and Beyond	Education Program	Room 24	CME
Monday	12:00-1:15 PM	DEI Community Networking Lunch (for in-person participants)	Special- Interest Sessions	Marriott Marquis San Diego Marina, Marina Ballroom D	
Monday	12:30-1:30 PM	ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by Blood Global Hematology (For In- person Participants)	Scientific Program	Halls G-H - Blood Journals Studio	
Monday	2:45-4:00 PM	Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?	Education Program	Room 29	CME
Monday	7:30-9:30 PM	Women In Hematology Networking Event (for in-person participants)	Special- Interest Sessions	Manchester Grand Hyatt San Diego, Coronado Ballroom & Terrace	
Wednesday	5:00-6:00 PM	ASH Poster Walk on Health Equity in Hematology	Scientific Program	Virtual Program	

NON-CME SESSIONS

ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education's (AACME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any

presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of Non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform and an up-to-date list of sessions will also be available.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

Due to stricter ACCME guidelines regarding who may be allowed to control/present accredited content, the following sessions will not be certified for CME credit.

Marquee Sessions

Best of ASH Late-Breaking Abstracts Session Plenary Scientific Session

Special-Interest Sessions

ASH Clinicians in Practice (ACIP) Lunch - The Role of Artificial Intelligence in Hematology Practice: The Good, the Bad, and the Ugly

ASH Foundation Run/Walk

ASH Networking Reception for the Hemostasis and Thrombosis Community - Hosted by the *Blood Vessels, Thrombosis and Hemostasis* Journal

ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation

ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation

Blood Advances Presents: How to Peer Review a Scientific Paper

Blood Presents: How to Get Published in a Peer-Reviewed Journal

Center for Sickle Cell Disease Initiatives: Advancing Progress in Sickle Cell Disease Update and Reception: hosted by ASH and ASH Research Collaborative

DEI Community Networking Lunch

Grassroots Network Lunch

Health Equity Rounds Lunch

Health Equity Symposium: Race, Structural Racism and the Social Determinants of Health in Hematology

Hematology Inclusion Pathway (HIP)

LGBTQIA+ Community Networking Brunch

Women In Hematology Networking Event

Non-CME Programs

All sessions in the following programs are not accredited for CME credit:

ASH Poster Walks
ASH Wellness Studio
ASH-a-Palooza Events
Blood Journals Studio
Clinical Trial Showcases
Company Showcases
Health Equity Studio
Industry Forums
Industry Theaters

Oral and Poster Abstracts

Product Theaters Scientific Workshops

Trainee Activities and Services

SCHEDULE-AT-A-GLANCE

AMERICAN SOCIETY OF HEMATOLOGY 66TH ASH® ANNUAL MEETING AND EXPOSITION

SCHEDULE-AT-A-GLANCE

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

WEDNESDAY, DECEMBER 4, 2024

9:00 a.m. – 11:55 p.m. P

Preview Day on the Virtual Platform

Virtual Program

THURSDAY, DECEMBER 5, 2024

1:00 a.m. - 11:55 p.m.

Preview Day on the Virtual Platform

Registration and Materials Pick Up (for in-

person participants)

Virtual Program

8:00 a.m. – 9:00 p.m.

Registration and Materials Pick Up at the Airport (for in-person participants)

San Diego International Airport

Ballroom 20 Lobby

3:00 p.m. - 7:00 p.m.

FRIDAY, DECEMBER 6, 2024

8:00 a.m. – 9:00 p.m.

Registration and Materials Pick Up at the Airport (for in-person participants)

San Diego International Airport

7:00 a.m. - 6:00 p.m.

Registration and Materials Pick Up (for in-person participants)

Ballroom 20 Lobby

Manchester Grand Hyatt San Diego, Hotel Main Lobby Marriott Marquis San Diego Marina, East Lobby Lounge

7:00 a.m. - 6:00 p.m.

Learn, Engage, and Relax in ASH Central (for in-person participants)

Sails Pavilion

7:00 a.m. - 10:00 a.m. Satellite Symposia

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia - What Clinicians Want to Know

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

Advances in Paroxysmal Nocturnal Hemoglobinuria: Reshaping Management Decision-Making through Case Challenges Together with the International PNH Interest Group (For in-person participants) Grand Hyatt San Diego, Grant Hall C

An Interactive Case-based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates

Manchester Grand Hyatt San Diego, Grand Hall C

Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape Room 6B

Championing the Care of Relapsed/Refractory Multiple Myeloma: Practical Strategies to Integrate Bispecific Antibodies

Room 6A

Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience & Innovation for More Personalized Disease Control

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

MDS 2024: Let's Overcome the Challenges

Manchester Grand Hyatt San Diego, Grand Hall B

Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease

Marriott Marquis San Diego Marina, San Diego Ballroom AB

9:00 a.m. - 12:00 p.m. Training Program Directors Workshop

Hilton San Diego Bayfront, Indigo 204

11:00 a.m. - 2:00 p.m. Satellite Symposia

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-free Treatment Paradigm

Manchester Grand Hyatt San Diego, Grand Hall C

A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives (For in-person participants only)

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

A Violent Graft in a Vulnerable Host: The Future of aGVHD Management Room 29

Addressing Current Questions and Controversies in the Management of Myelofibrosis - What Clinicians Want to Know

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

Advances in the Management of Myeloproliferative Neoplasms and Systemic Mastocytosis: Diagnosis/Classification, Risk Stratification, and Optimal Therapeutic Selection (For in-person participants only)

Manchester Grand Hyatt San Diego, Grand Hall B

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Manchester Grand Hyatt San Diego, Grand Hall D

Collaborating for Optimal Immune Thrombocytopenia Care: Uniting Disease, Treatment, and Patient-Centered Considerations

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms

Marriott Marquis San Diego Marina, San Diego Ballroom AB

Emerging insights in biology and treatment approaches to Peripheral T cell Lymphomas (For in-person participants only)

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Evolving Treatment Paradigms for Patients with Hemoglobinopathies Room 30 A-E

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice Room 6A

Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts (For in-person participants)

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Maximizing Touchpoints to Empower Impactful Patient-Centered Care for Paroxysmal Nocturnal Hemoglobinuria

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

Medical Crossfire*: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Ballroom 20CD

Next Up: Conversations On Optimizing CD38 Antibody-Based Triplet Regimens for Early-Relapse Multiple Myeloma

Room 6B

Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL

Room 6DE

12:00 p.m. - 5:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Entrance at 5th and K St, Gaslamp Quarter

ASH Talks

Blood Buddies

Blood Drops

12:00 p.m. – 12:45 p.m. ASH-a-Palooza: Networking, Free Food, Blood Booths, and Welcome Performance by "Adverse Events Band" (Open to Trainees Only)

Gaslamp Quarter

12:45 p.m. – 1:00 p.m. ASH-a-Palooza: Trainee Council Chair Welcome (Open to Trainees Only)

Main Stage, Gaslamp Quarter

1:00 p.m. – 1:20 p.m. ASH-a-Palooza: ASH Talk #1 Artificial Intelligence and Data Science (Open to Trainees Only)

Main Stage, Gaslamp Quarter

2:00 p.m. - 5:00 p.m. Scientific Workshops

Scientific Workshop on Aging and Hematology

Room 7

Scientific Workshop on Challenges and Novel Technologies in Red Blood Cell Quality Assessment

Room 3

Scientific Workshop on Clonal Hematopoiesis

Room 8

Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm with Al Strategies for 'Real World' Patient Representation

Room 4

Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies Room 31

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Room 6CF

Scientific Workshop on Interplay Between Coagulation and Malignancy Room 24

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients

Room 2

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

Room 33

Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies

Room 28 A-D

2:10 p.m 2:30 p.m.	ASH-a-Palooza: ASH Talk #2 International
	Medical Graduates (Open to Trainees Only)

Main Stage, Gaslamp Quarter

3:00 p.m 3:50 p.m.	ASH-a-Palooza: Hearts of Hematology
	(HoH) (Open to Trainees Only)

Hasta Mañana Cantina, Gaslamp Quarter

3:00 p.m 6:00 p.m.	Satellite Symposia
--------------------	--------------------

A Step-By-Step Approach to CAR T-cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management Room 6B

Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia - What Clinicians Want to Know

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

Broadening the Impact of Whole-Genome and Transcriptome Sequencing (WG(T)S) in Hematological Malignancies (For in-person participants only)

Room 29

Cases and Conversations™: The Rationale for Utilizing Non-Factor Replacement Therapies in Hemophilia Care

Room 6A

Clinical assessment of gene therapies for hemophilia A and hemophilia B: Key takeaways for your practice

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Collaboration In Chronic ITP: Improving Quality Of Life And Patient Outcomes (For in-person participants only)

Ballroom 20AB

Complex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies

Marriott Marguis San Diego Marina, Marriott Grand Ballroom 2-4

Medical Crossfire": Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Ballroom 20CD

Medical Crossfire*: New Horizons in Acute Lymphoblastic Leukemia— How The Experts Apply New Evidence from AYA to Adult Scenarios

Room 30 A-E

Sharing Best Practices from the ALL/LBL Clinic: Navigating Patient-Centered Care with Asparaginase Therapies

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

Unleashing Emerging Therapies to Modify Myelofibrosis Pathogenesis: Shifting the Treatment Paradigm to Target Deeper Clinical and Molecular Responses

Room 6DE

4:00 p.m. – 4:15 p.m.	ASH-a-Palooza: Performance by Dr. Rizzo
	Rouce and Message from Committee on
	Training Chair (Open to Trainees Only)

Main Stage, Gaslamp Quarter

4:15 p.m 4:45 p.m.	ASH-a-Palooza: Blood Wars Trivia Game
	(Open to Trainees Only)

Main Stage, Gaslamp Quarter

5:00 p.m. – 7:00 p.m.	Trainee Welcome Reception (Open to
	Trainees Only)

Gaslamp Quarter

7:00 p.m. – 10:00 p.m. Satellite Symposia

Accelerating the Adoption of the Latest Evidence on Sequencing Therapies for Multiple Myeloma Across Practice Settings

Room 6DE

How We Do It": New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Room 30 A-E

Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Room 6A

Show Me the Data™: Pushing CAR T's Forward Across Lymphoid Malignancies... Accelerating Access in the Community and Treatment Strategies for the Road Ahead

Ballroom 20CD

SATURDAY, DECEMBER 7, 2024

7:00 a.m. – 6:00 p.m. Registration and Materials Pick Up (for in-person participants)

Ballroom 20 Lobby

Manchester Grand Hyatt San Diego, Hotel Main Lobby Marriott Marquis San Diego Marina, East Lobby Lounge

7:00 a.m. – 6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)

Sails Pavilion

7:00 a.m. – 7:45 a.m. ASH Yoga (for in-person participants)

ASH Park @ The Plaza

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

Sails Pavilion

8:00 a.m. - 9:00 a.m. How I Treat (Ticketed Sessions)

How I Treat: Acute Lymphoblastic Leukemia Incorporating New Treatment Options (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 314

How I Treat: Challenges and Management of Cancer Associated Thrombosis (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 300

How I Treat: Follicular Lymphoma Incorporating New Treatment Options (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 313

How I Treat: Gene Therapy in Sickle Cell Disease (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 311

How I Treat: Options for Long-Term Management of Hemophilia (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 310

8:00 a.m. - 9:00 a.m. Industry Forums

Nonmalignant Hematologic Disorders Forum: Deeper Dive Into PNH, aHUS, and ITP

Room 4

8:00 a.m. - 9:00 a.m. Meet the Scientist (Ticketed Sessions)

Justin Eyquem, PhD Meet the Scientist: CAR-T and CAR-NK in Therapy of Hematologic Malignancies (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon F

Hanna KA Mikkola, MD, PhD Meet the Scientist: Production of Functional Hematopoietic Stem Cells from Pluripotent Cells (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon D

Antonella Nai, PhD Meet the Scientist: Transferrin Receptor Physiology and Iron Metabolism (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon C

Stephen D. Nimer, MD Meet the Scientist: Therapy-Related Myeloid Neoplasms (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Agua Salon AB

Esther A. Obeng, MD, PhD Meet the Scientist: Epigenetic Regulation in Bone Marrow Failure (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon E

9:00 a.m. – 9:30 a.m. Meet the *Blood Vessels, Thrombosis & Hemostasis* Editors

Halls G-H - Blood Journals Studio

9:00 a.m. – 9:30 a.m. Coffee Break in the Poster Hall (for inperson participants)

Halls G-H

9:00 a.m. – 9:30 a.m. Health Equity Studio

Advocating for Language Justice in Hematology Sails Pavilion - ASH Health Equity Studio

9:00 a.m. - 7:30 p.m. Poster Session I - Viewing

Halls G-H

9:05 a.m. – 9:15 a.m. ASH Wellness Studio

Your New Superpower: Uncertainty Comfort (for in-person participants)
Sails Pavilion - ASH Wellness Studio

9:15 a.m. – 9:25 a.m. ASH Wellness Studio

Believing Beyond Burnout (for in-person participants)
Sails Pavilion - ASH Wellness Studio

9:30 a.m. - 10:45 a.m. Education Program

A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

AML M&Ms: How to Integrate Mutations and MRD Data

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

Moving the Needle in Hodgkin Lymphoma

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease

Room 6CF

Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

Optimizing Non-Curative Therapies for Sickle Cell Disease Room 33

The Expanding Landscape of Treatment for ITP

Room 28 A-D

9:30 a.m. - 10:45 a.m. Scientific Program

Scientific Committee on Plasma Cell Neoplasia: Proteo-Genomics to Better Study Multiple Myeloma Biology and Evolution

Marriott Marquis San Diego Marina, San Diego Ballroom AB

Scientific Committee on Red Cell Biology: Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology

Manchester Grand Hyatt San Diego, Grand Hall D

Scientific Committee on Transfusion Medicine: Understanding the Impact of Donor and Recipient Metabolic Variability on Blood Transfusion Outcomes

Room 7

9:30 a.m. - 11:00 a.m. **Oral Abstract Sessions**

102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation

Room 29

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire Room 24

401. Blood Transfusion: Advancements in Transfusion Science Room 31

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Epigenetic and Metabolic Control of Hematopoiesis

Room 6DE

508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH

602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies

Room 6A

603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Determinants of Venetoclax Resistance and Response

Manchester Grand Hyatt San Diego, Grand Hall B

617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies Hall B

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Multi-omic Applications for Disease Evolution and Response to Therapy

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma?

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies

Ballroom 20AB

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD Ballroom 20CD

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies

Room 30

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies Room 6B

908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care Manchester Grand Hyatt San Diego, Grand Hall C

9:30 a.m. - 11:00 a.m. **ASH Clinical Practice Guidelines on** Pediatric Venous Thromboembolism (VTE)

Room 25

11:00 a.m. - 11:30 a.m. Health Equity Studio

Ensuring Equitable Access to Quality Care for Undocumented Immigrants and Mixed-Status Families

Sails Pavilion - ASH Health Equity Studio

11:00 a.m. - 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ The Plaza

11:00 a.m. - 12:30 p.m. **Open Time for Lunch**

San Diego Convention Center

11:00 a.m. - 5:00 p.m. **Exhibits Open**

Halls C-F

11:05 a.m. - 11:15 a.m. ASH Wellness Studio

Fix Your Seat (for in-person participants) Sails Pavilion - ASH Wellness Studio

ASH Poster Walk on Hemostasis and 11:15 a.m. - 12:15 p.m. Thrombosis: from Basic Concepts to Clinical Applications Hosted by Blood Vessels, Thrombosis & Hemostasis (for in-person participants)

Halls G-H - Blood Journals Studio

11:15 a.m. – 12:15 p.m. Career Development Lunch (Open to Trainees Only)

Manchester Grand Hyatt San Diego, Coronado Ballroom

11:15 a.m. – 12:15 p.m. Blood Presents: How to Get Published in a Peer-Reviewed Journal

Room 24

11:15 a.m. - 12:15 p.m. Grassroots Network Lunch

Marriott Marquis San Diego Marina, Marina Ballroom DE

11:20 a.m. - 11:30 a.m. ASH Wellness Studio

Smarter Phone Use (for in-person participants)

Sails Pavilion - ASH Wellness Studio

11:30 a.m. - 12:30 p.m. Product Theaters

A New Treatment Strategy in cGVHD

Room 5A

Beyond the Data: Long-Term Efficacy & Safety Integrated Analyses and a Patient's Journey with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Room 1A

CAR T Cell Therapy for Second-Line (2L) LBCL

Room 2

Choosing a Different Approach: Clinical and Nonclinical Factors for Adults with PNH on FABHALTA

Room 5B

Getting Started and Transitioning to Outpatient Care for Patients With Relapsed or Refractory Multiple Myeloma

Room 3

Learn About an Alternative Treatment for Certain B-cell Malignancies

Room 4

Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL

Room 1B

11:35 a.m. - 11:45 a.m. ASH Wellness Studio

Wellbeing Strategies for High Performance (for in-person participants)
Sails Pavilion - ASH Wellness Studio

12:00 p.m. - 1:30 p.m. Oral Abstract Sessions

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease

Room 11

322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations

Room 29

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Humoral Coagulation Factors: Venous Thrombosis and Beyond

Room 28 A-D

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP

Room 30

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies

Room 25

802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies

Room 33

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care

Room 31

12:30 p.m. - 1:30 p.m. 2024 Ham-Wasserman Lecture

Hall B

1:30 p.m. – 1:45 p.m. Company Showcases

Invivoscribe - Partnering with Pharma to Streamline Oncological Clinical Development

Room 5B

Using Multi-Cancer Early Detection Testing to Screen for Cancers That Lack Recommended Screenings

Room 4

1:30 p.m. - 2:00 p.m. Meet the Blood Editors

Halls G-H - Blood Journals Studio

1:30 p.m. – 2:00 p.m. Coffee Break in the Exhibit Hall (for in-person participants)

Halls C-F

1:30 p.m. - 2:00 p.m. Health Equity Studio

Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research

Sails Pavilion - ASH Health Equity Studio

1:35 p.m. - 1:45 p.m. ASH Wellness Studio

Tools for Success in Early Medical Practice (for in-person participants)
Sails Pavilion - ASH Wellness Studio

1:45 p.m. – 1:55 p.m. ASH Wellness Studio

Practical Approaches to Combating Burnout (for in-person participants)
Sails Pavilion - ASH Wellness Studio

1:45 p.m. – 2:00 p.m. Company Showcases

10x Genomics Company Showcase

Room 5A

Fresh, Fit and Fast: Pioneering the Future of Cell Therapy through Decentralized Manufacturing

Room 3

2:00 p.m. - 3:15 p.m. Education Program

Chasing Zebras: Navigating Rare Myeloid Neoplasms Manchester Grand Hyatt San Diego, Grand Hall C

Newly Diagnosed Multiple Myeloma: Many Choices and More Questions Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

Beyond TTP: "Atypical" TMAs for the Hematologist

Room 24

Hematologic Challenges at the End-of-Life

Room 6A

Hematologic Management of the Patient with Heavy Menstrual Bleeding Room 28 A-D

Integrating New Therapies into the Management of Classical Heme Disorders

Room 30

Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios

Room 29

2:00 p.m. - 3:15 p.m. Scientific Program

Scientific Committee on Immunology and Host Defense: Host Factors Driving Anti-Leukemia Immunotherapy Outcomes

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

2:00 p.m. – 3:30 p.m. Distinguished Abstract Achievement Award Ceremony

Halls G-H - Blood Journals Studio

2:00 p.m. - 3:30 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche

Room 33

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease Room 31

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease Hall B

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets and Endothelium in Thrombotic Disorders

Room 25

503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation

Manchester Grand Hyatt San Diego, Grand Hall D

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms

Room 7

603. Lymphoid Oncogenesis: Basic: Molecular Insights into Acute Lymphoblastic Leukemias

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies

Manchester Grand Hyatt San Diego, Grand Hall B

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML

Ballroom 20CD

617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Targets in Aggressive Lymphomas

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Therapies for Mantle Cell Lymphoma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Personalized and Molecular Approaches in Myeloproliferative Neoplasms: Risk Stratification and Therapeutic Implications Ballroom 20AB

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes

Marriott Marquis San Diego Marina, San Diego Ballroom AB

653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

701. Experimental Transplantation: Basic and Translational: GVHD, Mucosal Immunology and the Microbiome

Room 6B

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Adult Patients
Room 6CF

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: AI Approaches to Drug Development, Classification and Outcomes

Room 6DE

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money! Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

907. Outcomes Research: Plasma Cell Disorders: Quality Matters and

Key Outcomes in Multiple Myeloma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

2:00 p.m. – 3:30 p.m. Symposium on Quality: Treating Fairly
- The Role of Quality Improvement in
Combating Health Care Disparities

Room 11

3:30 p.m. – 3:45 p.m. Clinical Trial Showcase:

The ALPHA3 Trial: Harnessing the Potential of Combining Next-Generation "Off-the-Shelf" Investigational CAR T Product with Advanced MRD Testing to Improve Outcomes in First Line LBCL

Room 4

3:30 p.m. - 3:45 p.m. Company Showcase:

Pixelgen Technologies: The Spatial Organization of Surface Proteins of Single Cells in Myelodysplastic Syndrome for Diagnostics and Drug Target Discovery by Molecular Pixelation (MPX)

Room 5B

3:30 p.m. – 4:00 p.m. Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work

Halls G-H - Blood Journals Studio

3:30 p.m. – 4:00 p.m. Coffee Break in the Exhibit Hall (for in-person participants)

Halls C-F

3:30 p.m. - 4:00 p.m. Health Equity Studio

Achieving Equity and Inclusion in Clinical Trial Enrollment: Challenges and Opportunities

Sails Pavilion - ASH Health Equity Studio

3:35 p.m. - 3:45 p.m. ASH Wellness Studio

The Performance Paradox (for in-person participants)
Sails Pavilion - ASH Wellness Studio

3:45 p.m. – 3:55 p.m. ASH Wellness Studio

The Anxious Achieving Brain (for in-person participants)
Sails Pavilion - ASH Wellness Studio

4:00 p.m. – 5:15 p.m. Education Program

Handling Bad News: How to Best Manage TP53 Myeloid Disease? Manchester Grand Hyatt San Diego, Grand Hall D

Monoclonal Gammopathies: When the Clone Is More Than a Positive Laboratory Finding

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

Room 28 A-D

4:00 p.m. – 5:15 p.m. Scientific Symposium: Interface of Complement and Coagulation

Room 33

4:00 p.m. - 5:30 p.m. Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Tools and Biomarkers for Improving Sickle Cell Disease Treatments

Room 30

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis in Pregnancy and Childhood

Room 29

508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Room 11

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

622. Lymphomas: Translational – Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS

Ballroom 20CD

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS

Ballroom 20AB

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions

Marriott Marquis San Diego Marina, San Diego Ballroom AB

702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells

Manchester Grand Hyatt San Diego, Grand Hall C

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients

Room 6DE

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Monitoring, Understanding and Optimizing GVHD Interventions

Room 6CF

902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments

Room 6B

904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Determinants of Health Equity Across the Spectrum

Room 31

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations

Room 6A

908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies

Manchester Grand Hyatt San Diego, Grand Hall B

4:00 p.m. – 5:30 p.m.	Artificial Intelligence in Hematology: From
	Generative AI to Ethics and Applications

Hall B

4:00 p.m. – 5:30 p.m.	ASH Research Collaborative Multiple
	Myeloma Network: Accelerating Research
	and Collaborative Clinical Care through
	Real-World Evidence Generation

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

4:00 p.m. – 5:35 p.m.	Scientific Program
-----------------------	--------------------

Scientific Committee on Blood Disorders in Childhood & Scientific Committee on Lymphoid Neoplasia: JOINT SESSION: Molecular Characterization of Lymphomas in Children, Adolescents, and Young Adults

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Scientific Committee on Hematopoiesis & Scientific Committee on Stem Cells and Regenerative Medicine: JOINT SESSION: The Fuel & Physiology of Regeneration

Room 24

Scientific Committee on Megakaryocytes and Platelets & Scientific Committee on Thrombosis & Vascular Biology: JOINT SESSION: Newly Described Functions in the Vascular Space

Room 25

5:30 p.m. – 7:30 p.m.	Welcome Reception in the Poster Hall (for in-person participants)

Halls G-H

5:30 p.m. – 7:30 p.m.	Poster Session I – Presentations
	(for in-person participants)

Halls G-H

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1069–1086) 102. Iron Homeostasis and Biology: Poster I (1087–1093)
- 112. Thalassemia and Globin Gene Regulation: Poster I (1094–1099)

- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1100–1115)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1116–1143)
- 201. Granulocytes, Monocytes, and Macrophages: Poster I (1144–1154)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1155–1163)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster I (1164–1173)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1174–1193)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1194–1203)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster I (1204–1215)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I (1216–1223)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I (1224–1235)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I (1236–1244)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1245–1264)
- 401. Blood Transfusion: Poster I (1265-1270)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1271–1281)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I (1282–1296)
- 506. Bone Marrow Microenvironment: Poster I (1297–1306)
- 508. Bone Marrow Failure: Acquired: Poster I (1307–1323)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1324–1332)
- 602. Myeloid Oncogenesis: Basic: Poster I (1333-1356)
- 603. Lymphoid Oncogenesis: Basic: Poster I (1357-1371)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1372–1401)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1402–1419)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1420–1431)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I (1432–1450)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1451–1468)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1469–1494)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I (1495–1504)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I (1505–1527)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I (1528–1567)
- 618A. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I (1568–1576)

621. Lymphomas: Translational – Molecular and Genetic: Poster I (1577–1607)

622. Lymphomas: Translational – Non-Genetic: Poster I (1608–1625)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1626–1661)

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I (1662–1674)

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I (1675–1693)

626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I (1694–1718)

627. Aggressive Lymphomas: Pharmacologic Therapies: Poster I (1719–1742)

628. Aggressive Lymphomas: Cellular Therapies: Poster I (1743–1750)

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1751–1764)

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1765–1780)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1781–1808)

636. Myelodysplastic Syndromes: Basic and Translational: Poster I (1809–1817)

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I (1818–1845)

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I (1846–1854)

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (1855–1875)

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (1876–1909)

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (1910–1927)

653. Multiple Myeloma: Clinical and Epidemiological: Poster I (1928–1972)

654. Multiple Myeloma: Pharmacologic Therapies: Poster I (1973-2000)

655. Multiple Myeloma: Cellular Therapies: Poster I (2001–2009)

701. Experimental Transplantation: Basic and Translational: Poster I (2010–2023)

702. CAR-T Cell Therapies: Basic and Translational: Poster I (2024–2053)

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I (2054–2063)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I (2064–2088)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I (2089–2100)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I (2101–2134)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I (2135–2157)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I (2158–2177)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2178–2193)

801. Gene Therapies: Poster I (2194-2202)

802. Chemical Biology and Experimental Therapeutics: Poster I (2203–2210)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I (2211–2236)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I (2237–2250)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2251–2264)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I (2265–2289)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I (2290–2300)

904. Outcomes Research: Hemoglobinopathies: Poster I (2301–2313)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2314–2332)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I (2333–2377)

907. Outcomes Research: Plasma Cell Disorders: Poster I (2378–2411g)

908. Outcomes Research: Myeloid Malignancies: Poster I (2412–2438)

909. Education, Communication, and Workforce: Poster I (2439–2448)

6:30 p.m. – 8:00 p.m. Hematology Inclusion Pathway (HIP) Oral Presentations - Classical Hematology

Marriott Marquis San Diego Marina, Marina Ballroom E

6:30 p.m. – 8:00 p.m. Hematology Inclusion Pathway (HIP) Oral Presentations - Health Services Outcomes

Marriott Marquis San Diego Marina, Marina Ballroom F

6:30 p.m. – 8:00 p.m. Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology

Marriott Marquis San Diego Marina, Marina Ballroom D

8:00 p.m. – 9:00 p.m. Hematology Inclusion Pathway (HIP)
Networking Reception

Marriott Marquis San Diego Marina, Marina Ballroom G

SUNDAY, DECEMBER 8, 2024

7:00 a.m. – 5:00 p.m. Registration and Materials Pick Up (for inperson participants)

Ballroom 20 Lobby

7:00 a.m. – 6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)

Sails Pavilion

7:00 a.m. – 9:00 a.m. ASH Foundation Run/Walk

San Diego Bayfront Park and South Embarcadero

7:30 a.m. – 9:30 a.m. Medical Educators Symposium

Marriott Marquis San Diego Marina, Marina Ballroom FG

8:00 a.m. – 9:00 a.m. ASH Pos

ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal Function to Malignancy Hosted by *Blood Neoplasia* (for in-person participants)

Halls G-H - Blood Journals Studio

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central

(for in-person participants)

Sails Pavilion

8:00 a.m. - 9:00 a.m. How I Treat (Ticketed Sessions)

How I Treat: A Personal Journey with Castleman Disease (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 300

How I Treat: Acute Myeloid Leukemia with Targetable Mutations (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 314

How I Treat: Adult Outpatient CAR T Therapy (ticketed session for inperson participants)

Hilton San Diego Bayfront, Aqua 311

How I Treat: Newly Diagnosed Multiple Myeloma (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 313

How I Treat: Sickle Cell Disease in Africa (ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua 310

8:00 a.m. - 9:00 a.m. Industry Theaters

KMT2A Rearrangements in Acute Leukemia

Room 5A

The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research

Room 1A

8:00 a.m. – 9:00 a.m. Meet the Scientist (Ticketed Sessions)

Sergei Doulatov, PhD Meet the Scientist: Pluripotent Stem Cell-Based Modeling of Hematologic Malignancies (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon E

Marina Konopleva, MD, PhD Meet the Scientist: Mechanisms of Drug Resistance in Acute Myeloid Leukemia (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon AB

Sean J. Morrison, PhD Meet the Scientist: Microenvironment Regulation of Hematopoietic Stem Cells (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon D

Laurent O. Mosnier, PhD Meet the Scientist: What Does the Future Hold for Management of Hemophilia? (Ticketed session for in-person participants)

Hilton San Diego Bayfront, Aqua Salon C

8:00 a.m. - 9:00 a.m. Product Theaters

Options When a Matched Allogeneic-HCT Source is Not Available Room 5B

Redefining Frontline Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Room 1B

The Science Behind HYMPAVZI (Marstacimab-hncq): Introducing an Innovative Treatment Option from Pfizer

Room 4

Transforming aTTP/iTTP Treatment and Management

Room 2

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL

Room 3

9:00 a.m. – 9:30 a.m. Meet the *Blood Neoplasia* Editors

Halls G-H - Blood Journals Studio

9:00 a.m. – 9:30 a.m. Coffee Break in the Poster Hall (for inperson participants)

Halls G-H

9:00 a.m. – 9:30 a.m. Health Equity Studio

Combating Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data

Sails Pavilion - ASH Health Equity Studio

9:00 a.m. – 8:00 p.m. Poster Session II - Viewing

Halls G-H

9:05 a.m. – 9:15 a.m. ASH Wellness Studio

Reframing "the Grind" (for in-person participants)

Sails Pavilion - ASH Wellness Studio

9:15 a.m. – 9:25 a.m. ASH Wellness Studio

The Appreciation Prescription (for in-person participants)

Sails Pavilion - ASH Wellness Studio

9:30 a.m. – 10:45 a.m. Education Program

MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy
Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

Overcoming Post-transplant Relapse: How to Win the Battle Royale Room 6CF

9:30 a.m. - 10:45 a.m. Scientific Program

Scientific Committee on Hematopathology & Clinical Laboratory Hematology: Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies.

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

9:30 a.m. - 10:45 a.m.

Scientific Symposium: Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

9:30 a.m. - 11:00 a.m. Oral Abstract Sessions

112. Thalassemia and Globin Gene Regulation: We're Going to Catch a Big One: Towards Targeted Therapies in Thalassemia Room 31

201. Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia

Manchester Grand Hyatt San Diego, Grand Hall D

301. Platelets and Megakaryocytes: Basic and Translational: Megakarocyte and Platelet Biology: From Formation to Function Room 28 A-D

321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag

Room 25

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism, Differentiation and Inflammation Room 7

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models Room 11

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

624. Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma

Ballroom 20AB

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas Ballroom 20CD

626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice
Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG

634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents

Manchester Grand Hyatt San Diego, Grand Hall C

653. Multiple Myeloma: Clinical and Epidemiological: Cellular and

Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing

Room 6A

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation

Room 6B

801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside

Room 30

900. Health Services and Quality Improvement: Hemoglobinopathies: Navigating and Optimizing Healthcare Systems

Hall B

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity

Manchester Grand Hyatt San Diego, Grand Hall B

9:30 a.m. – 11:00 a.m. ASH Clinical Practice Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

9:30 a.m. – 11:00 a.m. Health Equity Symposium: Race, Structural Racism and the Social Determinants of Health in Hematology

Room 6DE

9:30 a.m. - 11:00 a.m. Sickle Cell Disease Centers Session

Room 33

9:30 a.m. - 11:05 a.m. Scientific Program

Scientific Committee on Bone Marrow Failure & Scientific Committee on Transplantation Biology & Cellular Therapies: JOINT SESSION: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology

Room 29

Scientific Committee on Epigenetics and Genomics & Scientific Committee on Myeloid Neoplasia: JOINT SESSION: Emerging Therapeutic Strategies Targeting Epigenetic, Transcriptomic, and Metabolic Mechanisms

Room 24

10:00 a.m. – 5:00 p.m. Exhibits Open

Halls C-F

11:00 a.m. - 11:30 a.m. Health Equity Studio

Strengthening the Provider-Patient Relationship: A Guide to Building Trust

Sails Pavilion - ASH Health Equity Studio

11:00 a.m. – 12:30 p.m. Complimentary Light Lunch in the Exhibit Hall (for in-person participants)

Halls C-F

11:00 a.m. – 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

ASH Park @ The Plaza

11:00 a.m. – 12:30 p.m. LGBTQIA+ Community Networking Brunch (for in-person participants)

Manchester Grand Hyatt San Diego, Coronado DE

11:05 a.m. - 11:15 a.m. ASH Wellness Studio

Walking Wonders (for in-person participants)

Sails Pavilion - ASH Wellness Studio

11:15 a.m. – 12:15 p.m. ASH Poster Walk on What's New in Complement-Related Diseases? Hosted by Blood Red Cells & Iron (for In-person participants)

Halls G-H - Blood Journals Studio

11:15 a.m. – 12:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

Creating a Laboratory and Clinical Research Program from Scratch Room 31

Time Management in Clinical and Research: There are only 24 hours in a day or Everyone Needs a System

Room 33

11:15 a.m. – 12:15 p.m. Blood Advances Presents: How to Peer Review a Scientific Paper

Room 24

11:15 a.m. – 12:30 p.m. ASH Clinicians in Practice (ACIP) Lunch
- The Role of Artificial Intelligence in
Hematology Practice: The Good, the Bad,
and the Ugly

Marriott Marquis San Diego Marina, Marina Ballroom DE

11:20 a.m. - 11:30 a.m. ASH Wellness Studio

How to Stand (for in-person participants)

Sails Pavilion - ASH Wellness Studio

11:30 a.m. - 12:30 p.m. Industry Theaters

Exploring CLL and MCL: Disease Overview, Latest Treatment Options and Unmet Needs

Room 4

Innovations in Hemophilia Research: Fitusiran, An Investigational Rebalancing Agent for the Treatment of Hemophilia

Room 5A

11:30 a.m. - 12:30 p.m. Product Theaters

A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS

Room 5B

Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP Room 3

Discover Gene Therapy as a Treatment Option for Hemophilia B
Room 1A

Discover the Exciting Details About a BCMA Bispecific for 4L+ RRMM Room 1B

11:30 a.m. - 12:30 p.m. Health Equity Rounds Lunch

Manchester Grand Hyatt San Diego, Coronado Ballroom AB

11:35 a.m. - 11:45 a.m. ASH Wellness Studio

The Performance Paradox (for in-person participants)

Sails Pavilion - ASH Wellness Studio

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Regulation of Erythropoiesis

Room 6DE

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Improving Outcomes in Sickle Cell Disease Around the World

Room 28 A-D

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science

Room 30

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes

Room 29

506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Normal Hematopoiesis

Room 7

624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy

Ballroom 20CD

626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL

Ballroom 20AB

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies

Marriott Marquis San Diego Marina, San Diego Ballroom AB

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases

Room 11

900. Health Services and Quality Improvement: Hemoglobinopathies: Empowering Choices: Navigating Shared Decision-Making for Patient-Centric Care

Room 25

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients

Room 6A

12:30 p.m. – 1:30 p.m.	ASH-EHA Joint Symposium
Hall B	

1:30 p.m 2:00	p.m. Healtl	n Equity	Studio
1.00 p 2.00	p	. Equity	Otaaio

Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research

Sails Pavilion - ASH Health Equity Studio

1:30 p.m. – 2:00 p.m.	Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, and the Outstanding Service
	Award

Hall B

1:30 p.m 4:00 p.m.	Simulcast of Announcement of Awards
	and Plenary Scientific Session
	(for in-person participants)

Room 6A

Room 28 A-D

Manchester Grand Hyatt San Diego, Grand Hall B Marriott Marquis San Diego Marina, San Diego Ballroom AB

2:00 p.m. – 4:00 p.m.	Plenary Scientific Session
Hall B	

4:00 p.m. – 4:30 p.m.	Meet the <i>Blood Advances</i> Editors
Hella C. H. Bland Javen	aala Ctudia

Halls G-H - Blood Journals Studio

4:00 p.m 4:30 p.m.	Coffee Break in the Exhibit Hall (for in-
	person participants)

Halls C-F

4:00 n m = 4:30 n m	Health Equity Studio	
4:00 p.m. – 4:30 p.m.	nealth Equity Studio	

Achieving Equity and Inclusion in Clinical Trial Enrollment: Challenges and Opportunities

Sails Pavilion - ASH Health Equity Studio

4:05 p.m. - 4:15 p.m. ASH Wellness Studio

Foundations of Mindfulness (for in-person participants)

Sails Pavilion - ASH Wellness Studio

4:15 p.m. - 4:25 p.m. ASH Wellness Studio

Cultivating Compassion (for in-person participants)

Sails Pavilion - ASH Wellness Studio

4:30 p.m. - 5:45 p.m. Education Program

Challenges in Cancer-Associated Thrombosis

Hall B

Follicular Lymphoma: Playing the Long Game

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

4:30 b.m. – 5:45 b.m. — Scienunc Program	4:30 p.m 5:45	p.m.	Scientific Program
--	---------------	------	--------------------

Scientific Committee on Hemostasis: Paradigm Shifts in Hemostasis: From Mechanisms to Therapies and Back

Room 28 A-D

4:30 p.m. – 5:45 p.m.	Scientific Symposium: Cellular Heterogeneity and Relationship to Clinical
	Outcomes

Room 33

4:30 p.m. – 5:45 p.m.	Scientific Symposium: Newly Discovered Functions of Megakaryocytes and
	Platelets

Room 29

4:30 p.m. – 5:45 p.m. Race and Ancestry in Precision Medicine

Room 6DE

4:30 p.m 5:45	n m	Education St	ootlight Sessions
4:30 p.III 5:45	p.III.	Education Sp	Joungin Sessions

Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All

Room 30

The Clone Wars: Myeloid Neoplasia Risk in Clonal Hematopoiesis Manchester Grand Hyatt San Diego, Grand Hall C

Biology Underlying Disparities in Lymphoid Malignancies

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Inflammation as a Regulator of Hematopoietic Homeostasis in Disease and Clonal Selection

Room 7

4:30 p.m. - 6:00 p.m. Oral Abstract Sessions

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications – Lessons from Preclinical Models

Room 31

Prognosis

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

622. Lymphomas: Translational - Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis

Manchester Grand Hyatt San Diego, Grand Hall D

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS

Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond

Marriott Marguis San Diego Marina, Pacific Ballroom Salons 21-22

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity

Marriott Marguis San Diego Marina, Marriott Grand Ballroom 2-4

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities

Room 6B

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA

Room 6A

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis

Room 6CF

907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes

Marriott Marquis San Diego Marina, San Diego Ballroom AB

4:30 p.m 6:00 p.m.	ASH Clinical Practice Guidelines on
	Amyloidosis

Manchester Grand Hyatt San Diego, Grand Hall B

4:30 p.m. – 6:00 p.m.	Symposium for Mid-Career Hematologists	
Room 24		
4:30 p.m. – 6:30 p.m.	Systems-Based Hematology Education and Networking Session: Anticoagulation	
	Stewardship and Al-Assisted Management	
Room 25		

Halls G-H

6:00 p.m. - 8:00 p.m.

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2449–2466)

person participants)

Poster Session II - Presentations (for in-

112. Thalassemia and Globin Gene Regulation: Poster II (2474-2479)

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2480-2494)

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2495–2522)

102. Iron Homeostasis and Biology: Poster II (2467–2473)

201. Granulocytes, Monocytes, and Macrophages: Poster II (2523-2533)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2534-2541)

301. Platelets and Megakaryocytes: Basic and Translational: Poster II (2542 - 2550)

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2551-2570)

321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (2571-2581)

322. Hemophilia A and B: Clinical and Epidemiological: Poster II (2582-

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II (2594-

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II (2602-2613)

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II (2614-2621)

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2622-2641)

401. Blood Transfusion: Poster II (2642-2647)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (2648-2659)

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II (2660-2675)

506. Bone Marrow Microenvironment: Poster II (2676–2685)

508. Bone Marrow Failure: Acquired: Poster II (2686-2702)

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2703-2710)

602. Myeloid Oncogenesis: Basic: Poster II (2711-2734)

603. Lymphoid Oncogenesis: Basic: Poster II (2735–2748)

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2749-2778)

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2779-2796)

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2797-2808)

- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II (2809–2828)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2829–2846)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2847–2872)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II (2873–2883)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II (2884–2907)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II (2908–2947)
- 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster II (2948–2956)
- 621. Lymphomas: Translational Molecular and Genetic: Poster II (2957–2987)
- 622. Lymphomas: Translational Non-Genetic: Poster II (2988-3006)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3007–3042)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II (3043–3055)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II (3056–3074)
- 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster II (3075–3099)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster II (3100–3123)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster II (3124–3132)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3133–3147)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3148–3163)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3164–3191)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster II (3192–3200)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II (3201–3228)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II (3229–3236)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3237–3257)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3258–3291)

- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3292–3309)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster II (3310–3353)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster II (3354–3381)
- 655. Multiple Myeloma: Cellular Therapies: Poster II (3382–3390)
- 701. Experimental Transplantation: Basic and Translational: Poster II (3391–3404)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster II (3405–3433)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II (3434–3444)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II (3445–3469)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II (3470–3481)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II (3482–3514)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II (3515–3537)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II (3538–3557)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3558–3573)
- 801. Gene Therapies: Poster II (3574-3583)
- 802. Chemical Biology and Experimental Therapeutics: Poster II (3584–3591)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II (3592–3616)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II (3617–3630)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (3631–3644)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II (3645–3668)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II (3669–3680)
- 904. Outcomes Research: Hemoglobinopathies: Poster II (3681–3693)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (3695–3713)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II (3714–3758)
- 907. Outcomes Research: Plasma Cell Disorders: Poster II (3759-3792h)
- 908. Outcomes Research: Myeloid Malignancies: Poster II (3793–3818)
- 909. Education, Communication, and Workforce: Poster II (3819–3828)

MONDAY, DECEMBER 9, 2024

7:00 a.m. – 5:00 p.m.	Registration and Materials Pick Up (for in-person participants)
Ballroom 20 Lobby	

Ballroom 20 Lobby

7:00 a.m. – 6:00 p.m.	Learn, Engage, and Relax in ASH Central (for in-person participants)

Sails Pavilion

7:00 a.m. – 7:45 a.m.	ASH Yoga (for in-person participants)

ASH Park @ The Plaza

7:30 a.m. – 8:30 a.m. ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by <i>Blood Immunology</i> & Cellular Therapy (for in-
person participants)

Halls G-H - Blood Journals Studio

Coffee and Collaboration in ASH Central 8:00 a.m. - 9:00 a.m. (for in-person participants)

Sails Pavilion

8:00 a.m. - 9:00 a.m. **Product Theaters**

A First-In-Class Treatment for RRMM Patients

Room 3

8:15 a.m. - 8:45 a.m. **Health Equity Studio**

Combating Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data

Sails Pavilion - ASH Health Equity Studio

8:30 a.m. - 9:00 a.m. Meet the Blood Editors

Halls G-H - Blood Journals Studio

9:00 a.m. - 10:00 a.m. E. Donnall Thomas Lecture and Prize

Hall B

9:00 a.m. - 8:00 p.m. **Poster Session III - Viewing**

Halls G-H

10:00 a.m. - 10:30 a.m. Best Practices for Peer Review: ASH Clinical News interviews the Blood **Advances Editors**

Halls G-H - Blood Journals Studio

10:00 a.m. - 10:30 a.m. Coffee Break in the Exhibit Hall (for inperson participants)

Halls C-F

10:00 a.m. - 10:30 a.m. Health Equity Studio

Ensuring Equitable Access to Quality Care for Undocumented Immigrants and Mixed-Status Families

Sails Pavilion - ASH Health Equity Studio

10:00 a.m. - 2:00 p.m. **Exhibits Open**

Halls C-F

10:05 a.m. - 10:15 a.m. ASH Wellness Studio

Vitamin V: Visualize to Revitalize (for in-person participants) Sails Pavilion - ASH Wellness Studio

10:15 a.m. - 10:25 a.m. ASH Wellness Studio

The Encouragement Elixir (for in-person participants)

Sails Pavilion - ASH Wellness Studio

10:30 a.m. - 11:45 a.m. Education Program

A Shifting Landscape: Treatment of MCL

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

Anticoagulation SOS: Navigating Monitoring Conundrums Room 28 A-D

Challenges and Opportunities of Sickle Cell Care in Africa Room 31

It's a Different World: CLL 2024

10:30 a.m. - 11:45 a.m. Scientific Program

Scientific Committee on Myeloid Biology: Leveraging Single Cell Multi-Omics to Understand Mechanisms of Myeloid Lineage Expansion in Aging and Disease.

Room 6DE

10:30 a.m. - 11:45 a.m. Education Spotlight Sessions

Making a Match: Optimal Donor HLA and Beyond

Room 24

Smoldering Myeloma: A Case for Early Intervention?

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

10:30 a.m. - 11:45 a.m. Scientific Spotlight Sessions

Phylogenetic Reconstruction of Hematopoiesis Room 7

10:30 a.m. - 12:00 p.m. Oral Abstract Sessions

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP

Room 29

322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term

Room 30

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML

Manchester Grand Hyatt San Diego, Grand Hall B

621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative

Manchester Grand Hyatt San Diego, Grand Hall C

641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant

Room 6A

902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials

Marriott Marquis San Diego Marina, San Diego Ballroom AB

903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases

Room 6B

10:30 a.m. – 12:00 p.m.	Early Faculty Career Development Session
-------------------------	--

Room 25

12:00 p.m. – 12:30 p.m.	The ABCs of Publishing for Authors: The
	Hematologist interviews the Blood Editors

Halls G-H - Blood Journals Studio

Advocating for Language Justice in Hematology Sails Pavilion - ASH Health Equity Studio

12:00 p.m. – 1:15 p.m.	DEI Community Networking Lunch (for in-
	person participants)

Marriott Marquis San Diego Marina, Marina Ballroom D

12:00 p.m. – 1:30 p.m.	Complimentary Light Lunch in the Exhibit
	Hall (for in-person participants)

Halls C-F

12:00 p.m. – 1:30 p.m.	Live Music and Outdoor Lunch Seating (for
	in-person participants)

ASH Park @ The Plaza Sails Pavilion Terrace

12:05 p.m. - 12:15 p.m. ASH Wellness Studio

The Life-Changing Effect of Meditation (for in-person participants)
Sails Pavilion - ASH Wellness Studio

12:15 p.m. – 1:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

Building, Nurturing, and Sustaining a Research Program

Room 33

Setting up a Health Services and Outcomes Research Program Room 31

12:15 p.m. - 1:15 p.m. Industry Theaters

Energizing Red Blood Cells: The Latest Clinical Trial Data of Mitapivat in Thalassemia

Room 5A

12:15 p.m. – 1:15 p.m. Product Theaters

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Room 2

What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma?

Room 3

12:20 p.m. - 12:30 p.m. ASH Wellness Studio

Whistle While You Work (for in-person participants)

Sails Pavilion - ASH Wellness Studio

12:30 p.m. – 1:30 p.m.	ASH Poster Walk on Improving Access	
	to Cell and Gene Therapies Hosted by	
	Blood Global Hematology (for in-person	
	participants)	

Halls G-H - Blood Journals Studio

12:35 p.m. - 12:45 p.m. ASH Wellness Studio

H2O-M-G! (for in-person participants)

Sails Pavilion - ASH Wellness Studio

1:00 p.m. - 1:30 p.m.

1:30 p.m. - 2:30 p.m.

Strengthening the Provider-Patient Relationship: A Guide to Building

Health Equity Studio

Sails Pavilion - ASH Health Equity Studio

Hall B	
2:30 p.m. – 2:45 p.m.	Coffee Break in the Poster Hall (for inperson participants)

Ernest Beutler Lecture and Prize

Halls G-H

2:45 p.m. – 4:00 p.m. Education Program

Adult ALL Advancements: Optimizing Cure in 2024

Ballroom 20AB

Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?

Room 29

2:45 p.m. - 4:00 p.m. Education Spotlight Sessions

Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?

Room 24

2:45 p.m. - 4:00 p.m. Scientific Spotlight Sessions

Fulfilling the Promise: Pluripotent Stem Cells as Models for Human Blood Development and Disease

Room 31

Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis

Room 30

2:45 p.m. - 4:15 p.m. Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: The Effects of Sickle Cell Disease on Organ Function Room 33

201. Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis

Room 6DE

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis: Models, Risk Factors, and Outcomes

Room 28 A-D

506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease

Room 11

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma

Ballroom 20CD

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell diseases

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML

Manchester Grand Hyatt San Diego, Grand Hall C

618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment Manchester Grand Hyatt San Diego, Grand Hall B

621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS Manchester Grand Hyatt San Diego, Grand Hall D

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity

Room 6B

702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy

Room 6CF

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies

Hall B

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival Room 6A

907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies

Marriott Marquis San Diego Marina, San Diego Ballroom AB

2:45 p.m. – 4:15 p.m. ASH Quality Improvement Champions

Room 7

4:30 p.m. – 5:45 p.m. Education Program

Addressing Unmet Needs in T Cell Lymphomas

Ballroom 20AB

Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)
Room 24

Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist

Room 25

4:30 p.m. – 5:45 p.m. Scientific Program

Scientific Committee on Iron and Heme: Crosstalk Between Iron Homeostasis and Metabolism

Room 29

4:30 p.m. - 5:45 p.m. Scientific Symposia

Placing the Brakes on Accelerated Aging

Room 30

4:30 p.m. - 6:00 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease

Room 28 A-D

503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences

Manchester Grand Hyatt San Diego, Grand Hall C

602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia

Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma Ballroom 20CD

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6

617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World Manchester Grand Hyatt San Diego, Grand Hall B

622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapyfree Combinations for Relapsed Aggressive Lymphomas

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis

Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia

Manchester Grand Hyatt San Diego, Grand Hall D

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations

Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22

654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma

Hall B

655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells

Room 6CF

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Avoiding GVHD and Improving Outcomes

Room 6E

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse

801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies

Room 33

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease Room 6DE

4:30 p.m. – 6:00 p.m.	Special Symposium on the Basic Science
	of Hemostasis and Thrombosis

Room 31

4:30 p.m. – 6:00 p.m.	ASH Research Collaborative Data Hub
	Sickle Cell Disease Network: Accelerating
	Research and Collaborative Clinical Care
	through Real-World Evidence Generation

Room 11

6:00 p.m. – 7:30 p.m.	ASH Networking Reception for the Hemostasis and Thrombosis Community - Hosted by the <i>Blood Vessels, Thrombosis</i> and Hemostasis Journal (for in-person
	participants)

East Terrace (Upper Level)

6:00 p.m. – 8:00 p.m. Center for Sickle Cell Disease Initiatives Advancing Progress in Sickle Cell Disease Update and Reception: hosted by ASH an ASH Research Collaborative

Room 11 & West Terrace

6:00 p.m. – 8:00 p.m.	Poster Session III - Presentations (for in-	
	person participants)	

Halls G-H

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3829–3847)

102. Iron Homeostasis and Biology: Poster III (3848–3854)

112. Thalassemia and Globin Gene Regulation: Poster III (3855–3860)

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (3861–3876)

- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (3877–3904)
- 201. Granulocytes, Monocytes, and Macrophages: Poster III (3905–3916)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3917–3924)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster III (3925–3934)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3935–3953)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (3954–3964)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster III (3965–3976)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III (3977–3985)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III (3986–3998)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III (3999–4006)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4007–4026)
- 401. Blood Transfusion: Poster III (4027-4032)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4033–4044)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III (4045–4060)
- 506. Bone Marrow Microenvironment: Poster III (4061–4070)
- 508. Bone Marrow Failure: Acquired: Poster III (4071-4087)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4088–4096)
- 602. Myeloid Oncogenesis: Basic: Poster III (4098-4119)
- 603. Lymphoid Oncogenesis: Basic: Poster III (4120-4133)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (4134–4162)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (4163–4180)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (4181–4191)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III (4192–4211)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4212–4229)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4230–4254)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III (4255–4265)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III (4266–4288)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III (4289–4327)
- 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III (4328–4337)
- 621. Lymphomas: Translational Molecular and Genetic: Poster III (4338–4367)
- 622. Lymphomas: Translational Non-Genetic: Poster III (4368-4386)

- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4387–4422)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III (4423–4434)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III (4435–4453)
- 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4454–4478)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III (4479–4502)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster III (4503-4511)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4512–4525)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4526–4541)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4542–4569)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster III (4570–4578)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III (4579–4605)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III (4606–4613)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4614–4634)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4635–4668)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (4669–4685)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster III (4686–4729)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster III (4730-4757)
- 655. Multiple Myeloma: Cellular Therapies: Poster III (4758-4766)
- 701. Experimental Transplantation: Basic and Translational: Poster III (4767–4780)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster III (4781–4810)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III (4811–4821)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III (4822–4846)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III (4847–4858)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III (4859–4892)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III (4893–4915)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III (4916–4936)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4937–4952)
- 801. Gene Therapies: Poster III (4953–4962)
- 802. Chemical Biology and Experimental Therapeutics: Poster III (4963–4971)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III (4972–4996)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III (4997–5010)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (5011–5024)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III (5025–5048)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III (5049–5059)

904. Outcomes Research: Hemoglobinopathies: Poster III (5060–5072)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (5073–5091)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III (5092–5137) 907. Outcomes Research: Plasma Cell Disorders: Poster III (5138–5170h)

908. Outcomes Research: Myeloid Malignancies: Poster III (5171–5197) 909. Education, Communication, and Workforce: Poster III (5198–5207)

7:30 p.m. – 9:30 p.m. Women In Hematology Networking Event (for in-person participants)

Manchester Grand Hyatt San Diego, Coronado Ballroom & Terrace

TUESDAY, DECEMBER 10, 2024

7:00 a.m. – 1:30 p.m.	Registration and Materials Pick Up (for in-person participants)	9:30 a.m. – 9:45 a.m.	Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals		
Ballroom 20 Lobby			Meuais		
		Hall B			
7:00 a.m. – 2:45 p.m.	Learn, Engage, and Relax in ASH Central				
	(for in-person participants)	9:45 a.m. – 11:15 a.m.	2024 Presidential Symposium		
Sails Pavilion		Hall B	Hall B		
7:30 a.m. – 9:00 a.m.	Coffee and Late-Breaking Abstracts (for in-person participants)	11:15 a.m. – 11:30 a.m.	Business Meeting and Ceremonial Passing of the ASH President's Gavel		
Hall B		Hall B			
		11:30 a.m. – 1:00 p.m.	Best of ASH		
		Hall B			

WEDNESDAY, DECEMBER 11, 2024

1:00 a.m. – 11:55 p.m.	Binge-Watch Content on the Virtual	10:00 a.m. – 11:00 a.m.	ASH Poster Walks (Virtual Program)
	Platform		

Virtual Program

ASH Poster Walk on Hello, World! A Walk Through The Artificial Intelligence Network

Virtual Program

ASH Poster Walk on Health Equity in Hematology

Virtual Program

THURSDAY, DECEMBER 12, 2024

1:00 a.m. – 11:55 p.m. Binge-Watch Content on the Virtual Platform
--

Virtual Program

FRIDAY, DECEMBER 13, 2024

1:00 a.m 11:55 p.m.	Binge-Watch Content on the Virtual
	g
	Platform
	Fiationii

Virtual Program

MARQUEE SESSIONS

These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential Symposium. Many of the Marquee Sessions also honor distinguished leaders in the field through awards and special lectures.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

2024 Ham-Wasserman Lecture

Saturday 12:00 p.m. - 1:30 p.m. Hall B

Sickle Cell Disease in Developing Countries

Chair:

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York, NY

Speakers:

DIPTY LALIT JAIN, Indira Gandhi Government Medical College and Hospital, Arihant Multispeciality Hospital, Nagpur, India

SUNDAY

ASH-EHA Joint Symposium

Sunday 12:30 p.m. - 1:30 p.m. Hall B

Co-Chairs:

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York, NY

Antonio Medina Almeida, MD, PhD, Hospital da Luz Lisboa, Lisbon, Portugal

Speakers:

AMY E. DEZERN, MD, Johns Hopkins University, Baltimore, MD

Prognostication and risk stratification strategies for patients with myelodysplastic syndromes

Matteo Giovanni Della Porta, MD, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy Targeting of Cytopenias in Low-Risk MDS

Announcement of Awards: Wallace H. **Coulter Award for Lifetime Achievement** in Hematology, ASH Mentor Awards, **ASH Award for Leadership in Promoting** Diversity, and the Outstanding Service **Award**

1:30 p.m. - 2:00 p.m. Sunday Hall B

Chair:

Mohandas Narla, DSc. President, American Society of Hematology, New York Blood Center, New York,

Plenary Scientific Session 4

2:00 p.m. - 4:00 p.m. Sunday Hall B

Co-Chairs:

Belinda Avalos, MD, President-Elect, American Society of Hematology, Atrium Health Levine Cancer Institute, Charlotte, N

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York,

MONDAY

E. Donnall Thomas Lecture and Prize

Monday 9:00 a.m. – 10:00 a.m. Hall B

Hematopoietic Stem Cell Maintenance

Chair:

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York, NY

Speakers:

Sean J. Morrison, PhD, University of Texas Southwestern Medical Center, Dallas, TX

Ernest Beutler Lecture and Prize

Monday 1:30 p.m. – 2:30 p.m. Hall B

Controlling Hemoglobin Genes and Curing the Hemoglobin Disorders

Chair

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York, NY

Speakers:

STUART H. ORKIN, MD, Harvard Stem Cell Institute, Boston, MA *Basic Science*

JOHN TISDALE, MD, National Institutes of Health, Bethesda, MD Clinical/Translational Science

TUESDAY

Late-Breaking Abstracts Session

Tuesday 7:30 a.m. – 9:00 a.m. Hall B

Co-chairs:

JOHN KORETH, MD MBBS, PHD, DPHIL, Dana-Farber Cancer Institute, Harvard Medical School, Boston,

Rakhi Naik, MD, Johns Hopkins Hospital, Baltimore, MD

Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals

Tuesday 9:30 a.m. – 9:45 a.m. Hall B

Chair:

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York, NY

2024 Presidential Symposium

Tuesday 9:45 a.m. – 11:15 a.m. Hall B

Chair:

Mohandas Narla, DSc, President, American Society of Hematology, New York Blood Center, New York, NY

Speakers:

Patrick G. Gallagher, MD, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH

Mature Red Cell Membrane Disorders (including genome-wide screening and PK activators)

NAOMI TAYLOR, MD, National Institutes of Health, Bethesda, MD

Metabolism and Erythropoiesis (including metabolism, IDH mutations and relevance to MDS, sideroblastic anemia)

OLIVIER HERMINE, MD, PhD, IMAGINE Institute Paris France, Paris, France

Ineffective Erythropoiesis in Thalassemia and Sickle Cell Disease

Business Meeting and Ceremonial Passing of the ASH President's Gavel

Tuesday 11:15 a.m. - 11:30 a.m.

Hall B

Best of ASH 4

Tuesday 11:30 a.m. - 1:00 p.m.

Hall B

Co-Chairs:

Jennifer J. Trowbridge, PhD, The Jackson Laboratory, Bar Harbor, ME
Sant-Rayn Pasricha, MD, PhD, Walter and Eliza
Hall Institute of Medical Research, Fitzroy North,
Victoria, Australia

Notes:		

SCIENTIFIC SESSIONS

Scientific Program Co-Chairs:

SANT-RAYN PASRICHA, MD, PHD, Walter and Eliza Hall Institute of Medical Research, Fitzroy North, Victoria, Australia

JENNIFER J. TROWBRIDGE, PHD, The Jackson Laboratory, Bar Harbor, ME

Scientific Program

These sessions were developed by the Society's 18 Scientific Committees. They highlight emerging areas of science in the field of hematology and address topics referenced in ASH's Agenda for Hematology Research. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained.

Scientific Symposia

These sessions are crowd-sourced from the hematology community and feature transformative basic, translational, and clinical research poised to advance the field. There will be a panel discussion at the end of each session, during which questions from the audience will be entertained.

Spotlight Sessions

These sessions are crowd-sourced from the hematology community and cover niche topic areas that are of interest to specific communities. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained. There will be no Q&A after each individual speaker's presentation.

Scientific Workshops

The Scientific Workshops are interactive discussions of the latest science developments in a particular field of hematology.

All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

ASH Poster Walks

These sessions highlight posters selected for the Annual Meeting showcasing emerging science in hematology. Five poster walks will take place as in-person sessions in the Blood Journals Studio during the Annual Meeting, and two will take place virtually following the Annual Meeting.

ASH Poster Walks are not offered for CME credit.

Meet the Scientist (Ticketed)

These sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed lunch will be provided.

Tickets are restricted to medical and academic research professionals only and will be available on site on a first-come, first-served basis; no industry or financial businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 5, at the Ticketed Sessions Counter in the San Diego Convention Center, Ballroom 20 Foyer.

Ticket Prices (per session)

Active or International Members
and Non-Members \$75

Associate, International Associate,
Resident, Graduate/Medical
Student, Non-Member in Training,
Allied Health Professional, or
Honorary/Emeritus Members \$50

Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY

Scientific Workshop on Aging and Hematology

Friday	2:00 p.m. – 5:00 p.m.
	Room 7

Co-Chairs:

KAH POH LOH, MD, MBBCH BAO, MS, University of Rochester, Rochester, NY

MEGAN WEIVODA, PhD, Mayo Clinic, Rochester, MN

2:00 p.m. – 2:03 p.m.	Opening Remarks
2:03 p.m. – 2:45 p.m.	Cell Intrinsic Mechanisms Driving Hematologic Aging
2:46 p.m. – 3:28 p.m.	Adapting to the Aged Bone Marrow Microenvironment (BMME)
3:30 p.m. – 4:12 p.m.	The Contribution of Immune System to Hematologic Aging
4:15 p.m. – 4:57 p.m.	Translational Geroscience Biomarkers in Hematologic Malignancies

Closing Remarks

Scientific Workshop on Challenges and Novel Technologies in Red Blood Cell Quality Assessment

Friday	2:00 p.m. – 5:00 p.m. Room 3	

Co-Chairs:

4:57 p.m. – 5:00 p.m.

OSMAN BERK USTA, PHD, Massachusetts General Hospital, Boston, MA

UMUT GURKAN, PhD, Case Western Reserve University, Cleveland, OH

2:00 p.m. – 2:10 p.m.	Opening Remarks
2:10 p.m. – 3:25 p.m.	Challenges in Red Blood Cell Quality Testing
3:30 p.m. – 4:45 p.m.	Novel Technologies in Red Blood Cell Quality Assessment
4:50 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Clonal Hematopoiesis

Friday	2:00 p.m. – 5:00 p.m. Room 8

Co-Chairs:

Lambert Busque, MD, University of Montreal, Montreal, Quebec, Canada

MICHAEL R. SAVONA, MD, Vanderbilt University Medical Center, Nashville, TN

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:45 p.m.	Germline Predisposition for Clonal Hematopoiesis
2:45 p.m. – 3:50 p.m.	Clonal Hematopoiesis Lesions and Gene Editing
3:50 p.m. – 4:55 p.m.	Clinical Trial Approaches in Clonal Hematopoiesis
4:55 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm with AI Strategies for 'Real World' Patient Representation

Friday	2:00 p.m. – 5:00 p.m.
	Room 4

Co-Chairs:

UMA BORATE, MD, The Ohio State University, Columbus, OH

Stephanie Valer Seremetis, MD, Novo Nordisk, Plainsboro, NJ

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:52 p.m.	Trial Designs for Decentralized Clinical Trials
3:04 p.m. – 3:51 p.m.	Implementation of Decentral- ized Clinical Trials
4:03 p.m. – 4:55 p.m.	Data Management and Analysis of Decentralized Clinical Trials
4:55 p.m. – 5:00 p.m.	Closing Remarks

Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies

Friday	2:00 p.m. – 5:00 p.m.	
	Room 31	

Co-Chairs:

Stefano Rivella, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Nathan Singh, MD, Washington University School of Medicine, Saint Louis, MO

2:00 p.m. – 2:03 p.m.	Opening Remarks
2:03 p.m. – 3:00 p.m.	Understanding Immediate Toxicities of Current Gene and Cell Therapy Tools
3:15 p.m. – 4:14 p.m.	Emerging and Long-term Toxicities

4:14 p.m. – 4:53 p.m. How Do We Effectively Capture

Adverse Events, Particularly Infections Post Hematopoietic Stem Cell Transplantation?

4:55 p.m. – 5:00 p.m. Closing Remarks

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Friday 2:00 p.m. – 5:00 p.m. Room 6CF

Co-Chairs:

Lucy Godley, MD, PhD, Northwestern University, Chicago, IL

Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

2:00 p.m. – 2:02 p.m. Opening Remarks

2:02 p.m. – 2:41 p.m. Germline RUNX1-Mediated Dis-

ease

2:41 p.m. – 3:25 p.m. DDX41-Mediated Malignancies

3:26 p.m. – 4:06 p.m. Rapid Presentations of New

Insights

4:06 p.m. – 4:56 p.m. New Scientific Discoveries

4:56 p.m. – 5:00 p.m. Closing Remarks

Scientific Workshop on Interplay Between Coagulation and Malignancy

Friday 2:00 p.m. – 4:30 p.m. Room 24

Co-Chairs:

LISA BAUMANN KREUZIGER, MD, MS, Versiti, Milwaukee, WI

Jeffrey I. Zwicker, MD, Memorial Sloan Kettering Cancer Center, New York, NY

2:00 p.m. – 2:05 p.m. Opening Remarks

2:05 p.m. – 3:05 p.m. Tissue Factor(TF) and Tissue

Factor Pathway Inhibitor(TFPI) in Cancer Associated Thrombo-

sis

3:10 p.m. – 4:25 p.m. Thromboinflammation of Can-

cer Associated Thrombosis

4:25 p.m. – 4:30 p.m. Closing Remarks

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients

Friday 2:00 p.m. – 5:00 p.m. Room 2

Co-Chairs:

Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

AARON D. SCHIMMER, MD, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

2:00 p.m. – 2:05 p.m. Opening Remarks

2:05 p.m. – 2:50 p.m. Mitochondria and Metabolism -

Fundamental Discovery

3:05 p.m. – 3:50 p.m. Translational Research- Target-

ing Mitochondria and Metabo-

lism in Cancer

4:05 p.m. – 4:50 p.m. Mitochondria and Metabolism -

Blood Cancer Clinical Trials

4:55 p.m. – 5:00 p.m. Closing Remarks

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

Friday 2:00 p.m. – 5:00 p.m. Room 33

Co-Chairs:

Christina Glytsou, PhD, Rutgers University, Piscataway, NJ

Panagiotis Ntziachristos, PhD, Ghent University, Ghent, Belgium

Daniel Starczynowski, PhD, University of Cincinnati College of Medicine, Cincinnati, OH

2:00 p.m. – 2:03 p.m. Opening Remarks

2:03 p.m. – 2:44 p.m. Epigenetic And Chromatin

Mechanisms

2:44 p.m. – 3:25 p.m. Post-transcriptional Mecha-

nisms

3:35 p.m. – 4:16 p.m. Translational and Post-transla-

tional Mechanisms

4:17 p.m. – 4:58 p.m. Metabolic Mechanisms and

Mitochondria Biology

4:58 p.m. – 5:00 p.m. Closing Remarks

Opening Remarks

Examining the Malignant Ge-

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

2:00 p.m. – 2:05 p.m.

2:05 p.m. – 2:41 p.m.

Scientific Workshop on Understanding and
Overcoming Tumor-intrinsic Resistance to
CAR-T Therapies for Lymphoid Malignancies

CAR-T Therapies for Lymphoid Malignancies		F	nome in CAR-T Patients
Friday	2:00 p.m. – 5:00 p.m. Room 28 A-D	2:41 p.m. – 3:27 p.m.	Engaging Elusive Tumor Cells with Immune Effectors
Co-Chairs: Francesco Maura, MD, University of Miami, Miami,		3:42 p.m. – 4:18 p.m.	Functional Laboratory Studies of Resistance
FL JONATHAN H. SCHATZ, MD, University of Miami,	4:18 p.m. – 4:54 p.m.	CAR-19 Resistance in Acute Lymphoblastic Leukemia	
Miami, FL		4:54 p.m. – 5:00 p.m.	Closing Remarks

SATURDAY

Meet the Scientist: Production of Functional Hematopoietic Stem Cells from Pluripotent Cells (For in-person participants). ♠

Saturday 8:00 a.m. – 9:00 a.m. Aqua Salon D Hilton San Diego Bayfront

Speaker:

Hanna Mikkola, MD, PhD, University of California Los Angeles, Los Angeles, CA

Meet the Scientist: CAR-T and CAR-NK in Therapy of Hematologic Malignancies (For inperson participants). ♠

Saturday 8:00 a.m. – 9:00 a.m. Aqua Salon F Hilton San Diego Bayfront

Speaker:

Justin Eyquem, PhD, University of California San Francisco, San Francisco, CA

Meet the Scientist: Transferrin Receptor Physiology and Iron Metabolism (For in-person participants). ♠

Saturday 8:00 a.m. – 9:00 a.m. Aqua Salon C Hilton San Diego Bayfront

Speaker:

Antonella Nai, PhD, IRCCS San Raffaele Scientific Institute, Milan, Italy

Meet the Scientist: Epigenetic Regulation in Bone Marrow Failure (For in-person participants) 🗳

Saturday 8:00 a.m. – 9:00 a.m. Aqua Salon E Hilton San Diego Bayfront

Speaker:

ESTHER A. OBENG, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Meet the Scientist: Therapy-Related Myeloid Neoplasms (For in-person participants) ♠

Saturday 8:00 a.m. – 9:00 a.m. Aqua Salon AB Hilton San Diego Bayfront

Speaker:

Stephen D. Nimer, MD, Sylvester Comprehensive Cancer Center, Miami, FL

Scientific Program: Proteo-Genomics to Better Study Multiple Myeloma Biology and Evolution 4

Saturday 9:30 a.m. – 10:45 a.m.
San Diego Ballroom AB
Marriott Marquis San Diego Marina

Scientific Committee on Plasma Cell Neoplasia

Chair

Paola Neri, MD, PhD, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

Speakers:

Jan Kronke, MD, Charité – Universitätsmedizin Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany Defining the Proteomic Landscape of Multiple Myeloma

Francesco Maura, MD, University of Miami, Miami, FL

Genomic Drivers Involved in Myeloma Progression and Development of Resistance

Fabiana Perna, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Proteo-Genomics to Better Study Cell Surfaceome in Multiple Myeloma

Scientific Program: Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology 4

Saturday 9:30 a.m. – 10:45 a.m.

Grand Hall D

Manchester Grand Hyatt 9

Manchester Grand Hyatt San Diego

Scientific Committee on Red Cell Biology

Chair:

Peng Ji, MD, PhD, Northwestern University Medical School, Chicago, IL

Speakers:

Wassim El Nemer, PhD, French Blood Establishment (EFS), Marseille, France

Post-Transcriptional and Signaling Mechanisms in Ineffective Erythropoiesis in Hemoglobinopathies

ELIZABETH S. EGAN, MD, PhD, Stanford University School of Medicine, Stanford, CA Plasmodium Falciparum Influences Erythropoiesis

Sergei Doulatov, PhD, University of Washington School of Medicine, Seattle, WA Ineffective Erythropoiesis in Myeloid Neoplasms

Scientific Program: Understanding the Impact of Donor and Recipient Metabolic Variability on Blood Transfusion Outcomes **4**

Saturday 9:30 a.m. – 10:45 a.m. Room 7

Scientific Committee on Transfusion Medicine

Chair:

Cassandra Dorothy Josephson, MD, Johns Hopkins University School of Medicine and All Children's Hospital, Cancer and Blood Disorders Institute, St. Petersburg, FL

Speakers:

Angelo D'Alessandro, PhD, University of Colorado Anschutz Medical Campus, Aurora, CO Blood Donor Genetics and Biology Impact Red Blood Cell Transfusion Outcomes

Moritz Stolla, MD, Bloodworks Northwest Research Institute & University of Washington, Seattle, WA

Unveiling Platelet Metabolism: Implications for Storage and Transfusion

CHERYL LOBO, PhD, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY Impact of RBC Metabolism on the Disease Outcomes of Transfusion Dependent Patients

ASH Poster Walk on Hemostasis and Thrombosis: from Basic Concepts to Clinical Applications Hosted by *Blood Vessels*, *Thrombosis & Hemostasis* (For In-person Participants)

Saturday 11:15 a.m. – 12:15 p.m. Halls G-H - Blood Journals Studio

Chair:

Mettine Bos, PhD, Leiden University Medical Center, Leiden, Netherlands

Scientific Program: Host Factors Driving Anti-Leukemia Immunotherapy Outcomes 2

Saturday 2:00 p.m. – 3:15 p.m.
Pacific Ballroom Salons 18-19
Marriott Marquis San Diego Marina

Scientific Committee on Immunology and Host Defense

Chair:

ROBERT ZEISER, MD, Universitätsklinikum Freiburg, Freiburg, Germany

Speakers:

Catherine J. Wu, MD, Harvard Medical School, Boston, MA

Immune Microenvironment and GVL Effects

Takanori Teshima, MD, PhD, Hokkaido University, Sapporo, Hokkaido, Japan Firing Up COLD Tumor Microenvironment to Facilitate GVL

Franziska Blaeschke, MD, PhD, German Cancer Research Center (DKFZ), Heidelberg, Germany Knockin Sequences to Program Durable Cell Therapies Acting Against Leukemia Cells

Scientific Symposia: Interface of Complement and Coagulation **5**

Saturday 4:00 p.m. – 5:15 p.m. Room 33

Chair:

David Kavanagh, New Castle University, Newcastle Upon Tyne, England, United Kingdom

Speakers:

David Kavanagh, New Castle University, Newcastle Upon Tyne, England, United Kingdom Complement and the Prothrombotic State

Efthymia Vlachaki, Consultant Hematologist, Hippokrateon Hospital, Thessaloniki, Greece Complement Activation and Preclampsia

Lubka T. Roumenina, PhD, INSERM UMRS1138 Cordeliers Research Center, Paris, France Sickle Cell Disease and Complement Activation

Scientific Program: JOINT SESSION: Molecular Characterization of Lymphomas in Children, Adolescents, and Young Adults 2

Saturday 4:00 p.m. - 5:35 p.m.

Marriott Grand Ballroom 2-4 Marriott Marquis San Diego Marina

Scientific Committee on Blood Disorders in Childhood & Scientific Committee on Lymphoid Neoplasia

Co-Chairs:

JEAN L. KOFF, MD, MSc, Winship Cancer Institute of Emory University, Atlanta, GA

NICOLE KUCINE, MD, MS, Weill Cornell Medicine, New York, NY

Speakers:

LISA GIULINO ROTH, MD, Weill Cornell Medicine, New York, NY

Genomic Landscape in Hodgkin Lymphoma

Томоніко Аокі, MD, PhD, Princess Margaret Cancer Center, Toronto, Ontario, Canada Sequencing Technologies in Hodgkin Lymphoma

Birgit Burkhardt, MD, PhD, University Hospital Münster, Muenster, Germany Age-Related Molecular Changes in Burkitt Lymphoma BJÖRN CHAPUY, MD, Charité - University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany

Functional Genomics of Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults

Scientific Program: JOINT SESSION: The Fuel & Physiology of Regeneration 4

Saturday 4:00 p.m. – 5:35 p.m. Room 24

Scientific Committee on Hematopoiesis & Scientific Committee on Stem Cells and Regenerative Medicine

Co-Chairs:

Keisuke Ito, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Hanna Mikkola, MD, PhD, University of California Los Angeles, Los Angeles, CA

Speakers:

ROBERT SIGNER, PhD, University of California San Diego, La Jolla, CA

Proteomic Health in Hematopoietic Stem Cells

Marie-Dominique Filippi, PhD, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH Energy Management in Hematopoietic Stem Cells

NINA CABEZAS-WALLSCHEID, PHD, ETH Zürich, Zürich, Switzerland & Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Integrating Nutrients to Hematopoietic Stem Cell Regulation

Britta Will, PhD, Albert Einstein College of Medicine, Bronx, NY Iron Homeostasis in Hematopoietic Stem Cells

Scientific Program: JOINT SESSION: Newly Described Functions in the Vascular Space 5

Saturday 4:00 p.m. – 5:35 p.m. Room 25

Scientific Committee on Megakaryocytes and Platelets & Scientific Committee on Thrombosis & Vascular Biology

Co-Chairs:

Hartmut Weiler, PhD, Versiti Blood Research Institute, Milwaukee, WI

Lijun Xia, MD, PhD, Oklahoma Medical Research Foundation, Oklahoma City, OK

Speakers:

CLAUS NERLOV, PhD, University of Oxford, Oxford, England, United Kingdom *Platelets and Aging*

NICHOLA COOPER, MD, Imperial College, London, England, United Kingdom
New Insights in MK/PLT Functions and Diseases.

LISA LESNIEWSKI, PhD, University of Utah Health, Salt Lake City, UT

Age-Related Endothelial Function

ZE ZHENG, MBBS, PhD, Medical College of Wisconsin & Versiti Blood Research Institute, Milwaukee, WI Novel Functions of Fibrinolytic Factors in Shaping the Pro-Atherogenic Lipid Profile in Plasma.

SUNDAY

ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal Function to Malignancy Hosted by *Blood Neoplasia* (For In-person Participants)

Sunday 8:00 a.m. - 9:00 a.m.

Halls G-H - Blood Journals Studio

Chair:

Manja Wobus, University Hospital Dresden, TU Dresden, Dresden, Germany

Meet the Scientist: Pluripotent Stem Cell-Based Modeling of Hematologic Malignancies (For inperson participants) ♠

Sunday 8:00 a.m. - 9:00 a.m.

Aqua Salon E

Hilton San Diego Bayfront

Speaker:

Sergei Doulatov, PhD, University of Washington School of Medicine, Seattle, WA

Meet the Scientist: Microenvironment Regulation of Hematopoietic Stem Cells (For inperson participants) **5**

Sunday 8:00 a.m. - 9:00 a.m.

Agua Salon D

Hilton San Diego Bayfront

Speaker:

Sean J. Morrison, PhD, University of Texas Southwestern Medical Center, Dallas, TX

Meet the Scientist: What Does the Future Hold for Management of Hemophilia? (For in-person participants). ♠

Sunday 8:00 a.m. – 9:00 a.m.

Aqua Salon C

Hilton San Diego Bayfront

Speaker:

Laurent O. Mosnier, PhD, The Scripps Research Institute, La Jolla, CA

Meet the Scientist: Mechanisms of Drug Resistance in Acute Myeloid Leukemia (For inperson participants) ♠

Sunday 8:00 a.m. - 9:00 a.m.

Aqua Salon AB

Hilton San Diego Bayfront

Speaker:

Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Scientific Symposia: Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies 2

Sunday 9:30 a.m. – 10:45 a.m.

Marriott Grand Ballroom 11-13 Marriott Marquis San Diego Marina

Chair:

Melody Smith, MD, MS, Stanford University School of Medicine, Stanford, CA

Speakers:

FLORENT MALARD, MD, PHD, Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Centre de Recherche Saint-Antoine UMRs938, Paris, France Fecal Microbiota Transplant As a Strategy to Mitigate Infection and Gvhd Following TCT

Lawrence A. David, PhD, Duke University, Durham, NC

Deciphering Nutritional Intake from Metagenomic Data Using Computational Tools

Tessa Andermann, MD, MPH, University of North Carolina, Chapel Hill, Chapel Hill, NC Impact of Antibiotic Exposure on Outcomes Following TCT

Scientific Program: JOINT SESSION:
Therapeutic Gene Editing of Stem Cells in
Classical and Malignant Hematology **5**

Sunday 9:30 a.m. – 11:05 a.m. Room 29

Scientific Committee on Bone Marrow Failure & Scientific Committee on Transplantation Biology & Cellular Therapies

Co-Chairs:

Marcela V Maus, MD, PhD, Harvard University/ Massachusetts General Hospital, Boston, MA

Hannah Tamary, MD, Tel Aviv University, Israel, Ramat Gan, Israel

Speakers:

Justin Eyquem, PhD, University of California San Francisco, San Francisco, CA New Gene Editing Technologies

Paula Rio, PhD, IIS-FJD, UAM, Madrid, Spain Gene Editing for Fanconi Anemia Bone Marrow Failure

Pietro Genovese, PhD, Boston Children's Hospital, Boston, MA Stem Cell Gene Editing

Julia Skokowa, MD, PhD, University Hospital Tübingen, Tübingen, Germany Gene Editing for Severe Congenital Neutropenia – Current Advances and Critical Considerations Scientific Program: JOINT SESSION: Emerging Therapeutic Strategies Targeting Epigenetic, Transcriptomic, and Metabolic Mechanisms 2

Sunday 9:30 a.m. – 11:05 a.m. Room 24

Scientific Committee on Epigenetics and Genomics & Scientific Committee on Myeloid Neoplasia

Co-Chairs:

DINESH S. RAO, MD, PhD, University of California Los Angeles, Los Angeles, CA

Daniel Starczynowski, PhD, Cincinnati Children's Hospital, Cincinnati, OH

Speakers:

Hannah J. Uckelmann, PhD, Frankfurt Cancer Institute, Frankfurt, Germany Novel Inhibitors of Transcriptional Mechanisms

GERALD R. CRABTREE, MD, Stanford University, Stanford, CA

Heterobifunctional Molecules Targeting Epigenetic Mechanisms

Benjamin Cravatt, PhD, The Scripps Research Institute, San Diego, CA Inhibitors of RNAs and RNA Binding Proteins

 $\begin{array}{ll} \hbox{Courtney Jones, PhD, Cincinnati Children's Hospital,} \\ \hbox{Cincinnati, OH} \end{array}$

Targeting Metabolic Vulnerabilities

Scientific Program: Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies. **2**

Sunday 9:30 a.m. – 10:45 a.m.

Pacific Ballroom Salons 15-17 Marriott Marquis San Diego Marina

Scientific Committee on Hematopathology & Clinical Laboratory Hematology

Chair:

Megan S. Lim, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY

Speakers:

JÜRGEN MAXIMILIAN RULAND, Technical University of Munich, Munich, Germany Novel Insights in Metabolic Deregulation in Lymphoid Malignancies

PAOLO GALLIPOLI, MD, PHD, Queen Mary University of London, London, England, United Kingdom Targeting Metabolic Deregulation in Acute Myeloid Leukemia

Ananda Goldrath, PhD, Allen Institute, Seattle, WA Metabolic Control of T Cell Differentiation and Function in Tumor Immunity

ASH Poster Walk on What's New in Complement-Related Diseases? Hosted by *Blood Red Cells & Iron* (For In-person Participants)

Sunday 11:15 a.m. – 12:15 p.m.

Halls G-H - Blood Journals Studio

Chair:

ELENI GAVRIILAKI, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece

Scientific Symposia: Cellular Heterogeneity and Relationship to Clinical Outcomes 2

Sunday 4:30 p.m. - 5:45 p.m.

Room 33

Chair:

Craig Byersdorfer, MD, University of Pittsburgh, Pittsburgh, PA

Speakers:

ZINAIDA GOOD, PhD, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

Heterogeneity of CD19 CAR T Cells

Julia Carnevale, MD, University of California San Francisco, San Francisco, CA Purposeful Heterogeneity of CAR T Cells

Megan Levings, University of British Columbia, Canada, Vancouver, British Columbia, Canada Heterogeneity of Cells in Transplantation

Scientific Symposia: Newly Discovered Functions of Megakaryocytes and Platelets 2

Sunday 4:30 p.m. - 5:45 p.m.

Room 29

Chair:

Alessandra Balduini, MD, Tufts University, Medford, MA

Speakers:

Karin M. Hoffmeister, MD, Versiti Blood Research Institute, Milwaukee, WI Unveiling the Sweet Side of Platelet Formation:

Exploring the Pivotal Role of Glycans

TOBIAS PETZOLD, MD, MSc, Charité – Universitätsmedizin Berlin, Berlin, Germany Regulation of Platelet Function During Immobilty

Anna S. Nam, MD, Weill Cornell Medicine, New York, NY

Platelet ER Stress in Thrombosis

Spotlight Sessions: Biology Underlying Disparities in Lymphoid Malignancies **5**

Sunday 4:30 p.m. – 5:45 p.m.

Pacific Ballroom Salons 18-19 Marriott Marquis San Diego Marina

Speakers:

CHRISTOPHER R. FLOWERS, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX Tumor Sequencing to Investigate Disparities in Non-Hodgkin Lymphoma

Wendy Cozen, DO, MPH, UCI, School of Medicine, Orange, CA

Tumor Microenvironment Profiling to Investigate Disparities in Hodgkin Lymphoma and Multiple Myeloma

Spotlight Sessions: Inflammation as a Regulator of Hematopoietic Homeostasis in Disease and Clonal Selection 2

Sunday 4:30 p.m. – 5:45 p.m.

Room 7

Speakers:

Hitoshi Takizawa, PhD, Kumamoto University, Kumamoto, Japan

Inflammation As a Regulator of Hematopoietic Homeostasis in Disease

Serine Avagyan, MD, PhD, University of California San Francisco, San Francisco, CA Inflammation As a Regulator of Hematopoietic Homeostasis in Clonal Selection

Scientific Program: Paradigm Shifts in Hemostasis: From Mechanisms to Therapies and Back Δ

Sunday 4:30 p.m. – 5:45 p.m.

Room 28 A-D

Scientific Committee on Hemostasis

Chair

LAURENT O. MOSNIER, PhD, The Scripps Research Institute, La Jolla, CA

Speakers:

Annette von Drygalski, MD, PharmD, RMSK, University of California San Diego, San Diego, CA Paradigm Shifts in Hemophilia.

Daniël Verhoef, MSc, PhD, Leiden University Medical Center, Leiden, Netherlands Paradigm Shifts in the Reversal of DOACs

Cristina Puy Garcia, PhD, Oregon Health & Science University, Portland, OR New Mechanisms That May Fuel the Paradigm Shifts of the Future

MONDAY

ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by *Blood Immunology & Cellular Therapy* (For In-person Participants)

Monday 7:30 a.m. - 8:30 a.m.

Halls G-H - Blood Journals Studio

Chair:

Samer Al Hadidi, MD, MSc, University of Arkansas for Medical Sciences, Little Rock, AR

Spotlight Sessions: Phylogenetic Reconstruction of Hematopoiesis 5

Monday 10:30 a.m. – 11:45 a.m.

Room 7

Speakers:

Jyoti Nangalia, MBBChir, Wellcome Sanger Institute, Hinxton, England, United Kingdom Incorporating Genetic and Epigenetic Marks in Phylogenetic Reconstruction of Blood Cells

CHARLES GAWAD, MD, Stanford University, Memphis, TN/Novel Single-Cell Genomics Technologies to Reconstruct Phylogenetics of Human Blood Cells

Scientific Program: Leveraging Single Cell Multi-Omics to Understand Mechanisms of Myeloid Lineage Expansion in Aging and Disease. **2**

Monday 10:30 a.m. – 11:45 a.m.

Room 6DE

Scientific Sessions

Scientific Committee on Myeloid Biology

Chair:

Esther A. Obeng, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Speakers:

ELISA LAURENTI, PHD, University of Cambridge, Cambridge, England, United Kingdom Hematopoietic Stem Cell Commitment to the Myeloid Lineage

JOHN E. Dick, PhD, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Hematopoietic Stem Cell and Myeloid Progenitor Cell Response to Inflammation

 $\begin{array}{lll} {\bf Allon\ Moshe\ Klein,\ PhD,\ Harvard\ Medical\ School,} \\ {\bf Boston,\ MA} \end{array}$

Myeloid Progenitor and Mature Neutrophil Responses in Cancer

ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by *Blood Global Hematology* (For In-person Participants)

Monday 12:30 p.m. – 1:30 p.m.

Halls G-H - Blood Journals Studio

Chair:

Natalie Grover, MD, University of North Carolina, Chapel Hill, NC

Spotlight Sessions: Fulfilling the Promise: Pluripotent Stem Cells as Models for Human Blood Development and Disease 4

Monday 2:45 p.m. - 4:00 p.m.

Room 31

Speakers:

ELIZABETH W. NG, MD, Kansas City Cancer Center, Overland Park, KS

Hematopoietic Stem Cell Development from Human Pluripotent Stem Cells

EIRINI PAPAPETROU, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY Modeling Blood Disorders Using Human Pluripotent Stem Cells

Spotlight Sessions: Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis 4

Monday 2:45 p.m. – 4:00 p.m. Room 30

Speakers:

Janis L. Abkowitz, MD, University of Washington, Seattle, WA

Role of Heme and Iron in Effective and Ineffective Erythropoiesis

Radek C. Skoda, MD, University Hospital Basel, Basel, Switzerland

Impact of Iron Availability on Megakaryopoiesis

Scientific Symposia: Placing the Brakes on Accelerated Aging **5**

Monday 4:30 p.m. – 5:45 p.m. Room 30

Chair:

Ashley Rosko, MD, The Ohio State University, Columbus, OH

Speakers:

Els Mansell, PhD, Erasmus Medical Center, Rotterdam, Netherlands & Lund University, Lund, Sweden

Aging of Hematopoietic Stem Cells and Their Niche

CHRISTIN E. BURD, PhD, Ohio State, Columbus, OH Geroscience and Geri-Omics in Hematologic Malignancies

Marcel R.M. van den Brink, MD, PhD, City of Hope National Medical Center, Duarte, CA Targeting Rejuvenation Therapies to Decelerate Aging

Scientific Symposia: Special Symposium on the Basic Science of Hemostasis and Thrombosis **3**

Monday 4:30 p.m. – 6:00 p.m. Room 31

Co-Chairs:

Laurent O. Mosnier, PhD, The Scripps Research Institute, La Jolla, CA

HARTMUT WEILER, PHD, Versiti Blood Research Institute, Milwaukee, WI

LIJUN XIA, MD, PhD, Oklahoma Medical Research Foundation, Oklahoma City, OK

Speakers:

YESIM DARGAUD, MD, PhD, Hospital Edouard Herriot, Lyon, France

Efficacy of Platelet-Inspired Hemostatic Nanoparticles on Bleeding in Von Willebrand Disease Murine Model

JIEQING ZHU, PHD, Versiti Blood Research Institute, Milwaukee, WI

Platelet Integrin Structure, Function and Role in Disease

Yu Hou, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China Platelet TGFb1 in the Pathogenesis of Immune Thrombocytopenia Purpura

Amelia K. Haj, MD, PhD, Massachusetts General Hospital & The Broad Institute of MIT and Harvard, Harvard Medical School, Cambridge, MA Abstract 133: Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism

Scientific Program: Crosstalk Between Iron Homeostasis and Metabolism **5**

Monday 4:30 p.m. – 5:45 p.m. Room 29

Scientific Committee on Iron and Heme

Chair:

Francesca Vinchi, PhD, New York Blood Center, New York, NY

Speakers:

Antonella Nai, PhD, IRCCS San Raffaele Scientific Institute & Vita-Salute San Raffaele University, Milan, Italy

Iron, Erythropoiesis, and Glucose Metabolism

Wei Ying, PhD, University of California San Diego, La Jolla, CA

Iron and Lipid Metabolism

Norbert Leitinger, University of Virginia, Charlottesville, VA Heme and Macrophage Metabolism.

ASH Poster Walk on Hello, World! A Walk Through the Artificial Intelligence Network

Wednesday 10:00 a.m. – 11:00 a.m. Virtual Program

Chair:

Barbara Lam, MD, Beth Israel Deaconess Medical Center, Boston MA

ASH Poster Walk on Health Equity in Hematology

Wednesday 5:00 p.m. – 6:00 p.m. Virtual Program

Chair:

Warren Fingrut, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX

EDUCATION SESSIONS

EDUCATION SESSIONS

The Education Program will be held from Saturday, December 07, through Monday, December 09.

Education Program Co-Chairs:

JOHN KORETH, MD, MBBS, PHD, DPHIL, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

RAKHI P. NAIK, MD, Johns Hopkins University, Baltimore, MD

Education Program Sessions

Education Program Sessions are held Saturday, December 7, through Monday, December 9. A question-and-answer period will occur at the end of each individual speaker presentation. Chapters based on these sessions will be published in *Hematology* 2024, the ASH Education Program.

Spotlight Sessions

Spotlight Sessions are intended to provide an indepth review on specific scientific topics. Speakers will discuss current challenges and controversies in exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions.

Each 90-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

How I Treat Sessions (Ticketed)

How I Treat Sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed lunch will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 5, at the Ticketed Sessions Counter in the San Diego Convention Center, Ballroom 20 Foyer.

How I Treat Ticket Prices (per session)

Active or International Members and Non-Members

\$75

Associate, International Associate, Resident, Graduate/Medical Student, Non-Member in Training, Allied Health Professional, or Honorary/Emeritus Members

\$50

Attention Trainees!

A number of tickets for these sessions will be reserved for trainees. Proof of status as an Associate, International Associate, Resident, or Graduate/Medical Student member, or Non-Member in Training will be required to purchase a ticket.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

How I Treat: Acute Lymphoblastic Leukemia Incorporating New Treatment Options (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m.

Aqua 314

Hilton San Diego Bayfront

Speaker:

Marlise R. Luskin, MD, Dana-Farber Cancer Institute. Boston, MA

How I Treat: Challenges and Management of Cancer Associated Thrombosis (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m.

Aqua 300

Hilton San Diego Bayfront

Speaker:

Avi Leader, MD, Memorial Sloan Kettering Cancer Center, New York, NY

How I Treat: Follicular Lymphoma Incorporating New Treatment Options (ticketed session for inperson participants)

Saturday 8:00 a.m. - 9:00 a.m.

Aqua 313

Hilton San Diego Bayfront

Speaker:

CARLA CASULO, MD, Wilmot Cancer Institute, University of Rochester, Rochester, NY

How I Treat: Gene Therapy in Sickle Cell Disease (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m.

Aqua 311

Hilton San Diego Bayfront

Speaker:

JOHN TISDALE, MD, National Institutes of Health, Bethesda, MD

How I Treat: Options for Long-Term Management of Hemophilia (ticketed session for in-person participants)

Saturday 8:00 a.m. - 9:00 a.m.

Agua 310

Hilton San Diego Bayfront

Speaker:

CHRISTINE L. KEMPTON, MD, Emory University, Atlanta. GA

Education Program: A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs with Leukemia and Lymphoma

Saturday 9:30 a.m. - 10:45 a.m.

Marriott Grand Ballroom 2-4 Marriott Marquis San Diego Marina

Chair:

Maria Monica Gramatges, MD, PhD, Texas Children's Hospital, Houston, TX

Speakers:

Xu Ji, PhD, Emory University School of Medicine, Atlanta, GA

The Lasting Impact of the ACA: How Medicaid Expansion Reduces Outcome Disparities in AYAs With Leukemia and Lymphoma Puja J. Umaretiya, MD, Children's Medical Center Dallas, UT Southwestern, Dallas, TX Targeting Hardship: Poverty as a Modifiable Risk Factor in Childhood Leukemia and Lymphoma Treatment

Nupur Mittal, Rush University Medical Center, Chicago, IL

Sharing is Caring: A Network Collaborative Approach to Identify and Address Barriers in Accessing Clinical Trials in AYAs with Leukemia and Lymphoma

Education Program: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease

Saturday 9:30 a.m. – 10:45 a.m.

Room 6CF

Chair:

V. Koneti Rao, MD, National Institutes of Health, Bethesda, MD

Speakers:

V. Koneti Rao, MD, National Institutes of Health, Bethesda, MD

Beyond FAScinating: Advances in Diagnosis and Management of Autoimmune Lymphoproliferative Syndrome and Activated PI3 Kinase δ Syndrome

Charlotte Cunningham-Rundles, MD, PhD, Mount Sinai School of Medicine, New York, NY Common Variable Immunodeficiency (CVID): Hematologic Presentation and Advances in Molecular Diagnosis

THIERRY LAMY, MD, PhD, Pontchaillou Hospital Rennes University Hospital, Rennes, France Large Granular Lymphocytosis (LGL): A Clonal Disorder with Autoimmune Manifestations

Education Program: AML M&Ms: How to Integrate Mutations and MRD Data

Saturday 9:30 a.m. - 10:45 a.m.

Seaport Ballroom ABCD

Manchester Grand Hyatt San Diego

Chair:

COURTNEY D. DINARDO, MD, MSc, MD Anderson Cancer Center, Houston, TX

Speakers:

Jerald P. Radich, MD, University of Washington School of Medicine, Seattle, WA Mutations and MRD: Clinical Implications of Clonal Ontogeny

MICHAEL HEUSER, MD, Hannover Medical School, Hannover, Germany Mutation and MRD-informed Treatment Decisions

for the Transplant-Eligible Patient

COURTNEY D. DINARDO, MD, MSc, MD Anderson Cancer Center, Houston, TX Incorporating Mutational Data and MRD Assessments into Treatment Decisions for Transplant-Ineligible Patients

Education Program: Moving the Needle in Hodgkin Lymphoma

Saturday 9:30 a.m. - 10:45 a.m.

Pacific Ballroom Salons 15-17 Marriott Marquis San Diego Marina

Chair:

ALEX F. HERRERA, MD, City of Hope, Duarte, CA

Speakers:

RYAN C. LYNCH, MD, Fred Hutchinson Cancer Research Center, Seattle, WA Has PD1 Blockade Changed the Standard of Care for cHL?

RANJANA H. ADVANI, MD, Stanford University, Stanford, CA When Should We Use It? The Role of Brentuximab Vedotin in 2024

MIGUEL ANGEL PERALES, MD, Memorial Sloan Kettering Cancer Center, New York, NY When to Use Stem Cell Transplantation for cHL

Education Program: Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation

Saturday 9:30 a.m. - 10:45 a.m.

Pacific Ballroom Salons 21-22 Marriott Marquis San Diego Marina

Chair:

LUKE Y. C. CHEN, MD, MED, Dalhousie University, Halifax, Nova Scotia, Canada

Speakers:

DAVID C. FAJGENBAUM, MD, University of Pennsylvania, Philadelphia, PA Identifying Castleman Disease from Non-Clonal Inflammatory Causes of Generalized

Lymphadenopathy

LUKE Y. C. CHEN, MD, MED, Dalhousie University, Halifax, Nova Scotia, Canada *IgG-4 Disease for the Hematologist*

RAYNE ROUCE, MD, Texas Children's Hospital, Houston, TX

EBV and Post-transplant Lymphoproliferative Disorder (PTLD): A Complex Relationship

Education Program: Optimizing Non-Curative Therapies for Sickle Cell Disease

Saturday 9:30 a.m. - 10:45 a.m. Room 33

Chair:

Susan Elizabeth Creary, MD, MSc, Ohio State University College of Medicine, Columbus, OH

Speakers:

Susan Elizabeth Creary, MD, MSc, Ohio State University College of Medicine, Columbus, OH Practical Guide for Disease-Modifying Management of Children and Adolescents with SCD

AMANDA M. BRANDOW, DO, MS, Medical College of Wisconsin, Milwaukee, WI Beyond IV Push: Alternative Methods for Management of Acute Pain in SCD

Pablo Bartolucci, MD, PhD, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France Novel Clinical Care Models for Patients with Sickle Cell Disease

Education Program: The Expanding Landscape of Treatment for ITP

Saturday 9:30 a.m. - 10:45 a.m. Room 28 A-D

Chair:

MICHELE P. LAMBERT, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:

WALEED GHANIMA, MD, PHD, Østfold Hospital, Gralum,

Insights on Treatment of ITP: Algorithm for Management and Role of Multi-Modal Therapy

Annemarie E. Fogerty, MD, Massachusetts General Hospital, Boston, MA Management of ITP during Pregnancy

MICHELE P. LAMBERT, MD, Children's Hospital of Philadelphia, Philadelphia, PA On the Horizon: Upcoming New Agents for the Management of ITP

Education Program: Beyond TTP: "Atypical" TMAs for the Hematologist

Saturday 2:00 p.m. – 3:15 p.m. Room 24

Chair:

MARK CROWTHER, MS, MSc, McMaster University, Hamilton, Ontario, Canada

Speakers:

Anuja Java, Washington University in St. Louis, St. Louis, MO

Atypical HUS: Diagnosis, Management, and Discontinuation Therapy

Ang Li, MD, MS, Baylor College of Medicine, Houston, TX

Transplant Associated TMA: The Conundrum of Diagnosis and Treatment

Mark Crowther, MS, MSc, McMaster University, Hamilton, Ontario, Canada Catastrophic Antiphospholipid Syndrome (CAPS) and Anticoagulant-Refractory APS

Education Program: Chasing Zebras: Navigating Rare Myeloid Neoplasms

Saturday 2:00 p.m. – 3:15 p.m.

Grand Hall C

Manchester Grand Hyatt San Diego

Chair:

Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX

Speakers:

ROBERT P. HASSERJIAN, MD, Massachusetts General Hospital, Boston, MA

The Spectrum of Ph Negative Disease: CNL and CSF3R-Related Disorders

Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX BPDCN State of the Art

OLGA K. WEINBERG, MD, UT Southwestern, Dallas, TX How to Think About Acute Leukemia of Ambiguous Lineage

Education Program: Hematologic Challenges at the End-of-Life

Saturday 2:00 p.m. – 3:15 p.m. Room 6A

Chair:

Anna L. Parks, MD, University of Utah Health, Salt Lake City, UT

Speakers:

Kah Poh (Melissa) Loh, MD, University of Rochester, Rochester, NY

Challenges in Hospice and End-of-Life Care in the Transfusion-Dependent Patient

Anna L. Parks, MD, University of Utah Health, Salt Lake City, UT

Anticoagulation at the End of Life: Whether, When, and How to Treat

EMILY E. JOHNSTON, MD, University of Alabama at Birmingham, Birmingham, AL End-of-Life in the Sickle Cell Patient: Life Expectancy and the Role of Palliative Care

Education Program: Hematologic Management of the Patient with Heavy Menstrual Bleeding

Saturday 2:00 p.m. – 3:15 p.m. Room 28 A-D

Chair:

JULIANA PEREZ BOTERO, MD, Mayo Clinic, Rochester, MN

Speakers:

Allison P. Wheeler, MD, MSci, Washington Center for Bleeding Disorders, Seattle, WA Quantifying Menorrhagia and Overview of Non-Surgical Management of Heavy Menstrual Bleeding

JULIANA PEREZ BOTERO, MD, Mayo Clinic, Rochester, MN

Von Willebrand Disease and Heavy Menstrual Bleeding: When and How to Test

Janice Staber, MD, University of Iowa Stead Family Children's Hospital, Iowa City, IA Heavy Menstrual Bleeding Clinics for Adolescents

Education Program: Integrating New Therapies into the Management of Classical Heme Disorders

Saturday 2:00 p.m. – 3:15 p.m. Room 30

Chair:

ALI T. TAHER, MD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon

Speakers:

Volker Hans Haase, MD, Vanderbilt University, Nashville, TN

Hypoxia-Inducible Factor Activators: A Novel Class of Oral Drugs for the Treatment of Anemia of Chronic Kidney Disease

ALI T. TAHER, MD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon Luspatercept: A Treatment for Ineffective Erythropoiesis in Thalassemia

Amy Dickey, MD, Massachusetts General Hospital, Boston, MA

Givosiran: A Targeted Treatment for Acute Intermittent Porphyria

Education Program: Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios

Saturday 2:00 p.m. – 3:15 p.m. Room 29

Chair:

NORBERT GATTERMANN, MD, Heinrich Heine University Dusseldorf, Dusseldorf, Germany

Speakers:

Domenico Girelli, MD, PhD, University of Verona, Verona, Italy

Diagnosis and Management of Hereditary Hemochromatosis: Lifestyle Modification, Phlebotomy, and Blood Donation

Norbert Gattermann, MD, Heinrich Heine University Dusseldorf, Dusseldorf, Germany Iron Overload in Acquired Sideroblastic Anemias and MDS: Pathophysiology and Role of Chelation and Luspatercept

Rebecca Karp Leaf, MD, Massachusetts General Hospital Cancer Center, Boston, MA Porphyria Cutanea Tarda: A Unique Iron-Related Disorder

Education Program: Newly Diagnosed Multiple Myeloma: Many Choices and More Questions

Saturday 2:00 p.m. – 3:15 p.m.
Pacific Ballroom Salons 24-26
Marriott Marguis San Diego Marina

Chair:

SHAJI KUMAR, MD, Mayo Clinic, Rochester, MN

Speakers:

Shaji Kumar, MD, Mayo Clinic, Rochester, MN What Is the Ideal Approach – Doublet, Triplet or Quadruplet(s)?

Aurore Perrot, MD, PhD, University and Hospital of Toulouse, Toulouse, France *Transplant in Myeloma: Who, When, and Why?*

Sonja Zweegman, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands Supportive Care in Myeloma – When Treating the Clone Alone Is Not Enough

Education Program: Handling Bad News: How to Best Manage TP53 Myeloid Disease?

Saturday 4:00 p.m. – 5:15 p.m.

Grand Hall D

Manchester Grand Hyatt San Diego

Chair:

DANIEL C. LINK, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO

Speakers:

Daniel C. Link, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO *Are TP53 Mutations All Alike?*

MARINA KONOPLEVA, MD, PHD, Albert Einstein College of Medicine, Houston, TX

Non transplant Treatment Approaches for High ris

Non-transplant Treatment Approaches for High-risk TP53 Myeloid Disease

Hugo Francisco Fernandez, MD, Moffitt Malignant Hematology and Cellular Therapy, Pembroke Pines, FL

Transplant Options and Outcomes for TP53 Myeloid Disease

Education Program: HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

Saturday 4:00 p.m. – 5:15 p.m. Room 28 A-D

Chair:

Toyosi Onwuemene, MD, MS, Duke University, Durham, NC

Speakers:

JORI E. MAY, MD, University of Alabama at Birmingham, Birmingham, AL Practical Guide to Diagnosis and Management of "Typical" HIT(T)

Toyosi Onwuemene, MD, MS, Duke University, Durham, NC

Alternative Approaches to Management of HIT in Complex Scenarios, including Cardiac Surgery

Marie Scully, MD, University College London, London, England, United Kingdom Demystifying Autoimmune HIT: What It Is, When to Test, and How to Treat

Education Program: Monoclonal Gammopathies: When the Clone Is More Than a Positive Laboratory Finding

Saturday 4:00 p.m. – 5:15 p.m.

Pacific Ballroom Salons 21-22 Marriott Marquis San Diego Marina

Chair:

MICHAELA LIEDTKE, MD, Stanford University Cancer Center, Stanford, CA

Speakers:

MICHAELA LIEDTKE, MD, Stanford University Cancer Center, Stanford, CA MGUS Where Do We Stand Today?

Frank Bridoux, MD, PhD, CHU Poitiers, Poitiers, France
Renal Manifestations of MGUS

M. Teresa Cibeira López, MD, PhD, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain Neurological Manifestations of MGUS

SUNDAY

How I Treat: A Personal Journey with Castleman Disease (ticketed session for in-person participants)

Sunday 8:00 a.m. - 9:00 a.m.

Agua 300

Hilton San Diego Bayfront

Speaker:

David C. Fajgenbaum, MD, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

How I Treat: Acute Myeloid Leukemia with Targetable Mutations (ticketed session for inperson participants)

Sunday 8:00 a.m. - 9:00 a.m.

Aqua 314

Hilton San Diego Bayfront

Speaker:

COURTNEY D. DINARDO, MD, MSc, The University of Texas, MD Anderson Cancer Center, Houston, TX

How I Treat: Adult Outpatient CAR T Therapy (ticketed session for in-person participants)

Sunday 8:00 a.m. – 9:00 a.m.

Aqua 311

Hilton San Diego Bayfront

Speaker:

MICHAEL R. BISHOP, MD, University of Chicago, Chicago, IL

How I Treat: Newly Diagnosed Multiple Myeloma (ticketed session for in-person participants)

Sunday 8:00 a.m. - 9:00 a.m.

Agua 313

Hilton San Diego Bayfront

Speaker:

Shaji Kumar, MD, Mayo Clinic, Rochester, MN

How I Treat: Sickle Cell Disease in Africa (ticketed session for in-person participants)

8:00 a.m. - 9:00 a.m. Sunday

Agua 310

Hilton San Diego Bayfront

Speaker:

ISAAC ODAME, MBBCH, The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, Ontario, Canada

Education Program: MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy

Sunday 9:30 a.m. - 10:45 a.m.

Seaport Ballroom EFGH

Manchester Grand Hyatt San Diego

Chair:

Ann Mullally, MD, Stanford University School of Medicine, Stanford, CA

Speakers:

ADAM J. MEAD, PhD, University of Oxford, Oxford, England, United Kingdom

Molecular Profiling in MPN: Who Should Have It and Why?

JEAN-JACQUES KILADJIAN, MD, PhD, Hospital Saint-Louis, Paris, France

Pegylated IFN: The Who, Why, and How

CHI-JOAN How, MD, Brigham and Women's Hospital, Boston, MA

Pregnancy: MPN Management Before, During, and After Pregnancy

Education Program: Overcoming Post-transplant Relapse: How to Win the Battle Royale

Sunday 9:30 a.m. - 10:45 a.m.

Room 6CF

Chair:

Luca Vago, MD, PhD, IRCCS Ospedale San Raffaele, Milan, Italy

Speakers:

Luca Vago, MD, PhD, IRCCS Ospedale San Raffaele, Milan, Italy

Biology of Transplant Relapse: Actionable Features

Antonio Pierini, MD, PhD, University of Perugia, Perugia, Italy

Novel Conditioning and Prophylaxis Regimens for Relapse Prevention

SAWA ITO, MD, PhD, University of Pittsburgh, Pittsburgh, PA

Post-transplant Strategies for Relapse Prevention and Treatment

Education Program: Challenges in Cancer-**Associated Thrombosis**

Sunday 4:30 p.m. - 5:45 p.m.

Hall B

Chair:

Tzu-Fei Wang, MD, MPH, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada

Speakers:

Avi Leader, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Management of Anticoagulation in Patients With Brain Metastasis

JEFFREY ZWICKER, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Trousseau's Syndrome: Management of Refractory

CIHAN Ay, MD, Medical University of Vienna, Vienna, Austria

Treatment of VTE in the Thrombocytopenic Cancer Patient

Education Program: Follicular Lymphoma: Playing the Long Game

Sunday 4:30 p.m. - 5:45 p.m.

> **Marriott Grand Ballroom 11-13** Marriott Marguis San Diego Marina

Chair:

JUDITH TROTMAN, MBCHB, Concord Repatriation General Hospital, Concord, New South Wales, Australia 🚡

Speakers:

JUDITH TROTMAN, MBCHB, Concord Repatriation General Hospital, Concord, New South Wales, Australia

Follicular Lymphoma: In Pursuit of a Functional

CARLA CASULO, MD, James P. Wilmot Cancer Center, Rochester, NY

The POD24 Challenge: Where Do We Go from Here in Follicular Lymphoma?

Nancy L. Bartlett, MD, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

Sequencing Bispecific Antibodies and CAR T-cells for FL

Spotlight Session: Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All

Sunday 4:30 p.m. – 5:45 p.m. Room 30

Chair:

Kenneth I. Ataga, MD, University of Tennessee Health Science Center, Memphis, TN

Speakers:

Santosh L. Saraf, MD, University of Illinois Chicago, Chicago, IL

Curative Therapies in Sickle Cell Disease: Which Patient, What Modality, and When to Refer

Payal Desai, MD, Wake Forest University, Charlotte, NC

Systemic Barriers to Curative Therapy and Need for Integrated Care

Spotlight Session: The Clone Wars: Myeloid Neoplasia Risk in Clonal Hematopoiesis

Sunday 4:30 p.m. – 5:45 p.m.

Grand Hall C

Manchester Grand Hyatt San Diego

Chair:

Luca Malcovati, MD, University of Pavia & S. Matteo Hospital, Pavia, Italy

Speakers:

Luca Malcovati, MD, University of Pavia & S. Matteo Hospital, Pavia, Italy Predicting Risk of MN in CH

Kirsten Gronbaek, MD, DMSc, University of Copenhagen, Copenhagen, Denmark How to Follow CH Patients

MONDAY

Education Program: A Shifting Landscape: Treatment of MCL

Monday 10:30 a.m. – 11:45 a.m.

Marriott Grand Ballroom 2-4 Marriott Marquis San Diego Marina

Chair:

Камі J. Maddocks, MD, The Ohio State University, Columbus, OH

Speakers:

Kami J. Maddocks, MD, The Ohio State University, Columbus, OH

Your Chemo is No Good Here: Management of High-Risk MCL

Martin Dreyling, MD, LMU University Hospital Munich, Munich, Germany

To Consolidate or Not to Consolidate – The Role of Autologous Stem Cell Transplantation in MCL

Maria Lia Palomba, MD, Memorial Sloan Kettering Cancer Center, New York, NY T-cell–based Therapies for Treating Relapsed or Refractory Mantle Cell Lymphoma

Education Program: Anticoagulation SOS: Navigating Monitoring Conundrums

Monday 10:30 a.m. – 11:45 a.m.

Room 28 A-D

Chair:

Deborah Siegal, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada

Speakers:

Deborah Siegal, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada *Measuring the effect of DOACs: Why, When, and How?*

CHERYL L. MAIER, MD, PhD, Emory University, Atlanta, GA
Troubleshooting Heparin Resistance

Hannah Cohen, MD, University College London Hospitals NHS Foundation Trust, London, England, United Kingdom

Warfarin and Heparin Monitoring in Antiphospholipid Syndrome

Education Program: Challenges and Opportunities of Sickle Cell Care in Africa

10:30 a.m. - 11:45 a.m. Monday Room 31

Chair:

ISAAC ODAME, MBBCH, The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, Ontario, Canada

Speakers:

Obiageli E. Nnodu, MD, University of Abuja, Abuja,

Newborn Screening Initiatives for Sickle Cell Disease in Africa

ISAAC ODAME, MBBCH, The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, Ontario, Canada

Transfusion, Disease-Modifying Treatments, and Curative Therapies for Sickle Cell Disease in Africa: Where Are We Now?

Kofi A. Anie, PhD, London North West University Healthcare NHS Trust & Imperial College London, London, England, United Kingdom The Intersection of Sickle Cell Disease, Stigma, and Pain in Africa

Education Program: It's a Different World: CLL 2024

10:30 a.m. - 11:45 a.m. Monday Hall B

Chair:

JENNIFER A. WOYACH, MD, The Ohio State University, Columbus, OH

Speakers:

STEPHAN STILGENBAUER, MD, University of Ulm, Ulm, Germany

Risk-Stratification in Frontline CLL Therapy

JENNIFER A. WOYACH, MD, The Ohio State University, Columbus, OH

The Evolving Frontline Management of CLL: Are Triplets Better Than Doublets? How Will We Find Out?

ARNON P. KATER, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands Relapsed Refractory CLL: The Role of SCT, Cellular and Non-cellular Immunotherapy

Spotlight Session: Making a Match: Optimal **Donor HLA and Beyond**

10:30 a.m. - 11:45 a.m. Monday Room 24

Chair:

MOHAMAD MOHTY, MD, PhD, Saint-Antoine Hospital, Paris, France

Speakers:

HEATHER E. STEFANSKI, MD, PhD, CIBMTR (Center for International Blood and Marrow Transplant Research), National Marro Donor Program, Minneapolis, MN

HLA: Optimizing the 'Full HLA Match'

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France

Beyond HLA: Optimizing Non-HLA Variables

Spotlight Session: Smoldering Myeloma: A Case for Early Intervention?

Monday 10:30 a.m. - 11:45 a.m. Pacific Ballroom Salons 18-19 Marriott Marguis San Diego Marina

Chair:

Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain

Speakers:

Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain Point: Yes, That Is the Only Way We Can Cure

Myeloma?

KARTHIK RAMASAMY, MD, PhD, University of Oxford, Oxford, England, United Kingdom Counterpoint: No, It Just Adds Cost and Toxicity?

Education Program: Adult ALL Advancements: Optimizing Cure in 2024

Monday 2:45 p.m. - 4:00 p.m. **Ballroom 20AB**

Chair:

Marlise R. Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA

Speakers:

Marlise R. Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA

PH+ ALL: New Approaches for Upfront Therapy

Matthias Stellies, MD, University Hospital Muenster, Muenster, Germany Ph- ALL: Impact of Immunotherapy in Upfront **Treatment**

PARTOW KEBRIAEI, MD, MD Anderson Cancer Center, Houston, TX

Transplant in ALL: Who, When, and How?

Education Program: Sex Hormones. Contraceptives, and Thrombotic Risk: Where Are We Now?

Monday 2:45 p.m. - 4:00 p.m. **Room 29**

Chair:

SASKIA MIDDELDORP, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands

Speakers:

Leslie Skeith, MD, University of Calgary, Calgary, Alberta, Canada

Estrogen, Progestin, and Beyond: Thrombotic Risk and Contraceptive Choices

JOSEPH J. SHATZEL, MD, Oregon Health & Science University, Portland, OR Gender-Affirming Hormone Therapy in the Transgender Patient: Influence on Thrombotic Risk

SASKIA MIDDELDORP, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands Hormone-Related Thrombosis: Duration of Anticoagulation, Risk of Recurrence, and the Role of Hypercoagulability Testing

Spotlight Session: Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?

Monday 2:45 p.m. - 4:00 p.m. Room 24

Chair:

BARBARA A. KONKLE, MD, Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA

Speakers:

Frank W.G. Leebeek, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands The Promise of Gene Therapy for Severe Hemophilia Α

CHRISTINE L. KEMPTON MD, Emory University, Atlanta,

Unknowns of Gene Therapy and Successes of Medical Therapies for Hemophilia A

Education Sessions

Education Program: Addressing Unmet Needs in T Cell Lymphomas

Monday 4:30 p.m. – 5:45 p.m. **Ballroom 20AB**

Chair:

Neha Mehta-Shah, MD, MSci, Washington University in St. Louis, St Louis, MO

Speakers:

Neha Mehta-Shah, MD, MSci, Washington University in St. Louis, St Louis, MO

BV and Beyond: How to Incorporate Novel Agents into PTCL Management

STEVEN HORWITZ, MD, Memorial Sloan-Kettering Cancer Center, New York, NY Through Thick and Thin: Confronting the Aggressive Cutaneous T-cell Lymphomas

Peter Dreger, MD, Universitätsklinikum, Heidelberg, Germany The Role of Stem Cell Transplant (auto and allo) in PTCL and CTCL

Education Program: Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)

Monday 4:30 p.m. - 5:45 p.m. Room 24

Chair:

MICHAEL R. BISHOP, MD, University of Chicago, Chicago, IL

Speakers:

XIN SHELLEY WANG, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX Patient-Reported Outcomes After CAR T-cell Therapy in Patients with Hematological Malignancies

MICHAEL R. BISHOP, MD, University of Chicago, Chicago, IL

Late Complications and Long-term Care of Adult CAR T cell Patients

Tania Jain, MD, Johns Hopkins University, Baltimore, MD

Mitigating and Managing Infection Risk in Adults Treated with CAR T-Cell Therapy

Education Program: Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist

Monday 4:30 p.m. - 5:45 p.m.

Room 25

Chair:

SHELLEY E. CRARY, MD, MS, Arkansas Children's Hospital, Little Rock, AR

Speakers:

MIIKKA VIKKULA, MD, PhD, Universite Catholique De Louvain, Brussels, Belgium Molecular Landscape and Classification of Vascular **Anomalies**

ALEXANDRA JANE BORST, MD, The University of North Carolina at Chapel Hill, Chapel Hill, NC Targeted Medical Therapies for Vascular Anomalies

SHELLEY E. CRARY, MD, MS, Arkansas Children's Hospital, Little Rock, AR Hemostasis and Thrombosis Risks and Management in Vascular Anomalies

Notes:		

SPECIAL INTEREST SESSIONS

87

SPECIAL INTEREST SESSIONS

These smaller sessions provide the opportunity for ASH's various communities to focus on specific topics of interest, ranging from coping with physician stress and burnout, to counseling fellows on careers in hematology, to the impact of ASH's international outreach programs.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY

Training Program Directors Workshop

Friday 9:00 a.m. – 12:00 p.m.

Indigo 204, Hilton San Diego Bayfront

Chair:

Pallawi Torka, MD, Roswell Park Cancer Center, Buffalo, NY

Speakers:

SCOTT MOERDLER, MD, Children's Hospital at Montefiore, New Brunswick, NJ

LAYLA N. VAN DOREN, MD, MBA, Tufts Medical Center, Boston, MA

Innovative Fellowship Curriculum

Angela C Weyand, MD, University of Michigan, Ann Arbor, MI

Leveraging and Enriching Social Media

Gerald Hsu, MD, PhD, University of California San Francisco, San Francisco, CA

Sunandana Chandra, MD, Northwestern University, Chicago, IL

Best Practices to Support Fellows in the Job Search

SATURDAY

		ASH Health Equity Studio, Sails Pavilion from CME		
	9:00 AM - 9:30 AM	Advocating for Language Justice in Hematology		
	11:00 AM - 11:30 AM	Ensuring Equitable Access to Quality Care for Undocumented Immigrants and Mixed-		
		Status Families		
	1:30 PM - 2:00 PM	Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical		
		Research		
	3:30 PM - 4:00 PM	Achieving Equity and Inclusion in Clinical Trial Enrollment: Challenges and Opportunities		
		ASH Wellness Studio, Sails Pavilion Chon-CME		
	7:00 AM - 7:45 AM	ASH Yoga, ASH Park @ The Plaza		
	9:05 AM - 9:15 AM	Your New Superpower: Uncertainty Comfort		
	9:15 AM - 9:25 AM	Believing Beyond Burnout		
	11:05 AM - 11:15 AM	Fix Your Seat		
	11:20 AM - 11:30 AM	Smarter Phone Use		
	11:35 AM - 11:45 AM	Wellbeing Strategies for High Performance		
	1:35 PM - 1:45 PM	Tools for Success in Early Medical Practice		
	1:45 PM - 1:55 PM	Practical Approaches to Combating Burnout		
	3:35 PM - 3:45 PM	The Performance Paradox		
	3:45 PM - 3:55 PM	The Anxious Achieving Brain		
	Blood Journals Studio, Halls G-H Gon-CME			
	9:00 AM - 9:30 AM	Meet the Blood Vessels, Thrombosis & Hemostasis Editors		
	11:15 AM - 12:15 PM	ASH Poster Walk on Hemostasis and Thrombosis: from Basic Concepts to Clinical		
		Applications Hosted by Blood Vessels, Thrombosis & Hemostasis		
	1:30 PM - 2:00 PM	Meet the <i>Blood</i> Editors		
	2:00 PM - 3:30 PM	Distinguished Abstract Achievement Award Ceremony		
	3:30 PM - 4:00 PM	Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work		
1				

Meet the Blood Vessels, Thrombosis & Hemostasis Editors

9:00 a.m. - 9:30 a.m. Saturday

Halls G-H - Blood Journals Studio

Panelists:

KEITH R. McCrae, MD, Editor-in-Chief, Blood VTH, Cleveland Clinic, Cleveland, OH KARIN HOFFMEISTER, MD, Deputy Editor, Blood VTH,

Versiti Blood Research Institute, Milwaukee, WI

ASH Clinical Practice Guidelines on

Pediatric Venous Thromboembolism (VTE)

9:30 a.m. - 11:00 a.m. Saturday

Room 25

Chair:

PAUL MONAGLE, MD, BS, MSc, FRACP, FRCPA, MB, University of Melbourne Royal Children's Hospital, Parkville, Victoria, Australia

Speakers:

Leslie Raffini, MD, Children's Hospital of Philadelphia, Philadelphia, PA Why Revise the Guidelines?

RUKHMI BHAT, MD, MS, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL Asymptomatic VTE in Pediatric Patients

Marisol Betensky, MD, Johns Hopkins All Children's Hospital, Saint Petersburg, FL Duration of Therapy for Provoked and Unprovoked

TINA BISS, MD, The Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom Use of Anticoagulants in Children

Blood Presents: How to Get Published in a Peer-Reviewed Journal

Saturday 11:15 a.m. - 12:15 p.m. Room 24

Special Interest Sessions

VTE in Pediatric Patients

Panelists:

Nancy Berliner, MD, Blood Editor-in-Chief, Brigham and Women's Hospital, Boston, MA Andrew W. Roberts, MBBS, PhD, Blood Deputy Editor-in-Chief, Parkville, Victoria, Australia

Grassroots Network Lunch

Saturday 11:15 a.m. - 12:15 p.m.

Marina Ballroom DE, Marriott Marquis

San Diego Marina

Co-Chairs:

JENNIFER HOLTER-CHAKRABARTY, MD, University of Oklahoma Stephenson Cancer Center, Oklahoma

BART L. Scott, MD, Fred Hutchinson Cancer Center. Seattle, WA

Speakers:

Kirk Bado, National Journal, Washington, DC

Meet the **Blood** Editors

Saturday 1:30 p.m. - 2:00 p.m.

Halls G-H - Blood Journals Studio

Panelists:

NIZAR J. BAHLIS, MD, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta,

JASON GOTLIB, MD, MS, Stanford Cancer Institute & Stanford University School of Medicine, Stanford,

Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating **Health Care Disparities**

2:00 p.m. - 3:30 p.m. Saturday

Room 11

Co-Chairs:

ADAM CUKER, MD, MS, University of Pennsylvania, Philadelphia, PA

Angela C. Weyand, MD, University of Michigan, Ann Arbor, MI

Speakers:

Melissa Creary, PhD, MPH, University of Michigan School of Public Health, Ann Arbor, MI MSHIELD - Michigan Social Health Interventions to Eliminate Disparities

MICHELLE SHOLZBERG, MDCM, MSc, St. Michael's Hospital, Toronto, Ontario, Canada Raise the Bar - Combatting Disparities in the Recognition and Management of Iron Deficiency

THOMAS G. KNIGHT, MD, Atrium Health, Charlotte, NC Cancer and Poverty - Mitigating the Impact of Financial Toxicity in Patients with Hematologic **Malignancies**

Distinguished Abstract Achievement Award Ceremony

Saturday 2:00 p.m. - 3:30 p.m.

Halls G-H - Blood Journals Studio

Moderator:

CHRISTOPHER R. FLOWERS, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX

Hemato-Logic: How to Share Your Cases with the ASH Image Bank and Blood Work

Saturday 3:30 p.m. – 4:00 p.m.

Halls G-H - Blood Journals Studio

Moderator:

SANAM LOGHAVI, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Panelists:

AARON GOODMAN, MD, UCSD Moores Cancer Center, La Jolla, CA

KAMRAN M. MIRZA, MD, MPH, Loyola University Chicago, Maywood, IL

ARISTOTELIS TSIRIGOS, PhD, New York University School of Medicine, New York, NY

ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through **Real-World Evidence Generation**

Saturday 4:00 p.m. - 5:30 p.m.

Pacific Ballroom Salons 24-26, Marriott

Marquis San Diego Marina

Chair:

Kenneth C. Anderson, MD, Dana-Farber Cancer Institute, Boston, MA

Speakers:

WILLIAM A. WOOD, MD, MPH, University of North Carolina At Chapel Hill Hospital, Chapel Hill, NC Building a National Multiple Myeloma Data Hub to Accelerate Research and Enhance Clinical Care

SAAD Z. USMANI, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept

SHAJI KUMAR, MD, Mayo Clinic, Rochester, MN

Pushing Data Frontiers: How Artificial Intelligence and Molecular Data can Facilitate Translational Research in the Network

IESUS MARIA HERNANDEZ RIVAS, MD, Hospital Universitario de Salamanca, University of Salamanca, IBSAL, IBMCC, CSIC, Salamanca, Spain Panel Discussion: Real World Experience with Establishing Registries and Reporting Results (Panelist 1)

ELENA ZAMAGNI, MD, Bologna University School of Medicine, Bologna, Italy

Panel Discussion: Real World Experience with Establishing Registries and Reporting Results (Panelist 2)

Doris K. Hansen, MD, H. Lee Moffitt Cancer Center & Research Institution, Tampa, FL Panel Discussion: Real World Experience with Establishing Registries and Reporting Results (Panelist 3)

Artificial Intelligence in Hematology: From Generative AI to Ethics and Applications

4:00 p.m. - 5:30 p.m. Saturday Hall B

Chair:

OLIVIER ELEMENTO, PHD, MS, BS, Weill Cornell Medicine, New York, NY

Speakers:

JAMES ZOU, PHD, Stanford University, Stanford, CA The Potential and Pitfalls of Generative AI in Basic and Clinical Research

CAMILLE NEBEKER, EdD, MS, University of California San Diego, San Diego, CA

From Principles to Practice: Ensuring Ethical Integrity in AI-Driven Biomedical Research

CLAUDIA HAFERLACH, MD, MLL Munich Leukemia Laboratory, Munich, Germany The Application of Artificial Intelligence in Hematological Diagnostics

Hematology Inclusion Pathway (HIP) **Oral Presentations: Room I (Malignant** Hematology)

Saturday 6:30 p.m. - 8:00 p.m.

Marina Ballroom D, Marriott Marquis San Diego Marina

Moderators:

ANITA D'SOUZA, MD, Medical College of Wisconsin, Milwaukee, WI

JORGE MONGE, MD, Weill Cornell Medicine, New York, NY

Mazie Tsang, MD, MAS, MD, Mayo Clinic, Phoenix, AZ

Speakers:

JOHN ROY LOZADA, MD, University of Minnesota, Minneapolis, MN

An Integrated Systems Biology Approach to Understanding the Phenotypic and Functional Diversity of Natural Killer Cells in Cancer

Sofia E. Luna, Leland Stanford Stanford Junior University, Stanford, CA

Engineering Hematopoietic Stem Cells to Generate Therapeutic Antibody Secreting B Cells

Fathima Mohamed, PhD, University of Minnesota, Minneapolis, MN

Metabolic Regulation of the Germinal Center Reaction in Chronic Graft Versus Host Disease

Andres J. Rubio, MS, Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX

A Role for PSMD3 in Regulating Oxidative Energy Metabolism in Acute Myeloid Leukemia (AML)

Catherine Gutierrez, MD, PhD, Massachusetts General Hospital, Boston, MA

Identifying Mechanisms of Resistance to ATR Inhibition in Myelodysplastic Syndromes with Splicing Factor Mutations

Kelly Meza, MD, Baylor College of Medicine, Houston, TX

Retrospective Analysis of the PET/CT Imaging Features of Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL) Patients

JOANE TITUS, MD, MS, HCA Florida Healthcare GME Consortium, University of Central Florida, Orlando, FL

Retrospective Review of Care for Black/African American Veterans with Multiple Myeloma at the Orlando VA

Kalay Bertulfo, MS, MA, MPhil, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY

Therapeutic Targeting of JAK/STAT Signaling and Histone Acetyltransferase Activity in Post-Myeloproliferative Neoplasm Secondary AML

QUENTON BUBB, MPHIL, Leland Stanford Junior University, Stanford, CA

Development of Multivalent Cell Therapies for Treatment of Hematologic Malignancies

JOICE KANEFSKY, PhD, Fox Chase Cancer Center, Philadelphia, PA

Disruption of Polyunsaturated Fatty Acid Biosynthesis Drives Sting-Dependent Acute Myeloid Leukemia Cell Maturation and Death Kristopher Adrian Knight, Molecular and Systems Pharmacology, Emory University, Atlanta, GA Development of a Novel L-Asparaginase with Enhanced Properties Using Ancestral Sequence Reconstruction

Owhofasa Agbedia, MBBS, MPH, MD Anderson Cancer Center, Houston, TX Targeting Aggressive NK-Cell Leukemia and Other

CD94-Expressing NK/T-Cell Lymphoproliferative Disorders with CAR T-Cell Therapy

Hematology Inclusion Pathway (HIP) Oral Presentations: Room II (Health Services Outcomes)

Saturday

6:30 p.m. – 8:00 p.m. Marina Ballroom F, Marriott Marquis San Diego Marina

Moderators:

JOANNA ROBLES, MD, Atrium Health Wake Forest Baptist Brenner Children's Hospital, Winston-Salem, NC

Oreofe Odejide, MD MPH, Dana-Farber Cancer Institute, Boston, MA

STACI ARNOLD, MD, MBA, MPH, Emory University, Atlanta, GA

Speakers:

EMILY FRANCO, MD, The Warren Alpert Medical School of Brown University, Davie, FL Exploring Mental Health in Sickle Cell Disease: Implementing Routine Psychological Assessment in a Comprehensive Sickle Cell Clinic

RACHELLE MONTEAU, CUNY School of Medicine, New York, NY

Outcomes of Adult ALL/LBL Patients from Diverse Backgrounds Treated in the United States between 2000 and 2022

Osariemen Ogiamien, MD, University of California Riverside Science Library, Riverside, CA Neighborhood Socioeconomic/Environmental Disadvantage and Health Outcomes after Allogeneic Hematopoietic Cell Transplantation

Margarita Vazquez Almonte, SUNY Upstate Medical University, Bronx, NY

Parenthood While in Hematology: Perceived Barriers

Daniel Goyco Vera, MD, Baylor College of Medicine, Houston, TX

Outcomes of Patients Underrepresented in Pivotal Trials of CAR-T Cell Therapy

Michelle Nwachukwu, DO, University of Illinois at Chicago, Chicago, IL

The Impact of Structural Racism on Molecular Subtypes and Survival Outcomes in Acute Myeloid Leukemia Patients

IFEANYI NNAMDI UCHE, MBBS, Brookdale University Hospital and Medical Center, Brooklyn, NY Examining the Impact of Body Mass Index on Outcomes in Young Adults with Sickle Cell Disease: A Single-Center Study

Britney Bell, MD, Section of Hematology and Medical Oncology, Boston Medical Center, Boston, MA *Integration of Health Literacy Universal Precautions* into Clinical Practice as a Strategy to Improve Patient-Reported Outcomes in Patients with Hematologic Malignancies and Limited English Proficiency

EDEN AYELE BILTIBO, MD, MS, Vanderbilt University Medical Center, Nashville, TN Impact of Daratumumab in the Treatment of Vulnerable Transplant Eligible Multiple Myeloma Patients and Its Utilization in Blacks

GERARD HILLS, MD, Riley Hospital for Children at Indiana University Health, Indianapolis, IN A Step Toward Individualized Mortality Risk Prediction in Patients with Sickle Cell Disease in a National EHR-Derived Population Dataset

ALEXANDRA POWER-HAYS, MD, Cincinnati Children's Hospital, Cincinnati, OH

Alternative Dosing and Prevention of Transfusions (ADAPT): A Prospective Trial to Quantify the Change in Blood Transfusion Use with Hydroxyurea Treatment and the Feasibility of Pharmacokinetic-Guided Dosing in Children with Sickle Cell Anemia in Uganda

Hematology Inclusion Pathway (HIP) Oral Presentations: Room III (Classical Hematology)

Saturday 6:30 p.m. - 8:00 p.m.

> Marina Ballroom E, Marriott Marquis San Diego Marina

Moderators:

CECELIA CALHOUN, MD, MBA, MPH, Yale School of Medicine, New Haven, CT

DAILIA FRANCIS, MD, PHD, Emory University School of Medicine, Brookhaven, GA Imo Akpan, MD, Columbia University, New York, NY

Speakers:

ABDI ABUD, MD, University of Missouri-Columbia, Saint Louis, MO

Validation of a Natural Language Processing Tool for Identification of Acute Deep Venous Thrombosis

VALERIA Brown, Brown University, Providence, RI Investigating the Role of Long Interspersed Element-1 (LINE-1) in Age-Related Clonal Hematopoiesis of Indeterminate Potential (CHIP) Driven by JAK2 V617F Mutation

ESTHER CHIOMA EMENALOM, BS, University of California San Diego, San Diego, CA

A Study of Postpartum Hemorrhage and a Cryoprecipitate Intervention at Hospital Central De Maputo

Maria Fernanda Albuia Altamirano, MD, Lincoln General Hospital, New York, NY

Incidence of Thrombotic and Bleeding Complications in Patients with Cancer Undergoing Lower Extremity Arthroplasty, an Administrative Database Study

Ashley Crosby, MD, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC Monocyte Distribution Width as a Marker of Red Cell Alloimmunization

Ayotola A. Fatola, MD, Johns Hopkins University School of Medicine, Baltimore, MD Evaluating the Role of Voxelotor and Percent Modified Hemoglobin (Hemoglobin X) on Laboratory and Clinical Responses in Patients with Sickle Cell Disease

OLISAEMEKA OGBUE, MBBS, Cleveland Clinic Foundation, Rocky River, OH Can Emergency Hematopoiesis Due to Sepsis Lead to Clonal Hematopoiesis? Implications for Understanding the Pathogenesis of Clonal Evolution

Maria Feliz Norberto, MS, Albert Einstein College of Medicine, Bronx, NY

Heterozygous DDX41 Mutations Promote Age-Dependent Hematopoietic Stem and Progenitor **Dysfunction**

CONROY O. FIELD, MS, The University of Pennsylvania School of Medicine, Philadelphia, PA Role of Platelet Factor 4 in the Prothrombotic Nature of Antiphospholipid Syndrome

SARAH MANSOUR, BS, Emory University, Atlanta, GA Methionine Sulfoxide and Other Metabolites from Bronchoalveolar Lavage Are Associated with Neutrophil-Dominated Lung Disease in Early Cystic Fibrosis

OLUFUNKE Y. MARTIN, MD, Children's National Hospital, Washington DC The Role of Red Blood Cell Vascular Adhesion

Biomarkers in Understanding Sickle Cell Disease-Associated Chronic Pain

WALATTA-TSEYON MESQUITTA, DPHIL, Boston Children's Hospital, Boston, MA

Interrogating TCF15 Function in Native Hematopoiesis Using TCF15 Overexpression and Conditional Knock out Mouse Models

Hematology Inclusion Pathway (HIP) Networking Reception

Saturday 8:00 p.m. - 9:00 p.m.

Marina Ballroom G, Marriott Marquis

San Diego Marina

Chair:

Satiro De Oliveira MD, University of California Los Angeles, Los Angeles, CA

SUNDAY

ASH Health Equity Studio, Sails Pavilion Good-CME		
9:00 AM - 9:30 AM	Combating Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data	
11:00 AM - 11:30 AM	Strengthening the Provider-Patient Relationship: A Guide to Building Trust	
1:30 PM - 2:00 PM	Global Hematology Collaboration: Advancing Diversity and Leadership in Clinical Research	
4:00 PM - 4:30 PM	Achieving Equity and Inclusion in Clinical Trial Enrollment: Challenges and Opportunities	
ASH Wellness Studio, Sails Pavilion (non-CME)		
9:05 AM - 9:15 AM	Reframing "the Grind"	
9:15 AM - 9:25 AM	The Appreciation Prescription	
11:05 AM - 11:15 AM	Walking Wonders	
11:20 AM - 11:30 AM	How to Stand	
11:35 AM - 11:45 AM	The Performance Paradox	
4:05 PM - 4:15 PM	Foundations of Mindfulness	
4:15 PM - 4:25 PM	Cultivating Compassion	
Blood Journals Studio, Halls G-H Gon-CME)		
8:00 AM - 9:00 AM	ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal	
	Function to Malignancy Hosted by Blood Neoplasia	
9:00 AM - 9:30 AM	Meet the Blood Neoplasia Editors	
11:15 AM - 12:15 PM	ASH Poster Walk on What's New in Complement-Related Diseases? Hosted by	
	Blood Red Cells & Iron	
4:00 PM - 4:30 PM	Meet the Blood Advances Editors	

Medical Educators Symposium

Special Interest Sessions

Sunday	7:30 a.m. – 9:00 a.m.			
	Marina Ballroom EG Marriott Mar			

Marina Ballroom FG, Marriott Marquis

San Diego Marina

Chair:

HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic, Cleveland, OH

Speakers:

ALISON LOREN, MD, University of Pennsylvania, Philadelphia, PA General Session 1: Paving a Career in Medical Education & Scholarship


MEGAN MURRAY DUPUIS, MD, PhD, Vanderbilt University, Houston, TX


General Session 2: Utilizing Humanities to Influence and Tailor Hematology Curriculum for Adult Learners

LAYLA VAN DOREN, MD, MBA, Yale University, New York, NY

General Session 3: Incorporating Health Equity Education in UME/GME Curriculum

ALEXANDER A. BOUCHER, MD, University of Minnesota Medical School, Minneapolis, MN General Session 3: Incorporating Health Equity Education in UME/GME Curriculum





Beverly Schaefer, MD, University of Buffalo, Buffalo, NY

Breakout 1: Challenges of Course Development

ARIELA L. MARSHALL, MD, University of Minnesota, Rochester, MN

Breakout 2: Developing Your Teaching Portfolio

JASON A. FREED, MD, Beth Israel Deaconess, Boston,

Breakout 3: Cutting-Edge Technology in Education Delivery

THOMAS W. LEBLANC, MD, MA, MSH, Duke Cancer Center, Durham, NC

Breakout 4: Developing a Palliative Care/Difficult Discussion Curriculum

Meet the **Blood Neoplasia** Editors

Sunday 9:00 a.m. - 9:30 a.m.

Halls G-H - Blood Journals Studio

Panelists:

JONATHAN D. LICHT, MD, Editor-in-Chief, Blood Neoplasia, University of Florida Health Cancer Center, Gainesville, FL

Maria Figueroa, MD, Deputy Editor, Blood Neoplasia, University of Miami Miller School of Medicine, Miami, FL

ASH Clinical Practice Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults

Sunday 9:30 a.m. - 11:00 a.m.

> Marriott Grand Ballroom 2-4, Marriott Marquis San Diego Marina

Chair:

SUMIT GUPTA, MD, PHD, Hospital for Sick Children, Toronto, Ontario, Canada

Speakers:

JULIE WOLFSON, MD, MSHS, The University of Alabama at Birmingham, Birmingham, AL Management of Frontline ALL in AYA

JENNIFER L. McNeer, MD, University of Chicago, Chicago, IL

Management of Frontline ALL in AYA

Kristen M. O'Dwyer, MD, University of Rochester Medical Center, Rochester, NY Management of Refractory and Relapse of ALL in Adolescents and Young Adults

LENA E. WINESTONE, MD, The Children's Hospital of Philadelphia, San Francisco, CA Management of Refractory and Relapse of ALL in Adolescents and Young Adults

Sickle Cell Disease Centers Session

Sunday 9:30 a.m. - 11:00 a.m.

Room 33

Co-Chairs:

CECELIA CALHOUN, MD, MBA, MPH, Yale New Haven Hospital, New Haven, CT

SOPHIE LANZKRON, MD, Thomas Jefferson University Hospital, Philadelphia, PA

Speakers:

TITILOPE FASIPE, MD, PhD, Texas Children's Cancer & Hematology Centers, Rosharon, TX

The Importance of Recognition of Pediatric Quality Metrics in SCD: The Role of US News and World Report

ALEXANDRA POWER-HAYS, MD, Cincinnati Children's Hospital, Cincinnati, OH

Will the Creation of CMS Quality Metrics Change Care in the Treatment of Painful Episodes in the Emergency Department?

CECELIA CALHOUN, MD, MBA, MPH, Yale New Haven Hospital, New Haven, CT

Leveraging Quality Metrics to Maintain Support of Your Sickle Cell Disease Center

Health Equity Symposium: Race, Structural Racism and the Social Determinants of **Health in Hematology**

9:30 a.m. - 11:00 a.m. Sunday

Room 6DE

Chair:

Deirdra R. Terrell, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Speakers:

JOSEPH L. GRAVES JR., PHD, North Carolina A&T State University, Greensboro, NC The Myth of Race in Medical Science

CHANITA HUGHES HALBERT, PhD, University of Southern California, Los Angeles, CA Structural Racism, the Social Determinants of Health, and Healthcare Outcomes – Understanding Inequity and What to Do About It

LGBTQIA+ Community Networking Brunch (for in-person participants)

Sunday 11:00 a.m. - 12:30 p.m.

Coronado DE, Manchester Grand Hvatt

San Diego

Moderator:

Jonas Jutzi, MD, PhD, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Panelists:

DIANE KRAUSE, MD, PhD, Yale University, New Haven, CT

ASH BLYTHE ALPERT, MD, MFA, Yale School of Medicine, New Haven, CT

Mouhamed Yazan Abou-Ismail, MD, University of Utah, Salt Lake City, UT

Blood Advances Presents: How to Peer Review a Scientific Paper 2

Sunday 11:15 a.m. - 12:15 p.m.

Room 24

Panelists:

CATHERINE M. BOLLARD, MD, Blood Advances Editor-in-Chief, Children's National Medical Center, Washington, DC

Andrew S. Weyrich, PhD, Blood Advances Deputy Editor-in-Chief, Oklahoma City, OK

ASH Clinicians in Practice (ACIP) Lunch - The Role of Artificial Intelligence in Hematology Practice: The Good, the Bad, and the Ugly

11:15 a.m. - 12:30 p.m. Sunday

Marina Ballroom DE, Marriott Marquis

San Diego Marina

Chair:

Mary-Elizabeth M. Percival, MD, Seattle Cancer Care Alliance, Seattle, WA

Speakers:

JIM WHITFILL, MD, MBA, Honor Health, Phoenix, AZ Artificial Intelligence in Health Care: Benefits and Pitfalls

CHRISTOPHER MANZ, MD, MSHP, DFCI, Boston, MA Artificial Intelligence as a Clinical Tool: Hacks in Practice

Gwen L. Nichols, MD, The Leukemia & Lymphoma Society, Rye Brook, NY

Patient Facing Artificial Intelligence: Uses and Ethical *Implications*

Health Equity Rounds Lunch

Sunday 11:30 a.m. – 12:30 p.m.

Coronado Ballroom AB, Manchester

Grand Hyatt San Diego

Hematologic Aspects of Gender Affirming Care

Co-Chairs:

SRINIVAS DEVARAKONDA, MD, LSU Health, Columbus,

YVONNE A. EFEBERA, MD, Department of Hematology, Blood and Marrow Transplant, Ohio Health, Columbus, OH

Speakers:

ASH BLYTHE ALPERT, MD, MFA, Yale School of Medicine, New Haven, CT

ERIC SCOTT MULLINS, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meet the Blood Advances Editors

Sunday 4:00 p.m. - 4:30 p.m.

Halls G-H - Blood Journals Studio

Panelists:

SHANNON L. MAUDE, MD, The Children's Hospital of Philadelphia, Philadelphia, PA

CARL E. ALLEN, MD, Texas Children's Hospital, Houston, TX

ASH Clinical Practice Guidelines on **Amyloidosis**

Sunday 4:30 p.m. - 6:00 p.m.

Grand Hall B, Manchester Grand Hyatt

San Diego

Chair:

VISHAL KUKRETI, MD, University of Healthcare Network, Toronto, Ontario, Canada

Speakers:

Joselle Cook, MBBS, Mayo Clinic, Rochester, MN Increasing Awareness of Risk Factors for AL Amyloidosis

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN HIRA SHAIKH, MD, University of Iowa Caver College of Medicine, Coralville, IA

Target Site vs Surrogate Site Biopsy for Diagnosis

NARESH BUMMA, MD, The Ohio State University, Columbus, OH

Congo Red Stain Bone Marrow Screening for AL **Amyloidosis**

Special Interest Sessions

Systems-Based Hematology Education and Networking Session: Anticoagulation Stewardship and Al-Assisted Management

Sunday 4:30 p.m. - 6:00 p.m.

Room 25

Chair:

CAMILA MASIAS, MD, MPH, Miami Cancer Institute. Miami, FL


Speakers:

GEOFFREY D. BARNES, MD, MSc, University of Michigan, Ann Arbor, MI *Improving Systems-Level Management of* Anticoagulants Within and Across Care Settings

DAMON E. HOUGHTON, MD, MS, Mayo Clinic, Rochester, MN

Artificial Intelligence (AI) and Machine Learning (ML) in the Context of Anticoagulation Management

Race and Ancestry in Precision Medicine 2



Co-Chairs:

SANT-RAYN PASRICHA, MD, PhD, Walter and Eliza Hall Institute of Medical Research, Fitzroy North, Victoria, Australia

JENNIFER J. TROWBRIDGE, PhD, The Jackson Laboratory, Bar Harbor, ME

Speakers:

Keolu Fox, PhD, University of California San Diego, San Diego, CA

Incorporating Indigenous Perspectives into Population Genetics

ANN-KATHRIN EISFELD, MD, The Ohio State University, Columbus, OH

Risk Re-Stratification Based on Black AML Patient Exome Data

Maureen Achebe, MD, MPH, Brigham and Women's Hospital, Boston, MA

How Inappropriate Reference Ranges Can Propagate Systemic Racism

Symposium for Mid-Career Hematologists

Sunday 4:30 p.m. - 6:00 p.m. Room 24

Co-Chairs:

Juan Pablo Alderuccio, MD, University of Miami Miller School of Medicine, Miami, FL

SHRUTI CHATURVEDI, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD

Speakers:

RUBEN A. MESA, MD, Atrium Health Wake Forest Baptist, Winston-Salem, NC

ALLISON A. KING, MD, PHD, MPH, Washington University School of Medicine, Saint Louis, MO Negotiating Your First Leadership Position

ROBERT F. SIDONIO, JR., MD, MSc, Emory University, Atlanta, GA

JEFFREY D. LEBENSBURGER, DO, University of Alabama at Birmingham, Birmingham, AL Your Next Job - How to Identify Academic Opportunities with the Best Payback

NINA SHAH, MD, AstraZeneca, San Francisco, CA DAVID P. STEENSMA, MD, FACP, Ajax Therapeutics, Lincoln, MA

Making the Jump - Careers Outside Academia

MONDAY

	ASH Health Equity Studio, Sails Pavilion (non-CME)	
8:15 AM - 8:45 AM	Combating Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data	
10:00 AM - 10:30 AM	Ensuring Equitable Access to Quality Care for Undocumented Immigrants	
	and Mixed-Status Families	
12:00 PM - 12:30 PM	Advocating for Language Justice in Hematology	
1:00 PM - 1:30 PM	Strengthening the Provider-Patient Relationship: A Guide to Building Trust	
ASH Wellness Studio, Sails Pavilion Gon-CME		
7:00 AM - 7:45 AM	ASH Yoga, ASH Park @ The Plaza	
10:05 AM - 10:15 AM	Vitamin V: Visualize to Revitalize	
10:15 AM - 10:25 AM	The Encouragement Elixir	
12:05 PM - 12:15 PM	The Life-Changing Effect of Meditation	
12:20 PM - 12:30 PM	Whistle While You Work	
12:35 PM - 12:45 PM	H2O-M-G!	
	Blood Journals Studio, Halls G-H GON-CME	
7:30 AM - 8:30 AM	ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and	
	Translational Insights Hosted by Blood Immunology & Cellular Therapy	
8:30 AM - 9:00 AM	Meet the <i>Blood</i> Editors	
10:00 AM - 10:30 AM	Best Practices for Peer Review: ASH Clinical News interviews the Blood Advances Editors	
12:00 PM - 12:30 PM	The ABCs of Publishing for Authors: The Hematologist interviews the Blood Editors	
12:30 PM - 1:30 PM	ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by Blood	
	Global Hematology	

Meet the **Blood** Editors

Monday 8:30 a.m. - 9:00 a.m.

Halls G-H - Blood Journals Studio

Panelists:

JORGE DI PAOLA, MD, Washington University School of Medicine, St Louis, MO

ELISABETH M. BATTINELLI, MD, PhD, Brigham and Women's Hospital, Boston, MA

Best Practices for Peer Review: ASH Clinical News interviews the Blood Advances **Editors**

Monday 10:00 a.m. - 10:30 a.m.

Special Interest Sessions

Halls G-H - Blood Journals Studio

Moderator:

AARON T. GERDS, MD, MS, Editor-in-Chief, ASH Clinical News, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Panelists:

CATHERINE M. BOLLARD, MD, Editor-in-Chief, Blood Advances, Children's National Hospital, Washington, DC

Andrew S. Weyrich, PhD, Deputy Editor, Blood Advances, Oklahoma Medical Research Foundation, Oklahoma City, OK


Early Faculty Career Development Session

Monday 10:30 a.m. - 12:00 p.m. Room 25

Co-Chairs:

ADAM SCOTT KITTAI, MD, The Ohio State University, Columbus, OH

Andrew G. Volk, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH



Speakers:

Betty S. Pace, MD, Augusta University, Augusta, GA

Adam Scott Kittai, MD, The Ohio State University, Columbus, OH

Identifying a Mentor and Optimizing the Mentor/ Mentee Relationship, How to be a Good Mentee?

JOSEPH MIKHAEL, MD, MED, FRCPC, FACP, Treasurer, American Society of Hematology, Translational Genomics Research Institute, Phoenix, AZ

Shannon Elf, PhD, Emory University, Chicago, IL The Warning Signs of a Problematic Mentoring Relationship and How to Fix it

Leidy Isenalumhe, MD, MS, Children's Hospital of Los Angeles, Los Angeles, CA

RAQUEL ESPIN PALAZON, PhD, Iowa State University, Ames, IA

Transitioning from Being a Mentee to Becoming a Mentor

The ABCs of Publishing for Authors: *The Hematologist* interviews the *Blood* Editors

Monday 12:00 p.m. - 12:30 p.m.

Halls G-H - Blood Journals Studio

Moderator:

Shaji Kumar, MD, Editor-in-Chief, *The Hematologist*, Mayo Clinic, Rochester, MN

Panelists:

NANCY BERLINER, MD, Editor-in-Chief, *Blood*, Brigham and Women's Hospital, Boston, MA

Andrew Roberts, MBBS, PhD, Deputy Editor, *Blood*, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

DEI Community Networking Lunch (for in-person participants)

Monday 12:00 p.m. – 1:15 p.m.

Marina Ballroom D, Marriott Marquis San Diego Marina

Moderators:

Sarwish Rafiq, PhD., Emory University School of Medicine, Atlanta, GA

Noha Soror, MD, MSc, University of Oklahoma Health Science Center, Edmond, OK

Panelist:

 $\ensuremath{\mathsf{MARCOS}}$ de Lima, MD, The Ohio State University, Columbus, OH

ASH Quality Improvement Champions

Monday 2:45 p.m. – 4:15 p.m. Room 7

Co-Chairs:

MING Y. LIM, MBBCHIR, University of Utah, Salt Lake City, UT

RACHEL P. ROSOVSKY, MD, Massachusetts General Hospital, Boston, MA

Speakers:

Josie Fernandez Sanchez, MD, Texas Children's Hospital, Baylor College of Medicine, Houston, TX Standardizing Emergency Department Management of Iron Deficiency Anemia from Heavy Menstrual Bleeding

PAOLO LOPEDOTE, MD, City of Hope National Medical Center, Monrovia, CA

Reduced Blood Transfusions in Patients with Chronic Liver Disease Undergoing Paracentesis

Asinamai M. Ndai, BPharm, MS, University of Florida Health Physicians, Gainesville, FL Optimized Management of Hemophilia in the

Emergency Department

ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating **Research and Collaborative Clinical Care** through Real-World Evidence Generation

Monday 4:30 p.m. - 6:00 p.m.

Room 11

Co-Chairs:

ALEXIS THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

TED WUN, MD, University of California Davis Comprehensive Cancer Center, Sacramento, CA

Speakers:

ALEXIS THOMPSON, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

Representing Sickle Cell Disease Health Concepts in Real World Evidence Generation: Examples from Real World Data (RWD) Initiatives and the Importance to the Sickle Cell Disease Community

PATTY STEINERT, PhD, MBA, Medical College of Wisconsin, Milwaukee, WI

The Role of RWD in Long-Term Follow-up of Cell and Gene Therapies in Sickle Cell Disease: The CIBMTR experience

SOPHIE LANZKRON, MD, Thomas Jefferson University Hospital, Philadelphia, PA

Challenges in Data Quality: Where EHR Data Acquisition Approaches and Highly-Curated Datasets Intersect (1)

ASHIMA SINGH, PhD, MS, Medical College of Wisconsin, Pewaukee, WI

Challenges in Data Quality: Where EHR Data Acquisition Approaches and Highly-Curated Datasets Intersect (2)

NICOLE VERDUN, MD, FDA, Silver Spring, MD Regulatory Perspective: Why RWD is Critical for Evaluation of SCD Disease Modifying Curative **Therapies**

LaVerne Perlie, MSN, BSN, RN, Health and Human Services, Washington, DC

Bringing It All Together: How the Federal Government Is Facilitating Collaboration across the Sickle Cell Data Landscape

ASH Networking Reception for the Hemostasis and Thrombosis Community: Hosted by the Blood Vessels, Thrombosis and Hemostasis Journal

Monday

6:00 p.m. - 7:30 p.m.

East Terrace (Upper Level)

Center for Sickle Cell Disease Initiatives: **Advancing Progress in Sickle Cell Disease** Update and Reception: hosted by ASH and **ASH Research Collaborative**

Monday

6:00 p.m. - 8:00 p.m. **Room 11 & West Terrace**

Women In Hematology Networking Event (for in-person participants)

Monday

7:30 p.m. - 9:30 p.m.

Coronado Ballroom & Terrace. Manchester Grand Hyatt San Diego

Moderators:

BETHANY SAMUELSON BANNOW, MD, Oregon Health and Science University, Portland, OR

GLAIVY BATSULI, MD, Stanford University, Stanford, CA

Speakers:

NINA BALANCHIVADZE, MD, Virginia Oncology Associates, Norfolk, VA

OYEBIMPE ADESINA, MD, MS, UC Davis Comprehensive Cancer Center, Sacramento, CA

ALISON LOREN, MD, University of Pennsylvania, Philadelphia, PA

Special Interest Sessions

TRAINEE ACTIVITIES

ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience.

The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows.

These activities are open only to individuals with a blue trainee badge or by invitation.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY

ASH-a-Palooza Gon-CME)

Friday 12:00 p.m. - 5:00 p.m.

Entrance at 5th and K St, Gaslamp

Quarter

Chair:

Kaitlyn C. Dykes, MD, BS, University of California San Diego, San Diego, CA

ASH-a-Palooza Street Festival will be held at the Gaslamp Quarter on 5th Avenue between I and K Streets. The Entrance is on the intersection on 5th Ave and K St. The Gaslamp Quarter is a short walk from the San Diego Convention Center and most hotels in the Gaslamp Quarter; there is no transportation provided for this year's event.

Free food will be served throughout the event. Doors open at 12:00 p.m. Before programming begins at 12:45 p.m., attendees will have the opportunity to grab lunch, network, and visit *Blood* Booth informational tables.

ASH provides a variety of high-quality education, career development, networking opportunities to help trainees make the most of their meeting experience. ASH-a-Palooza content has been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows and is only open to annual meeting attendees with a blue trainee badge.

ASH Talks: The ASH Talk sessions are 20-minute presentations, similar to a TED Talk, with dynamic speakers presenting timely topics. ASH Talks are the core plenary sessions of ASH-a-Palooza that take place at the top of each hour. The talks contain little to no slides and draw the entire audience of ASH-a-Palooza together, between the other microlearning and networking sessions that occur throughout the event (Blood Drops and Blood Buddies).

Blood Drops: The Blood Drop sessions are five to 10-minute presentations designed to provide short bursts of learning. Each micro-learning session will be done twice in a row and will allow the audience to move easily between each presentation.

Blood Buddies: In-person trainees will have the opportunity to meet with leaders in the field! Trainees can sign up for a one-on-one Blood Buddy 10-minute mentoring session with a faculty member.

Blood Booths: Trainees will have the opportunity to explore interactive booths at ASH-a-Palooza. Chat with peers, take part in live training sessions, learn from experts, and more!

Trainee Welcome Reception: This informal social event immediately follows ASH-a-Palooza for in-person attendees. The reception provides the opportunity for undergraduates, medical and graduate students, residents, and fellows (DO, MD and PhD) to network and celebrate with their peers.

Networking, Free Food, *Blood* Booths, and **Welcome Performance by Adverse Events** Band Gon-CME

Friday 12:00 p.m. - 12:45 p.m. **Gaslamp Quarter**

Plenary Session: Trainee Council Chair Welcome Gon-CME

12:45 p.m. - 1:00 p.m. Friday

Main Stage, Gaslamp Quarter

Speaker:

Kaitlyn C. Dykes, MD, BS, University of California San Diego, San Diego, CA

Plenary Session: ASH Talk #1 Artificial Intelligence and Data Science GON-CME)

Friday

1:00 p.m. - 1:20 p.m.

Main Stage, Gaslamp Quarter

Chair:

Kaitlyn C. Dykes, MD, BS, University of California San Diego, La Jolla, CA

Speaker:

Andrew Srisuwananukorn, MD, Ohio State University, Columbus, Ohio

Blood Buddies (non-CME)

Friday

1:30 p.m. - 2:00 p.m., 2:40 p.m. - 3:10 p.m., and 3:20 p.m. - 3:50 p.m. Café Sevilla Restaurant, Gaslamp Quarter

Adult Clinical Classical Hematology

Mary Cushman, University of Vermont, Burlington, VT PAYAL DESAI, MD, Atrium Health, Charlotte, NC Annemarie Fogerty, MD, Massachusetts General Hospital, Boston, MA

SIOBAN KEEL, MD, University of Washington, Seattle,

CHRISTINE L. KEMPTON, Emory University, Atlanta, GA SOPHIE LANZKRON, MD, Thomas Jefferson University, Baltimore, MD

RAKESH P. MEHTA, MD, Indiana University School of Medicine, Carmel, IN

SANA SAIF UR REHMAN, MD, Washington University, Saint Louis, MO

FARZANA A. SAYANI, MD, The Trustees of The University of Pennsylvania, Philadelphia, PA

TED WUN, MD, University of California, Davis, Sacramento, CA

Adult Clinical Malignant Hematology

JANIS L. ABKOWITZ, MD, University of Washington, Seattle, WA

JENNIFER AMENGUAL, MD, NYU Medical Center, Scarsdale,

AARON T. GERDS, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Monique A. Hartley-Brown, MD, Dana-Farber Cancer Institute, Boston, MA

GREEBALLA MAGZOUB, Oklahoma University Health Sciences Center, Oklahoma City, OK

Oreofe O. Odejide, MD, Dana-Farber Cancer Institute, Boston, MA

OLATOYOSI ODENIKE, MD, University of Chicago, Chicago,

JIA RUAN, MD, PHD, The New York and Presbyterian Hospital, New York, NY

Kerry J. Savage, MD, MSc, BC Cancer, Vancouver, British Columbia, Canada

ADAM SCOTT KITTAI, MD, The Ohio State University, Columbus, OH

SWAPNA THOTA, MD, University of Tennessee Health Science Center, Memphis, TN

ALISON R. WALKER, MD, MBA, MPH, H. Lee Moffitt Cancer Center and Research Institute, Wesley Chapel,

BMT Pediatric and Adult

Ramzi Abboud, Washington University School of Medicine, Clayton, MO

ALLEN R. CHEN, MD, Johns Hopkins Kimmel Cancer Center, Baltimore, MD

ZACHARY D. CREES, MD, Washington University School of Medicine, Frontenac, MO

CARLO DUFOUR, MD, Hematology Unit, IRCCS G. Gaslini Children's Hospital, Genova, Italy

TAXIARCHIS KOURELIS, MD, Mayo Clinic, Rochester, MN SARAH M. LARSON, MD. UCLA Health, Los Angeles, CA Lori Muffly, MD, Stanford University School of Medicine, Stanford, CA

MIGUEL ANGEL PERALES, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Gunjan L. Shah, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Diversity, Equity, and Inclusion

Maureen Achebe, Brigham and Women's Hospital, Boston, MA

LANETTA BRONTÉ-HALL, MD, MPH, MSPH, University of Miami, Miller School of Medicine, Hollywood, FL CHANCELLOR DONALD, MD, Tulane University School of Medicine, New Orleans, LA

YVONNE A. EFEBERA, MD, OhioHealth, Columbus, OH ARTURO MOLINA, MD, MS, FACP, Sutro Biopharma, South San Francisco, CA

Kerice A. Pinkney, MD, Joe DiMaggio Children's Hospital, Hollywood, FL

DEIRDRA R. TERRELL, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Future of Hematology (Artificial Intelligence)

Sanjay Ahuja, MD, MSc, Rainbow Babies and Children's Hospital, Cleveland, OH

JORDAN GAUTHIER, MD, MSc, Fred Hutchinson Cancer Center, Seattle, WA

Torsten Haferlach, MD, MLL Munich Leukemia Laboratory, Munich, Germany

BARBARA D. LAM, MD, Beth Israel Deaconess Medical Center, Boston, MA

Moses Miles, ATHN, Woodstock, GA

Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Industry Career Pathway

Maria Chaudhry, Bristol Myers Squibb, Madison, NJ PARAMESWARAN N. HARI, MD, MBBS, The Medical College of Wisconsin, Brookfield, WI

CHRISTOPHER HEERY, MD, Arcellx, Durham, NC NINA SHAH, MD, AstraZeneca, San Francisco, CA

Trainee Sessions

International Medical Graduates

MAYA ABDALLAH, MD, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, MA

OTHMAN S. AKHTAR, MD, Moffit Cancer Center, Milwaukee, WI

XIMENA JORDAN BRUNO, MD, University of Pennsylvania, Philadelphia, PA

SHRUTI CHATURVEDI, MBBS, Johns Hopkins Hospital, Baltimore, MD

CIARA LOUISE FREEMAN, PHD, MSc, FRCPC, MRCP, H. Lee Moffitt Cancer Center and Research Institute, Tampa,

Andres Gomez-De Leon, MD, Universidad Autonoma de Nuevo Leon. Facultad de Medicina y Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

Tania Jain, MD, Johns Hopkins University, Baltimore,

URVI A. SHAH, MD, Memorial Sloan Kettering Cancer Center, New York, NY

JESSICA M. STEMPEL, MD, Yale University, New Haven, CT

Medical Education

Allison Carilli, MD, VA Orlando Healthcare System, Orlando, FL

SCOTT GITLIN, University of Michigan, Ann Arbor, MI Annie Im, MD, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Myles Nickolich, MD, Pennsylvania State University, Philadelphia, PA

USHA PEREPU, MBBS, University of Iowa, Iowa City, IA TERESA A. SCORDINO, MD, University of Oklahoma, Oklahoma City, OK

Pediatric Clinical Classical Hematology

Susan Elizabeth Creary, MD, MSc, Nationwide Children's Hospital Research Institute, Columbus, OH DEEPIKA S. DARBARI, MBBS, MS, Children's National Hospital, Washington, DC

MEGHAN D. DRAYTON JACKSON, DO, Riley Hospital for Children, Plainfield, IN

Lewis L. Hsu, MD, PhD, University of Illinois at Chicago, Chicago, IL

Julie Jaffray, MD, MS, Rady Children's Hospital San Diego, San Diego, CA

JACQUELYN POWERS, MD, Baylor College of Medicine and Texas Children's Hospital, Houston, TX

Pediatric Clinical Malignant Hematology

ELLEN FRAINT, Montefiore Medical Center, Bronx, NY Maria Monica Gramatges, MD, PhD, Texas Children's Hospital, Houston, TX

Leidy Isenalumhe, Moffitt Cancer Center, Lutz, FL RAYNE ROUCE, MD, Clinical Care Center – Texas Children's Hospital, Houston, TX

PhD/Lab

LAWRENCE H. BOISE, PhD, Emory University, Atlanta, GA Ryan Morin, PhD, Simon Fraser University, Burnaby, British Columbia, Canada

HEATHER ANN O'LEARY, PhD. Northeast Ohio Medical University (NEOMED), Rootstown, OH

DAVID W. Scott, British Columbia Cancer, Vancouver, British Columbia, Canada

Santosha A. Vardhana, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Andrew Volk, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

ZE ZHENG, MBBS, PhD, Medical College of Wisconsin and Versiti Blood Research Institute, Milwaukee, WI

Quality Improvement

LISA K. HICKS, MD, University of Toronto, Toronto, Ontario, Canada

VISHAL KUKRETI, University Health Network, Toronto, Ontario, Canada

JORI E. MAY, MD, University of Alabama at Birmingham, Birmingham, AL

Blood Drops (non-CME)

Friday 1:30 p.m. – 1:40 p.m., 1:50 p.m. – 2:00 p.m. Stations 1-13, Gaslamp Quarter

ASH-Harold Amos Medical Faculty Development Program Award (AMFDP)

Toyosi Onwuemene, MD, MS, Duke, Durham, NC

ASH Advocacy

CHANCELLOR DONALD, MD, Tulane University School of Medicine, New Orleans, LA

Career Development and Job Searching

URSHILA DURANI, MD, MPH, Mayo Clinic, Rochester,

Diversity, Equity, and Inclusion

Naresh Bumma, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Federal Agencies

JULIE A. PANEPINTO, MD, MSPH, National Institutes of Health, Milwaukee, WI

ASH Hematology Opportunities for the Next Generation of Research Scientists Award (HONORS)

JOSHUA A. FEIN, MD, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY

Industry and Community Career Pathways

CHADI NABHAN, MD, MBA, Caris Life Sciences, Deerfield, IL

International Medical Graduates

ADITI SHASTRI, MD, Montefiore Medical Center, Bronx, NY

Malignant Hematology

Sonali M. Smith, MD, University of Chicago, Chicago

Benjamin G. Barwick, PhD, Emory University, Atlanta, GA

Trainee Sessions

Sickle Cell Disease

Daniel Bauer, Harvard University, Boston, MA

Translational Research Training in Hematology Program (TRTH)

SARA E. MEYER, PhD, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

Wellness

ALFRED I. LEE, MD, PHD, Yale University School of Medicine, New Haven, CT

Plenary Session: ASH Talk #2 International Medical Graduates (Concession)

Friday 2:10 p.m. – 2:30 p.m. Main Stage, Gaslamp Quarter

Chair:

Kaitlyn C. Dykes, MD, BS, University of California San Diego, La Jolla, CA

Speaker:

Jane S. Hankins, MD, MS, St. Jude Children's Research Hospital, Memphis, TN

Blood Drops (non-CME)

Friday 2:40 p.m. – 2:50 p.m., 3:00 p.m. – 3:10

p.m.

Stations 1-13, Gaslamp Quarter

ASH Advocacy

Jennifer Holter-Chakrabarty, MD, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK

Career Development and Job Searching

ALISON R. WALKER, MD, MBA, MPH, H. Lee Moffitt Cancer Center and Research Institute, Wesley Chapel, FL

Diversity, Equity, and Inclusion

Srinivas Devarakonda, MD, The Ohio State University, Columbus, OH

Federal Agencies

CINDY Roy, National Institute of Diabetes, Digestive, and Kidney Disease, Bethesda, MD

International Medical Graduates

NARENDRANATH EPPERLA, MD, MS, The Ohio State University, Columbus, OH

Malignant Hematology

JOHN C. Byrd, MD, University of Cincinnati, Cincinnati, OH

ASH Medical Educators Institute (MEI)

RONAK H. MISTRY, DO, Hospital of University of Pennsylvania, Philadelphia, PA

NMPD

Stephen R. Spellman, MBS, National Marrow Donor Program, Minneapolis, MN

PhD

Francesco Maura, MD, University of Miami, Coral Gables, FL

ASH Medical Student Physician-Scientist Award (Phy-Sci)

 $\mbox{\sc Haley L.}$ Klimaszewski, BS, The Ohio State, Columbus, OH

ASH Research Training Award for Fellows (RTAF)

Vidyasagar Koduri, MD, PhD, Dana Farber Cancer Institute, Brookline, MA

Sickle Cell Disease

SHERIF M. BADAWY, MD, Ann and Robert H. Lurie Children's Hospital, Chicago, IL

Wellness

Valentina Baez Sosa, MD, National Heart, Lung, and Blood Institute, Bethesda, MD

Hearts of Hematology (HoH) GOOD-CME

Friday 3:00 p.m. – 3:50 p.m.

Hasta Mañana Cantina, Gaslamp

Quarter

Moderator:

Anika Patel, Beth Israel Deaconess Medical Center, Boston, MA

Blood Drops (non-CME)

Friday 3:20 p.m. – 3:30 p.m., 3:40 p.m. – 3:50

p.m.

Stations 1–13, Gaslamp Quarter

ASH Advocacy

Bart L. Scott, MD, Fred Hutchinson Cancer Center, Seattle, WA

Career Development and Job Searching

YVONNE A. EFEBERA, MD. OhioHealth, Columbus, OH

ASH Clinical Research Training Institute (CRTI)

Brandon Blue, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Diversity, Equity, and Inclusion

Julie E. Chang, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI

Federal Agencies

ALICE M. CUSICK, MD, Veterans Affairs (LTC Charles S Kettles VA Medical Center), Ann Arbor, MI

Hematology Inclusion Pathway Medical Student Award (succeeding the MMSAP)

Sacha Belinda Mapombo Choupa, Meharry Medical College, Nashville, TN

Industry and Community Career Pathways

Nina Shah, MD, AstraZeneca, San Francisco, CA

International Medical Graduates

Nizar J. Bahlis, MD, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

Malignant Hematology

HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

PhD

 $\mbox{\it Michael R. Green}, \mbox{\it MD}$ Anderson Medical Center, Houston, $\mbox{\it TX}$

ASH Scholar Award

Andrew Yee, PhD, Regents of The University of Michigan, Houston, TX

Sickle Cell Disease

JOHN J. STROUSE, MD, PHD, Duke University School of Medicine, Durham, NC

Wellness

PAUL FISHKIN, Illinois Cancer Care, Peoria, IL

Plenary Session: Performance by Dr. Rizzo Rouce and Message from Committee on Training Chair (GOLLER)

Friday 4:00 p.m. – 4:15 p.m.

Main Stage, Gaslamp Quarter

Speakers:

RAYNE ROUCE, MD, Clinical Care Center – Texas Children's Hospital, Houston, TX HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Plenary Session: Message from ASH Committee on Training Chair

Friday 4:10 p.m. – 4:15 p.m.

Main Stage, Gaslamp Quarter

Speaker:

HETTY E. CARRAWAY, MD, MBA, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Plenary Session: Blood Wars Trivia Game

(non-CME)

Friday 4:15 p.m. – 4:45 p.m.

Main Stage, Gaslamp Quarter

Trainee Welcome Reception GON-CME)

Friday 5:00 p.m. – 7:00 p.m.

Entrance at 5th and K St, Gaslamp

Quarter

SATURDAY

Career Development Lunch GON-CMED

Saturday 11:15 a.m. – 12:15 p.m.

Coronado Ballroom, Manchester Grand

Hyatt San Diego

Co-Chairs:

Yvonne A. Efebera, MD, Ohio Health, Columbus, OH Leidy Isenalumhe, Moffitt Cancer Center, Lutz, FL

This session provides an intimate venue for trainees to meet with leaders in hematology to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research, PhD careers, careers in industry settings, and careers in private and clinical practice.

There will are multiple tables dedicated to each career area and one faculty member at each table leading the discussion. A lunch is provided. This is a first come, first served event that is usually very-well attended.

Adult BMT/Cellular Therapy

NARESH BUMMA, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH Monique A. Hartley-Brown, MD, DFCI, Boston, MA ABDULLAH MOHAMMAD KHAN, MD, MBBS, The Ohio State University, Columbus, OH

Adult Classical Hematology

OYEBIMPE ADESINA, MD, MS, UC Davis Comprehensive Cancer Center, Sacramento, CA

Hanny Al-Samkari, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA Payal Desai, MD, Wake Forest University, Charlotte, NC

Alfred I. Lee, MD, PhD, Yale University School of Medicine, New Haven, CT

Adult Malignant Hematology

MIKKAEL A. SEKERES, MD, University of Miami Miller School of Medicine, Miami, FL

Sara Wall, Ohio State University Medical Center, Columbus, OH

 $\ensuremath{\mathsf{BASEM}}$ M. William, MD, MRCP(UK), FACP, OhioHealth, Columbus, OH

Geriatric Hematology

Ashley Rosko, MD, The Ohio State University, Columbus, OH

Tanya Wildes, University of Nebraska, Omaha, NE

Government Careers (NIH and FDA)

ELAINE S. JAFFE, MD, National Cancer Institute, National Institute of Health, Bethesda, MD JULIE A. PANEPINTO, MD, MSPH, Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute, Bethesda, MD CARA RABIK, MD, PHD, Food and Drug Administration, Silver Spring, MD

Hematology-Focused Fellowship Training Program (HFFTP)

Rakhi P. Naik, MD, Johns Hopkins Hospital, Baltimore, MD

ROBERT STERN, Dana-Farber Cancer Institute, Inc., Boston, MA

Industry Careers

Maria Chaudhry, Bristol Myers Squibb, Madison, NJ E. Leila Jerome Clay, MD, Johns Hopkins, Watertown, MA

Danielle Townsley, Astra Zeneca, Potomac, MD

International Graduate Hematology

Shruti Chaturvedi, MBBS, Johns Hopkins University School of Medicine, Baltimore, MD Srikanth Nagalla, Baptist Health South Florida,

Miami, FL Pallawi Torka, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

International Opportunities Hematology

ALI BAZARBACHI, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon Kohei Hosokawa, MD, PhD, Kanazawa University, Kanazawa, Japan

EBRU Koca, Baskent University, Ankara, Turkey

Laboratory and Translational Hematology

Andrew Volk, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Randal Joseph Westrick, PhD, Oakland University, Rochester, MI

ALISA S. Wolberg, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC

Lifespan Hematology

Alexander A. Boucher, MD, University of Minnesota, Minneapolis, MN Rebecca Kruse-Jarres, MD, MPH, University of

Washington, Seattle, WA

Maternal Health

LISA BAUMANN KREUZIGER, MD, MS, Versiti, Milwaukee, WI

Paula James, MD, FRCPC, Queen's University, Kingston, Ontario, Canada

Medical Educators in Hematology

TAPAN M. KADIA, MD, MD Anderson Cancer Center, Houston, TX

Sanjay Mohan, MD, Vanderbilt University Medical Center, Nashville, TN

Sandhya Panch, National Institutes of Health, Seattle, WA

Medical Informatics & AI

James S. Blachly, MD, The Ohio State University, Columbus, OH

Lars Bullinger, University of Ulm, Berlin, Germany Matthew J. Maurer, DSc, Mayo University, Rochester, MN

Pediatric BMT/CAR-T

Sajad Khazal, MD Anderson Medical Center, Loma Linda, TX

Pediatric Clinical Hematology

SARAH H. O'BRIEN, MD, MSc, Ohio State University, Columbus, OH

Sara Vesely, PhD, The Univ. of OK Health Sciences Ctr., Oklahoma City, OK

Angela C. Weyand, MD, University of Michigan Medical School, Ann Arbor, MI

Pediatric Hematology

Maria Carter Febres, MD, Cincinnati Children's Hospital, Cincinnati, OH

ADRIENNE M. HAMMILL, MD, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH YI ZHENG, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

PhD Careers

SHANNON ELF, PhD, The University of Chicago, Chicago, IL

Margaret Goodell, PhD, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX Parvathi Ranganathan, PHD, Ohio State University, Columbus, OH

Private Practice Hematology

STEVEN FEIN, MD, MPH, University of Miami, Miami, FL

EMILY SAUL, Columbus Oncology & Hematology, Columbus, OH

Systems Based Hematology

VISHAL KUKRETI, University Health Network, Toronto, Ontario, Canada

Asнок Раі, MD, Kaiser Permanente, Oakland, CA

SUNDAY

Trainee Didactic Session: Creating a Laboratory and Clinical Research Program from Scratch

Sunday 11:15 a.m. – 12:15 p.m. Room 31

Chair:

Urshila Durani, MD, MPH, Mayo Clinic, Rochester, MN

Speakers:

ALEX F. HERRERA, MD, City of Hope, Duarte, CA COURTNEY JONES, PHD, Cincinnati Children's Hospital, Cincinnati, OH Trainee Didactic Session: Time Management in Clinical and Research: There Are Only 24 Hours in a Day or Everyone Needs a System

(non-CME)

Sunday 11:15 a.m. – 12:15 p.m. Room 33

Chair:

USHA PEREPU, MBBS, Mays Cancer Center, San Antonio, TX

Speakers:

MAYA ABDALLAH, MD, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, MA
Andrew Volk, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
JYOTI NANGALIA, MBBCHIR, Wellcome Sanger Institute, Hinxton, England, United Kingdom
DIANA PASSARO, Inserm Université, Paris, France
LY VU, PhD, Memorial Sloan-Kettering Cancer Center, Vancouver, British Columbia, Canada

MONDAY

Trainee Didactic Session: Building, Nurturing, and Sustaining a Research Program (ODE)

Monday 12:15 p.m. – 1:15 p.m. Room 33

Chair:

USHA PEREPU, MBBS, Mays Cancer Center, San Antonio, TX

Speakers:

Monica L. Guzman, PhD, Weill Cornell Medical College Division of Hematology/Oncology, New York, NY Allison A. King, MD, PhD, MPH, Washington University, St. Louis, MO

Trainee Didactic Session: Setting Up a Health Services and Outcomes Research Program (OUTCOME)

Monday 12:15 p.m. – 1:15 p.m. Room 31

Chair:

Urshila Durani, MD, MPH, Mayo Clinic, Rochester, MN

Speakers:

Areej El-Jawahri, MD, Massachusetts General Hospital, Allston, MA Lori Muffly, MD, Stanford University School of Medicine, Stanford, CA


Trainee Sessions




Introducing New Journals from the *Blood®* Journals Portfolio

Learn about ASH's new open access, online-only journals at **bloodjournals.org**









Stop by the Blood Journals Studio in the Poster Hall to learn more!

2024 SCIENTIFIC CATEGORIES

For the 2024 66th ASH Annual Meeting abstracts were submitted in 75 different scientific categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by

category number. Oral Abstract Sessions' titles begin with the category number and name. They are listed in the Program-at-a-Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by category number.

100s - Red Cell Physiology and Disorders

- 101 Red Cells and Erythropoiesis, Excluding Iron
- 102 Iron Homeostasis and Biology
- 112 Thalassemia and Globin Gene Regulation
- 113 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational
- 114 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

200s - Leukocytes, Inflammation, and Immunology

- 201 GranulocytesMonocytesand Macrophages
- 203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

300s - Hemostasis, Thrombosis, and Vascular Wall Biology

- 301 Platelets and Megakaryocytes: Basic and Translational
- 311 Disorders of Platelet Number or Function: Clinical and Epidemiological
- 321 Coagulation and Fibrinolysis: Basic and Translational
- 322 Hemophilia A and B: Clinical and Epidemiological
- 323 Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological
- 330 Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational
- 331 Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological
- 332 Thrombosis and Anticoagulation: Clinical and Epidemiological

400s - Transfusion Medicine

401 Blood Transfusion

500s - Hematopoiesis

- 501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational
- 503 Clonal Hematopoiesis, Aging, and Inflammation
- 506 Bone Marrow Microenvironment
- 508 Bone Marrow Failure: Acquired
- 509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

600s - Hematologic Malignancy

- 602 Myeloid Oncogenesis: Basic
- 603 Lymphoid Oncogenesis: Basic
- 604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
- 605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
- 612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological
- 613 Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation
- 614 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis
- 615 Acute Myeloid Leukemias: Clinical and Epidemiological
- 616 Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies
- 617 Acute Myeloid Leukemias: Commercially Available Therapies
- 618 Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis
- 619 Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment
- 621 Lymphomas: Translational—Molecular and Genetic
- 622 Lymphomas: Translational—Non-Genetic

Scientific Categories 107

2024 SCIENTIFIC CATEGORIES

- 623 Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
- 624 Hodgkin Lymphomas: Clinical and Epidemiological
- 625 T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological
- 626 Aggressive Lymphomas: Clinical and Epidemiological
- 627 Aggressive Lymphomas: Pharmacologic Therapies
- 628 Aggressive Lymphomas: Cellular Therapies
- 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
- 632 Chronic Myeloid Leukemia: Clinical and Epidemiological
- 634 Myeloproliferative Syndromes: Clinical and Epidemiological
- 636 Myelodysplastic Syndromes: Basic and Translational
- 637 Myelodysplastic Syndromes: Clinical and Epidemiological
- 641 Chronic Lymphocytic Leukemia: Basic and Translational
- 642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological
- 651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
- 652 MGUSAmyloidosisand Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological
- 653 Multiple Myeloma: Clinical and Epidemiological
- 654 Multiple Myeloma: Pharmacologic Therapies
- 655 Multiple Myeloma: Cellular Therapies

700s - Transplantation and Adoptive Cell Therapies

- 701 Experimental Transplantation: Basic and Translational
- 702 CAR-T Cell Therapies: Basic and Translational
- 703 Cellular Immunotherapies other than CAR-T Cells: Basic and Translational

- 704 Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
- 711 Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products
- 721 Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities
- 722 Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution
- 723 Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence
- 732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

800s - Gene Therapies, Chemical Biology, and Emerging Diagnostics

- 801 Gene Therapies
- 802 Chemical Biology and Experimental Therapeutics
- 803 Emerging Tools, Techniques, and Artificial Intelligence in Hematology

900s - Health Services, Quality Improvement, and Outcomes Research

- 900 Health Services and Quality Improvement: Hemoglobinopathies
- 901 Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies
- 902 Health Services and Quality Improvement: Lymphoid Malignancies
- 903 Health Services and Quality Improvement: Myeloid Malignancies
- 904 Outcomes Research: Hemoglobinopathies
- 905 Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies
- 906 Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders
- 907 Outcomes Research: Plasma Cell Disorders
- 908 Outcomes Research: Myeloid Malignancies
- 909 EducationCommunicationand Workforce

108 Scientific Categories

ORAL ABSTRACT SESSIONS

The Oral Abstract Sessions will be held Saturday, December 7, through Monday, December 9. Each abstract presentation will be followed immediately by a question-and-answer period with

the presenter. The Plenary Scientific Session will be held Sunday, September 10, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

All Grand Halls, Seaport Ballrooms, and the Harbor Ballroom are in the Manchester Grand Hyatt

All Pacific Ballrooms and San Diego Ballrooms are in the Marriott Marquis San Diego Marina

SATURDAY

9:30 a.m. - 11:00 a.m. Oral Abstract Sessions Con-CME

- 102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation (7–12) Room 29
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire (13–18) Room 24
- 401. Blood Transfusion: Advancements in Transfusion Science (19–24)

 Room 31
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Epigenetic and Metabolic Control of Hematopoiesis (25–30)

 Room 6DE
- 508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH (31–36) Room 11
- 602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies (37–42) Room 6A
- 603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL (43–48) Marriott Grand Ballroom 8-9
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Determinants of Venetoclax Resistance and Response (49–54) **Grand Hall B**
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies (55–60) Hall B
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Multi-omic Applications for Disease Evolution and Response to Therapy (61–66)

 Seaport Ballroom EFGH
- 628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas (67–72) Pacific Ballroom Salons 18-19

- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment (73–78)
 - **Marriott Grand Ballroom 5-6**

Ballroom 20CD

- 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma? (79–84) Pacific Ballroom Salons 24-26
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies (85–90) Ballroom 20AB
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities (91–96) Marriott Grand Ballroom 11-13
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD (97–102)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies (103–108)

 Room 30
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies (109–114) Room 6B
- 908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care (115–120) Grand Hall C

12:00 p.m. - 1:30 p.m. Oral Abstract Sessions Gon-CME)

- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease (121–126) Room 11
- 322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations (127–132)
 Room 29
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Humoral Coagulation Factors: Venous Thrombosis and Beyond (133–138) Room 28 A-D
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP (139–144) Room 30
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies (145–150) Room 25
- 802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies (151–156) Room 33
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care (157–162) Room 31

2:00 p.m. - 3:30 p.m. Oral Abstract Sessions Con-CME

- Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche (163–168)
 Room 33
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease (169–174) Room 31
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease (175–180) Hall B
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets and Endothelium in Thrombotic Disorders (181–186) Room 25
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation (187–192) Grand Hall D
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms (193–198) Room 7
- 603. Lymphoid Oncogenesis: Basic: Molecular Insights into Acute Lymphoblastic Leukemias (199–204) Marriott Grand Ballroom 8-9
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies (205–210) Grand Hall B
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML (211–216) Ballroom 20CD

- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML (217–222) Seaport Ballroom EFGH
- 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond (223–228) Seaport Ballroom ABCD
- 621. Lymphomas: Translational Molecular and Genetic: Molecular Profiling and Targets in Aggressive Lymphomas (229–234)

 Pacific Ballroom Salons 15-17
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Therapies for Mantle Cell Lymphoma (235–240) Marriott Grand Ballroom 11-13
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Personalized and Molecular Approaches in Myeloproliferative Neoplasms: Risk Stratification and Therapeutic Implications (241–246) Ballroom 20AB
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes (247–252) San Diego Ballroom AB
- 653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies (253–258) Pacific Ballroom Salons 21-22
- Experimental Transplantation: Basic and Translational: GVHD, Mucosal Immunology and the Microbiome (259–264)
 Room 6B
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Adult Patients (265–270) Room 6CF

- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: Al Approaches to Drug Development, Classification and Outcomes (271-276) Room 6DE
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money! (277-282) **Marriott Grand Ballroom 2-4**
- 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple Myeloma (283-288) **Marriott Grand Ballroom 5-6**

Oral Abstract Sessions Con-CME 4:00 p.m. - 5:30 p.m.

- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Tools and Biomarkers for Improving Sickle Cell Disease Treatments (289-294) Room 30
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis in Pregnancy and Childhood (295–300) Room 29
- 508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (301-306) Room 11
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients (307-312) Marriott Grand Ballroom 5-6
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL (313-318) **Marriott Grand Ballroom 8-9**
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms (319-324) Seaport Ballroom EFGH
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies (325-330) Seaport Ballroom ABCD
- 622. Lymphomas: Translational Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas (331-336) Pacific Ballroom Salons 15-17
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma (337–342) Marriott Grand Ballroom 11-13
- 636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS (343-348) Ballroom 20CD

- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS (349-354) **Ballroom 20AB**
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders (355–360) Pacific Ballroom Salons 18-19
- 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions (361–366) San Diego Ballroom AB
- 702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells (367-372) **Grand Hall C**
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients (373–378) Room 6DE
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Monitoring, Understanding and Optimizing GVHD Interventions (379-384) Room 6CF
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments (385-390) Room 6B
- 904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Determinants of Health Equity Across the Spectrum (391–396) Room 31
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations (397-402) Room 6A
- 908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies (403-408) **Grand Hall B**

SUNDAY

9:30 a.m. - 11:00 a.m. Oral Abstract Sessions Con-CME

- 112. Thalassemia and Globin Gene Regulation: We're Going to Catch a Big One: Towards Targeted Therapies in Thalassemia (409–414) Room 31
- Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia (415–420)
 Grand Hall D
- 301. Platelets and Megakaryocytes: Basic and Translational: Megakarocyte and Platelet Biology: From Formation to Function (421–426) Room 28 A-D
- 321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag (427–432) Room 25
- Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism, Differentiation and Inflammation (433–438)
 Room 7
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models (439–444) Room 11
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes (445–450) Seaport Ballroom ABCD
- 621. Lymphomas: Translational Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas (451–456) Marriott Grand Ballroom 5-6
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma (457–462)

 Ballroom 20AB
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas (463–468) Ballroom 20CD
- 626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma (469–474) Marriott Grand Ballroom 8-9

632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice (475–480)

Harbor Ballroom DEFG

- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents (481–486) Grand Hall C
- 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice (487–492) Pacific Ballroom Salons 21-22
- 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA (493–498)

Pacific Ballroom Salons 18-19

- 702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing (499–504) Room 6A
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation (505–510)
 Room 6B
- 801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside (511–516)

 Room 30
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Navigating and Optimizing Healthcare Systems (517–522) Hall B
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma (523–528) Pacific Ballroom Salons 24-26
- 908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity (529–534) Grand Hall B

12:00 p.m. - 1:30 p.m. Oral Abstract Sessions Con-CME

- 101. Red Cells and Erythropoiesis, Excluding Iron: Regulation of Erythropoiesis (535–540)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Improving Outcomes in Sickle Cell Disease Around the World (541–546) Room 28 A-D
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science (547–552)

 Room 30
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes (553–558)

 Room 29
- 506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Normal Hematopoiesis (559–564) Room 7

- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy (565-570)
 - Ballroom 20CD
- 626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas (571–576) **Marriott Grand Ballroom 5-6**
- 627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL (577–582) Ballroom 20AB
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL (583-588) **Marriott Grand Ballroom 8-9**
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies (589-594) San Diego Ballroom AB

- 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases (595-600) Room 11
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Empowering Choices: Navigating Shared Decision-Making for Patient-Centric Care (601-606) Room 25
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies (607–612) **Marriott Grand Ballroom 2-4**
- 909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients (613-618) Room 6A

2:00 p.m. - 4:00 p.m.

Plenary Scientific Session Con-CME

Hall B

Oral Abstract Sessions (non-CME) 4:30 p.m. - 6:00 p.m.

- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications - Lessons from Pre-clinical Models (619-624) Room 31
- 602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology (625-630) **Seaport Ballroom ABCD**
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL (631-636)
 - **Marriott Grand Ballroom 5-6**
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis (637-642) Seaport Ballroom EFGH
- 622. Lymphomas: Translational Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses (643-648) Pacific Ballroom Salons 15-17
- 626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma (649-654) **Marriott Grand Ballroom 8-9**
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis (655-660) **Grand Hall D**

- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS (661-666) **Harbor Ballroom DEFG**
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma (667-672) Pacific Ballroom Salons 24-26
- 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond (673–678) Pacific Ballroom Salons 21-22
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity (679-684) **Marriott Grand Ballroom 2-4**
- 721. Allogeneic Transplantation: Conditioning Regimens. Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities (685-690) Room 6B
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA (691-696) Room 6A
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis (697-702) Room 6CF
- 907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes (703-708) San Diego Ballroom AB

MONDAY

10:30 a.m. - 12:00 p.m. Oral Abstract Sessions Con-CME

- Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP (709–714)
 Room 29
- 322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term (715–720) Room 30
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies (721–726) Seaport Ballroom ABCD
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia (727–732) Marriott Grand Ballroom 11-13
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML (733–738) Grand Hall B
- 621. Lymphomas: Translational Molecular and Genetic: Singlecell and Spatial Analyses in Indolent Lymphomas (739–744) Marriott Grand Ballroom 5-6
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas (745–750) Marriott Grand Ballroom 8-9
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes (751–756) Grand Hall C

- 641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms (757–762)
 - Pacific Ballroom Salons 15-17
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma (763–768)

 Pacific Ballroom Salons 24-26
- 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma (769–774)

 Pacific Ballroom Salons 21-22
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant (775–780) Room 6A
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow Improving Access to Blood Cancer Treatments and Trials (781–786)

 San Diego Ballroom AB
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes (787–792)

 Seaport Ballroom EFGH
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases (793–798) Room 6B

2:45 p.m. - 4:15 p.m. Oral Abstract Sessions Con-CME

- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: The Effects of Sickle Cell Disease on Organ Function (799–804)
 Room 33
- 201. Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis (805–810)

 Room 6DE
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis: Models, Risk Factors, and Outcomes (811–816) Room 28 A-D
- 506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease (817–822)

 Room 11
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs (823–828) Seaport Ballroom ABCD
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma (829–834) Ballroom 20CD

- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell diseases (835–840) Marriott Grand Ballroom 2-4
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML (841–846) **Grand Hall C**
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment (847–852) **Grand Hall B**
- 621. Lymphomas: Translational Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas (853–858) Pacific Ballroom Salons 18-19
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia (859–864) Marriott Grand Ballroom 11-13

- 627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications (865–870)
 - Pacific Ballroom Salons 15-17
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes (871–876) Seaport Ballroom EFGH
- 636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS (877–882) Grand Hall D
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life (883–888) Marriott Grand Ballroom 5-6
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis (889–894) Pacific Ballroom Salons 21-22
- 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse (895–900) Pacific Ballroom Salons 24-26

- 701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity (901–906)

 Room 6B
- 702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy (907–912)

 Room 6CF
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics (913–918) Marriott Grand Ballroom 8-9
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies (919–924) Hall B
- 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival (925–930) Room 6A
- 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies (931–936) San Diego Ballroom AB

4:30 p.m. - 6:00 p.m. Oral Abstract Sessions Gon-CME

- Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease (937–942)
 Room 28 A-D
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences (943–948) **Grand Hall C**
- 602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia (949–954) Seaport Ballroom ABCD
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma (955–960) Ballroom 20CD
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies (961–966) Marriott Grand Ballroom 5-6
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World (967–972) Grand Hall B
- 622. Lymphomas: Translational Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies (973–978)

 Marriott Grand Ballroom 11-13
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas? (979–984)

 Pacific Ballroom Salons 15-17
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas (985–990) Pacific Ballroom Salons 18-19

- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome (991–996) Seaport Ballroom EFGH
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis (997–1002) Harbor Ballroom DEFG
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia (1003–1008) Grand Hall D
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations (1009–1014)

 Marriott Grand Ballroom 8-9
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM (1015–1020) Pacific Ballroom Salons 21-22
- 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma (1021–1026) Hall B
- 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma (1027–1032) Pacific Ballroom Salons 24-26
- 702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells (1033–1038)

 Room 6CF
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Avoiding GVHD and Improving Outcomes (1039–1044) Room 6B

- 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse (1045–1050) Room 6A
- 801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies (1051–1056) Room 33
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs (1057–1062) Marriott Grand Ballroom 2-4
- 904. Outcomes Research: Hemoglobinopathies: Non-Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease (1063–1068) Room 6DE

POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the San Diego Convention Center, Halls G-H. Presenters will stand beside their posters during the evening Presentation times. Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 9:00 a.m. (Pacific time) each day, as

well as access posters from previous days on the virtual platform.

The Poster Hall hours are as follows:

Saturday, December 7 9:00 a.m. – 7:30 p.m.

Sunday, December 8 9:00 a.m. – 8:00 p.m.

Monday, December 9 9:00 a.m. – 8:00 p.m.

Poster Sessions are not offered for CME credit.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY, DECEMBER 7, 2024

5:30 p.m. – 7:30 p.m. Poster Session I – Presentations Con-CME

Poster Session I - Viewing Con-CME

Halls G-H

9:00 a.m. - 7:30 p.m.

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1069–1086)
- 102. Iron Homeostasis and Biology: Poster I (1087-1093)
- 112. Thalassemia and Globin Gene Regulation: Poster I (1094–1099)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1100–1115)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1116–1143)
- 201. Granulocytes, Monocytes, and Macrophages: Poster I (1144–1154)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1155–1163)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster I (1164–1173)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1174–1193)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1194–1203)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster I (1204–1215)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I (1216–1223)
- 330. Vascular Biology, Thrombosis, and Thrombotic
 Microangiopathies: Basic and Translational: Poster I (1224–1235)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I (1236–1244)

- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1245–1264)
- 401. Blood Transfusion: Poster I (1265-1270)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1271–1281)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I (1282–1296)
- 506. Bone Marrow Microenvironment: Poster I (1297–1306)
- 508. Bone Marrow Failure: Acquired: Poster I (1307–1323)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1324–1332)
- 602. Myeloid Oncogenesis: Basic: Poster I (1333-1356)
- 603. Lymphoid Oncogenesis: Basic: Poster I (1357-1371)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1372–1401)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1402–1419)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1420–1431)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I (1432–1450)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I (1451–1468)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1469–1494)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I (1495–1504)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I (1505–1527)

- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I (1528-1567)
- 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I (1568-1576)
- 621. Lymphomas: Translational Molecular and Genetic: Poster I (1577-1607)
- 622. Lymphomas: Translational Non-Genetic: Poster I (1608-1625)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1626-1661)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I (1662-1674)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I (1675-1693)
- 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I (1694-1718)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster I (1719-1742)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster I (1743-1750)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1751–1764)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1765–1780)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1781-1808)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster I (1809-1817)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I (1818-1845)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I (1846-1854)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (1855-1875)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (1876–1909)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (1910–1927)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster I (1928-1972)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster I (1973–2000)
- 655. Multiple Myeloma: Cellular Therapies: Poster I (2001-2009)

- 701. Experimental Transplantation: Basic and Translational: Poster I (2010-2023)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster I (2024-2053)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I (2054-2063)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I (2064-2088)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I (2089-2100)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I (2101–2134)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I (2135-2157)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I (2158-2177)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2178-2193)
- 801. Gene Therapies: Poster I (2194-2202)
- 802. Chemical Biology and Experimental Therapeutics: Poster I (2203-2210)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I (2211-2236)
- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I (2237-2250)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2251–2264)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I (2265–2289)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I (2290-2300)
- 904. Outcomes Research: Hemoglobinopathies: Poster I (2301-2313)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2314-2332)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I (2333-2377)
- 907. Outcomes Research: Plasma Cell Disorders: Poster I (2378-2411g)
- 908. Outcomes Research: Myeloid Malignancies: Poster I (2412-2438)
- 909. Education, Communication, and Workforce: Poster I (2439-2448)

SUNDAY, **DECEMBER 8, 2024**

9:00 a.m. - 8:00 p.m. Poster Session II - Viewing Gon-CME

6:00 p.m. - 8:00 p.m. Poster Session II - Presentations (non-CME)

Halls G-H

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2449-2466)
- 102. Iron Homeostasis and Biology: Poster II (2467-2473)
- 112. Thalassemia and Globin Gene Regulation: Poster II (2474-2479)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2480-2494)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2495-2522)
- 201. Granulocytes, Monocytes, and Macrophages: Poster II (2523-2533)

- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2534–2541)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster II (2542–2550)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (2551–2570)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (2571–2581)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster II (2582–2593)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II (2594–2601)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II (2602–2613)
- Thrombotic Microangiopathies/Thrombocytopenias:
 Clinical and Epidemiological: Poster II (2614–2621)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (2622–2641)
- 401. Blood Transfusion: Poster II (2642-2647)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (2648–2659)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II (2660–2675)
- 506. Bone Marrow Microenvironment: Poster II (2676-2685)
- 508. Bone Marrow Failure: Acquired: Poster II (2686-2702)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (2703–2710)
- 602. Myeloid Oncogenesis: Basic: Poster II (2711-2734)
- 603. Lymphoid Oncogenesis: Basic: Poster II (2735–2748)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (2749–2778)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (2779–2796)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (2797–2808)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II (2809–2828)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II (2829–2846)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (2847–2872)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II (2873–2883)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II (2884–2907)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II (2908–2947)
- 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster II (2948–2956)
- 621. Lymphomas: Translational Molecular and Genetic: Poster II (2957–2987)
- 622. Lymphomas: Translational Non-Genetic: Poster II (2988-3006)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3007–3042)

- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II (3043–3055)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II (3056–3074)
- 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster II (3075–3099)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster II (3100–3123)
- 628. Aggressive Lymphomas: Cellular Therapies: Poster II (3124–3132)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3133–3147)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3148–3163)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3164–3191)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster II (3192–3200)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II (3201–3228)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II (3229–3236)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3237–3257)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3258–3291)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3292–3309)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster II (3310–3353)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster II (3354–3381)
- 655. Multiple Myeloma: Cellular Therapies: Poster II (3382-3390)
- 701. Experimental Transplantation: Basic and Translational: Poster II (3391–3404)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster II (3405–3433)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II (3434–3444)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II (3445–3469)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II (3470–3481)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II (3482–3514)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II (3515–3537)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II (3538–3557)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (3558–3573)
- 801. Gene Therapies: Poster II (3574-3583)
- 802. Chemical Biology and Experimental Therapeutics: Poster II (3584–3591)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II (3592–3616)

- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II (3617-3630)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (3631-3644)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II (3645-3668)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II (3669-3681)
- 904. Outcomes Research: Hemoglobinopathies: Poster II (3682-3693)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (3695-3713)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II (3714-3758)
- 907. Outcomes Research: Plasma Cell Disorders: Poster II (3759-3792h)
- 908. Outcomes Research: Myeloid Malignancies: Poster II (3793-3818)
- 909. Education, Communication, and Workforce: Poster II (3819-3828)

MONDAY, DECEMBER 9, 2024

9:00 a.m. - 8:00 p.m.

Poster Session III - Viewing Con-CME



6:00 p.m. - 8:00 p.m.

Poster Session III - Presentations Gon-CME)

Halls G-H

- 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (3829-3847)
- 102. Iron Homeostasis and Biology: Poster III (3848-3854)
- 112. Thalassemia and Globin Gene Regulation: Poster III (3855-3860)
- 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (3861-3876)
- 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (3877-3904)
- 201. Granulocytes, Monocytes, and Macrophages: Poster III (3905–3916)
- 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (3917-3924)
- 301. Platelets and Megakaryocytes: Basic and Translational: Poster III (3925-3934)
- 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (3935-3953)
- 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (3954-3964)
- 322. Hemophilia A and B: Clinical and Epidemiological: Poster III (3965-3976)
- 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III (3977-3985)
- 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III (3986-3998)
- 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III (3999–4006)
- 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4007-4026)
- 401. Blood Transfusion: Poster III (4027-4032)
- 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4033-4044)
- 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III (4045-4060)
- 506. Bone Marrow Microenvironment: Poster III (4061-4070)

- 508. Bone Marrow Failure: Acquired: Poster III (4071–4087)
- 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4088-4096)
- 602. Myeloid Oncogenesis: Basic: Poster III (4097-4119)
- 603. Lymphoid Oncogenesis: Basic: Poster III (4120-4133)
- 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (4134-4162)
- 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (4163-4180)
- 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (4181–4191)
- 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III (4192–4211)
- 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III (4212-4229)
- 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (4230-4254)
- 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III (4255–4265)
- 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III (4266-4288)
- 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III (4289-4327)
- 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III (4328–4337)
- 621. Lymphomas: Translational Molecular and Genetic: Poster III (4338-4367)
- 622. Lymphomas: Translational Non-Genetic: Poster III (4368-4386)
- 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (4387-4422)
- 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III (4423–4434)
- 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III (4435-4453)
- 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III (4454–4478)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III (4479-4502)

- 628. Aggressive Lymphomas: Cellular Therapies: Poster III (4503–4511)
- 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (4512–4525)
- 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (4526–4541)
- 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (4542–4569)
- 636. Myelodysplastic Syndromes: Basic and Translational: Poster III (4570–4578)
- 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III (4579–4605)
- 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III (4606–4613)
- 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (4614–4634)
- 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (4635–4668)
- 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (4669–4685)
- 653. Multiple Myeloma: Clinical and Epidemiological: Poster III (4686–4729)
- 654. Multiple Myeloma: Pharmacologic Therapies: Poster III (4730–4757)
- 655. Multiple Myeloma: Cellular Therapies: Poster III (4758-4766)
- 701. Experimental Transplantation: Basic and Translational: Poster III (4767–4780)
- 702. CAR-T Cell Therapies: Basic and Translational: Poster III (4781–4810)
- 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III (4811–4821)
- 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III (4822–4846)
- 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III (4847–4858)
- 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III (4859–4892)
- 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III (4893–4915)
- 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III (4916–4936)
- 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (4937–4952)
- 801. Gene Therapies: Poster III (4953-4962)
- 802. Chemical Biology and Experimental Therapeutics: Poster III (4963–4971)
- 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III (4972–4996)


- 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III (4997–5010)
- 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (5011–5024)
- 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III (5025–5048)
- 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III (5049–5059)
- 904. Outcomes Research: Hemoglobinopathies: Poster III (5060–5072)
- 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (5073–5091)
- 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III (5092–5137)
- 907. Outcomes Research: Plasma Cell Disorders: Poster III (5138–5170h)
- 908. Outcomes Research: Myeloid Malignancies: Poster III (5171–5197)
- 909. Education, Communication, and Workforce: Poster III (5198–5207)



OVER 6,000 Images!

The American Society of Hematology Image Bank

is a peer-reviewed web-based image library and teaching resource that offers a comprehensive collection of high-resolution images* relating to a wide range of hematologic topics.



*Commercial use requires a copyright license from Copyright Clearance Center



SATELLITE SYMPOSIA

These symposia will take place on Friday, December 6, 2024, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in this program. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

FRIDAY MORNING SYMPOSIA: 7:00 A.M. – 10:00 A.M.

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia: What Clinicians Want to Know

Friday 7:00 a.m. – 10:00 a.m.

Seaport Ballroom EFGH

Manchester Grand Hyatt San Diego

This program is provided by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd and Lilly.

CHAIR:

JEFF P. SHARMAN, MD, Willamette Valley Cancer Institute, Sarah Cannon Research, Eugene, OR

Speakers:

FARRUKH T. AWAN, MD, UT Southwestern Medical Center, Dallas, TX

BITA FAKHRI, MD, MPH, University of California, San Francisco, CA

KERRY A. ROGERS, MD, The Ohio State University, Columbus. OH

WILLIAM G. WIERDA, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia: What Clinicians Want to Know

Friday 7:00 a.m. – 10:00 a.m.
Seaport Ballroom ABCD
Manchester Grand Hyatt San Diego

This program is provided by Research To Practice and supported by an educational grant from Novartis.

Chair:

MICHAEL J. MAURO, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers:

Andreas Hochhaus, MD, Klinik für Innere Medizin II, Jena, Germany Douglas Smith, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

Advances in Paroxysmal Nocturnal Hemoglobinuria: Reshaping Management Decision-Making Through Case Challenges Together with the International PNH Interest Group

7:00 a.m. – 10:00 a.m. Ballroom 20AB

This program is provided by the International PNH Interest Group and supported by Alexion, Apellis and Sobi.

For in-person participants only.

Chair:

Petra Muus, MD, St James's University Hospital, Leeds, United Kingdom

Charles Parker, MD, University of Utah School of Medicine, Salt Lake City, UT

Speakers:

Rodrigo T. Calado, MD, PhD, University of Sao Paulo, Ribeirão Preto, Brazil Carlos M. de Castro, MD, Duke University,

Durham, NC

Morag Griffin, MBChB, MRCP, Leeds Teaching Hospitals, Leeds, United Kingdom

BING HAN, Peking Union Medical College Hospital, Beijing, China

Britta Höchsmann, MD, Institute for Clinical Transfusion Medicine and Immunogenetics, University of Ulm, Ulm, Germany

RICHARD J. KELLY, MBCHB, PHD, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP, King's College Hospital NHS Foundation Trust, London, United Kingdom

JENS PANSE, MD, University Hospital RWTH Aachen, Aachen, Germany

ALEXANDER RÖTH, MD, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany Phillip Scheinberg, MD, Hospital A Beneficência Portuguesa, São Paulo, Brazil Jeffrey Szer, MBBS, The Royal Melbourne Hospita

JEFFREY SZER, MBBS, The Royal Melbourne Hospital, Melbourne. Australia

Contact: Dawn McKnight
Email: dmcknight@kmgnet.com

An Interactive Case-Based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates

7:00 a.m. – 10:00 a.m. Grand Hall C

Manchester Grand Hyatt San Diego

This program is provided by Clinical Care Options and supported by educational grants from AstraZeneca, BeiGene and Lilly. Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options.

Chair:

Brian T. Hill, MD, PhD, The Cleveland Clinic Foundation, Cleveland, OH

Speakers:

Danielle M. Brander, MD, Duke University, Durham, NC

Sameer A. Parikh, MBBS, Mayo Clinic, Rochester, MN

Contact: Ishana Fleurant

Email: Ifleurant@clinicaloptions.com

Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape

Friday 7:00 a.m. – 10:00 a.m. Room 6B

This program is provided by Multiple Myeloma Research Foundation and supported by AbbVie Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi.

Chair:

Caitlin Costello, MD, University of California, San Diego, San Diego, CA

Speaker:

Rahul Banerjee, MD, University of Washington, Seattle, WA

Contact: Veronica Bohorquez-Medd Email: bohorquezv@themmrf.org

Championing the Care of Relapsed/Refractory Multiple Myeloma: Practical Strategies to Integrate Bispecific Antibodies

Friday 7:00 a.m. – 10:00 a.m. Room 6A

This program is provided by Multiple Myeloma Research Foundation and supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc.

Chair:

AJAI CHARI, MD, University of California, San Francisco, San Francisco, CA

Speaker:

Amrita Y. Krishnan, MD, City of Hope Comprehensive Cancer Center, Duarte, CA

Contact: Veronica Bohorquez-Medd Email: bohorquezv@themmrf.org

Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience & Innovation for More Personalized Disease Control

Friday 7:00 a.m. – 10:00 a.m.
Pacific Ballroom Salons 18-19
Marriott Marquis San Diego Marina

This program is provided by PVI, PeerView Institute for Medical Education and supported by Bristol Myers Squibb, Geron, GSK and CTI BioPharma Corp., a Sobi Company.

Chair:

CLAIRE HARRISON, MD, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Speakers:

Catriona Jamieson, MD, PhD, Sanford Stem Cell Institute, CIRM UC San Diego Alpha Stem Cell Clinic, La Jolla, CA Professor Francesco Passamonti, MD, University of Milan, Milan, Italy

Contact: Lauren Wilkes

Email: lauren.wilkes@peerview.com

MDS 2024: Let's Overcome the Challenges

Friday 7:00 a.m. – 10:00 a.m.

Grand Hall B

Manchester Grand Hyatt San Diego

This program is provided and supported by MDS Foundation, Inc.

Co-Chairs:

Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Casey L. O'Connell, MD, USC Keck School of Medicine, University of Southern California, Los Angeles, CA

Speakers:

LIONEL ADES, MD, PHD, Université Paris Cité, APHP, Hôpital Saint-Louis, Paris, France RENA BUCKSTEIN, MD, FRCPC, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

Aristoteles Giagounidis, MD, Marienhospital
Düsseldorf, Düsseldorf, Germany
Jaroslaw Maciejewski, Taussig Cancer Institute,
Cleveland Clinic Foundation, Cleveland, OH
GHULAM MUFTI, DM, FRCP, FRCPATH, King's College
Hospital, London, United Kingdom
Esther Natalie Oliva, MD, Grande Ospedale
Metropolitano Bianchi Melacrino Morelli, Reggio
Calabria, Italy

Magnus Tobiasson, MD, Karolinska Institutet, Stockholm, Sweden Lachelle D. Weeks, MD, PhD, Dana-Farber Cancer

Lachelle D. Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Contact: Lea Harrison

Email: lharrison@mds-foundation.org

Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease

Friday

7:00 a.m. – 10:00 a.m. San Diego Ballroom AB Marriott Marquis San Diego Marina

This program is provided by PVI, PeerView Institute for Medical Education and supported by AbbVie, Bristol Myers Squibb and Geron.

Chair:

Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Maria Diez-Campelo, MD, PhD, University Hospital of Salamanca, IBSAL, Salamanca, Spain Valeria Santini, MD, AOU Careggi, University of Florence, Florence, Italy

Contact: Lauren Wilkes

Email: lauren.wilkes@peerview.com

FRIDAY EARLY AFTERNOON SYMPOSIA: 11:00 A.M. – 2:00 P.M.

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-free Treatment Paradigm

Friday

11:00 a.m. – 2:00 p.m. Grand Hall C Manchester Grand Hyatt San Diego

This program is provided by Clinical Care Options and supported by AstraZeneca, Genmab US, Inc. and Ipsen Biopharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.

Chair:

Sonali M. Smith, MD, University of Chicago, Chicago, IL

Speakers:

Caron A. Jacobson, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA Peter Martin, MD, Weill Cornell Medicine, New York, NY

Contact: Ishana Fleurant

Email: Ifleurant@clinicaloptions.com

A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives

Friday

11:00 a.m. – 2:00 p.m.
Pacific Ballroom Salons 21-22
Marriott Marquis San Diego Marina

This program is provided by The France Foundation and supported by Sanofi. For in-person participants only.

Co-Chairs:

STACY E. CROTEAU, MD, MMS, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

Guy Young, MD, Children's Hospital Los Angeles, Los Angeles, CA

Speakers:

COLE KRUSE, Lived Experience Expert, Martinsville, IN JENNIFER MAAHS, MSN, PNP, RN, Indiana Hemophilia & Thrombosis Center, Indianapolis, IN JENNY McDaniel, MD, Novant Health Hemby Children's Hospital, Charlotte, NC

Contact: Janis Vajdos

Email: jvajdos@francefoundation.com

A Violent Graft in a Vulnerable Host: The Future of aGVHD Management

Friday

11:00 a.m. – 2:00 p.m. Room 29

This program is provided by RMEI Medical Education, LLC and supported by an independent educational grant from CSL Behring LLC.

Chair:

Sung W. Choi, MD, MS, University of Michigan, Ann Arbor, MI

Speakers:

Paul Campbell, Patient Speaker, Ann Arbor, MI Chelsea Honstain, MS, FNP-C, University of Michigan Health, Ann Arbor, MI Gianni Scappaticci, University of Michigan, Ann Arbor, MI

Contact: Lisa Pagliaccetti Email: lpagliaccetti@rmei.com

Addressing Current Questions and Controversies in the Management of Myelofibrosis: What Clinicians Want to Know

Friday 11:00 a.m. – 2:00 p.m.

Seaport Ballroom EFGH

Manchester Grand Hyatt San Diego

This program is provided by Research To Practice and supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation and Karyopharm Therapeutics.

Chair:

Andrew T. Kuykendall, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Speakers:

PRITHVIRAJ BOSE, MD, The University of Texas MD Anderson Cancer Center, Houston, TX Angela G. Fleischman, MD, PhD, University of California, Irvine, Irvine, CA Abdulraheem Yacoub, MD, University of Kansas Cancer Center, Leawood, KS

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma: What Clinicians Want to Know

Friday 11:00 a.m. – 2:00 p.m.

Seaport Ballroom ABCD

Manchester Grand Hyatt San Diego

This program is provided by Research To Practice and supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group and Regeneron Pharmaceuticals Inc.

Chair:

Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA

Speakers:

Jennifer L. Crombie, MD, Dana-Farber Cancer Institute, Boston, MA

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark Matthew Lunning, DO, University of Nebraska

Medical Center, Omaha, NE

Tycel J. J. Phillips, MD, City of Hope, Duarte, CA

Contact: Sylvia Eriksen

 ${\it Email: meetings@research top ractice.com}$

Advances in the Management of Myeloproliferative Neoplasms and Systemic Mastocytosis: Diagnosis/Classification, Risk Stratification, and Optimal Therapeutic Selection

Friday 11:00 a.m. – 2:00 p.m.

Grand Hall B

Manchester Grand Hyatt San Diego

This program is provided by HMP Global and supported by Blueprint Medicines Corporation, CTI BioPharma Corp., a Sobi Company, Incyte Corporation, and PharmaEssentia Corporation. For in-person participants only.

Chair:

JOHN O. MASCARENHAS, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:

Mariana Castells, MD, PhD, Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA

Daniel J. DeAngelo, MD, Dana-Farber Cancer Institute, Boston, MA

RAAJIT RAMPAL, MD, PHD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Kristin Ciszeski

Email: kciszeski@hmpglobal.com

Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Friday 11:00 a.m. – 2:00 p.m.

Grand Hall D

Manchester Grand Hyatt San Diego

This program is provided by Clinical Care Options and supported by AstraZeneca.

Chair:

Julie M. Vose, MD, MBA, University of Nebraska Medical Center, Omaha, NE

Speakers:

Brad S. Kahl, MD, Washington University School of Medicine in St. Louis, St. Louis, MO John P. Leonard, MD, Weill Cornell Medicine, New York, NY

Contact: Ishana Fleurant

Email: Ifleurant@clinicaloptions.com

Collaborating for Optimal Immune Thrombocytopenia Care: Uniting Disease, Treatment, and Patient-Centered Considerations

Friday 11:00 a.m. – 2:00 p.m.

Marriott Grand Ballroom 11-13 Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by SOBI, Novartis, and Rigel Pharmaceuticals, Inc.

Speakers:

Hanny Al-Samkari, MD, Massachusetts General Hospital, Cambridge, MA

RACHAEL F. GRACE, MD, MMSc, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

MICHAEL D TARANTINO, MD, Bleeding and Clotting Disorders Institute, Peoria, IL

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-Base Platforms

Friday 11:00 a.m. – 2:00 p.m.

San Diego Ballroom AB

Marriott Marquis San Diego Marina

This program is provided by PVI, PeerView Institute for Medical Education and supported by AstraZeneca, BeiGene, Janssen and Lilly.

Chair:

JOHN G. GRIBBEN, MD, DSc, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, London, United Kingdom

Speakers:

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

NICOLE LAMANNA, MD, Herbert Irving

Comprehensive Cancer Center, New York-

Presbyterian/Columbia University Medical Center, New York, NY

Meghan C. Thompson, MD, Memorial Sloan Kettering

Cancer Center, New York, NY

Contact: Lauren Wilkes

Email: lauren.wilkes@peerview.com

Emerging Insights in Biology and Treatment Approaches to Peripheral T-Cell Lymphomas

Friday 11:00 a.m. – 2:00 p.m.

Pacific Ballroom Salons 18-19 Marriott Marquis San Diego Marina

This program is provided by MD Education and supported by Acrotech Pharma. For in-person participants only.

Chair:

SWAMI P. IYER, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

KATE CWYNARSKI, MBBS, PhD, FRCP, FRCPATH, University College London Hospital, London, United Kingdom

Luis Malpica, MD, The University of Texas MD Anderson Cancer Center, Houston, TX Yun Kyoung Tiger, MD, PhD, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ Jasmine Zain, MD, City of Hope, Duarte, CA

Contact: Christopher Bolwell

Email: christopher.bolwell@md-education.com

Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis

Friday 11:00 a.m. – 2:00 p.m.

Marriott Grand Ballroom 8-9
Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by Prothena, Janssen and Alexion.

Chair

MORIE A. GERTZ, MD, Mayo Clinic, Rochester, MN

Speakers:

SUZANNE LENTZSCH, MD, PhD, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

VAISHALI SANCHORAWALA, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Evolving Treatment Paradigms for Patients with Hemoglobinopathies

Friday 11:00 a.m. – 2:00 p.m. Room 30 A-E

This program is provided by MJH Events and supported by Vertex Pharmaceuticals.

Chair:

Biree Andemariam, MD, University of Connecticut Health, West Hartford, CT

Speakers:

Farzana Sayani, MD, MSc, University of Pennsylvania, Philadelphia, PA Sujit Sheth, MD, Weill Cornell Medicine, New York, NY

Contact: Kelly McGregor

Email: *kmcgregor@mjhevents.com*

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Friday 11:00 a.m. – 2:00 p.m. Room 6A

This program is provided by MJH Events and supported by Sanofi and Takeda Pharmaceuticals USA, Inc.

Chair:

Krina K. Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

ALFRED L. GARFALL, MD, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA AJAY K. NOOKA, MD, MPH, Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA

Contact: Kelly McGregor

Email: kmcgregor@mjhevents.com

Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts

Friday 11:00 a.m. – 2:00 p.m.

Marriott Grand Ballroom 2-4 Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by F. Hoffmann-La Roche Ltd.

Chair:

Wendy Osborne, MD, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom

Speakers:

NATACHA BOLAÑOS, Patient Advocate, Madrid, Spain GARETH P. GREGORY, MBBS, PHD, FRACP, FRCPA, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia GILLES SALLES, MD, PHD, Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Maximizing Touchpoints to Empower Impactful Patient-Centered Care for Paroxysmal Nocturnal Hemoglobinuria

Friday 11:00 a.m. – 2:00 p.m.

Marriott Grand Ballroom 5-6 Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by Alexion and Novartis.

Speakers:

Srikanth Nagalla, Baptist Health South Florida, Miami, FL

CHRISTOPHER PATRIQUIN, MD, MSc, FRCPC, Division of Medical Oncology & Hematology, University Health Network, Toronto, Ontario, Canada

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Medical Crossfire®: Bridging Evidence to Practice in AML: Updates on FLT3, IDH1/2 Maintenance, Combos, and Clinical Trials

Friday 11:00 a.m. – 2:00 p.m. Ballroom 20CD

This program is provided by Physicians' Education Resource and supported by Bristol Myers Squibb, Jazz Pharmaceuticals, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc.

Chair:

NAVAL DAVER, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Jessica Altman, MD, Professor of Medicine, Hematology Oncology Division Northwestern University, Chicago, IL

Amir T. Fathi, MD, Massachusetts General Hospital Cancer Center, Boston, MA

Gail J. Roboz, MD, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY

JOSHUA F. ZEIDNER, MD, University of North Carolina, Chapel Hill, NC

Contact: Kelly McGregor

Email: kmcgregor@mjhevents.com

Next Up: Conversations On Optimizing CD38 Antibody-Based Triplet Regimens For Early-Relapse Multiple Myeloma

Friday 11:00 a.m. – 2:00 p.m. Room 6B

This program is provided by Answers in CME and supported by Sanofi.

Chair:

Thomas G. Martin, MD, Professor, University of California, San Francisco, CA, Associate Chief, Hematology/Oncology, San Francisco, CA

Speakers:

CARLYN ROSE TAN, MD, Memorial Sloan Kettering Cancer Center, New York, NY KENNETH CAPPS, JD, Patient Advocate, Asheville, NC

Contact: Emilie Desse

Email: emilie.desse@answersincme.com

Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL

Friday 11:00 a.m. – 2:00 p.m. Room 6DE

This program is provided and supported by PRIME Education, LLC.

Chair:

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

Douglas Burgoyne, Pharmd, FAMCP, University of Utah, Salt Lake City, UT

Nathan Fowler, MD, The University of Texas MD

Anderson Cancer Center, Houston, TX

Manali Kamdar, MD, MBBS, University of Colorado Cancer Center, Aurora, CO

Paolo Strati, MD, The University of Texas MD

Anderson Cancer Center, Houston, TX

Contact: Eryn Litvinas

Email: e.litvinas@primeinc.org

FRIDAY LATE AFTERNOON SYMPOSIA: 3:00 P.M. – 6:00 P.M.

A Step-By-Step Approach to CAR T-cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management

Friday 3:00 p.m. – 6:00 p.m. Room 6B

This program is provided by Answers in CME and supported by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Legend Biotech.

Chair:

Jesus G. Berdeja, MD, The Greco-Hainsworth Tennessee Oncology Centers for Research, Nashville, TN

Speaker:

ADRIANA ROSSI, MD, MSc, Mount Sinai, New York, NY

Contact: Emilie Desse

Email: emilie.desse@answersincme.com

Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia: What Clinicians Want to Know

Friday 3:00 p.m. – 6:00 p.m.

Seaport Ballroom ABCD

Manchester Grand Hyatt San Diego

This program is provided by Research To Practice and supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.

Chair:

EYTAN M. STEIN, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

Speakers:

ALEXANDER E. PERL, MD, University of Pennsylvania, Philadelphia, PA

RICHARD M. STONE, MD, Dana-Farber Cancer Institute, Boston, MA

EUNICE S. WANG, MD, Roswell Park Comprehensive

Cancer Center, Buffalo, NY

Andrew H. Wei, MBBS, PhD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

Addressing Current Questions and Controversies in the Management of Multiple Myeloma: What Clinicians Want to Know

Friday 3:00 p.m. – 6:00 p.m.

Seaport Ballroom EFGH

Manchester Grand Hyatt San Diego

This program is provided by Research To Practice and supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC and Karyopharm Therapeutics.

Chair:

Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, GA

Speakers:

PHILIPPE MOREAU, MD, PhD, University Hospital Hôtel-Dieu, Nantes, France ROBERT Z. ORLOWSKI, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX Noopur Raje, MD, Massachusetts General Hospital,

Boston, MA

Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA

Contact: Sylvia Eriksen

Email: meetings@researchtopractice.com

Bispecific Antibodies: A Playbook for Relapsed/ Refractory Follicular Lymphoma

Friday 3:00 p.m. – 6:00 p.m.

Marriott Grand Ballroom 11-13 Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by Genmab and AbbVie.

Chair:

Joshua Brody, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:

Krish Patel, MD, Swedish Cancer Institute, Seattle,

WA

LORNA WARWICK, Lymphoma Coalition, Mississauga, Ontario, Canada

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Broadening the Impact of Whole-Genome and Transcriptome Sequencing (WG(T)S) in Hematological Malignancies

Friday 3:00 p.m. – 6:00 p.m.

Room 29

This program is provided and supported by Illumina.

For in-person participants only.

Chair:

Eric Duncavage, MD, Washington University in St. Louis, St. Louis, MO

Speakers:

ERIC DUNCAVAGE, MD, Washington University in St. Louis, St. Louis, MO

James Han, Illumina, Inc., San Diego, CA Jonathan J. Keats, PhD, TGen, Phoenix, AZ

Manja Meggendorfer, PhD, MLL Munich Leukemia Laboratory, Munich, Bavaria, Germany

BRIAN D. PIENING, PhD, Providence, Portland, OR SUGGANTH DANIEL PILLEI, MD, Illumina, Irvine, CA

RICHARD ROSENQUIST, MD, PhD, Karolinska Institutet, Stockholm, Sweden

Contact: Pilar Ramos

Email: pramos@illumina.com

Cases and Conversations[™]: The Rationale for Utilizing Non-Factor Replacement Therapies in Hemophilia Care

Friday 3:00 p.m. – 6:00 p.m. Room 6A

This program is provided by MJH Events and supported by Novo Nordisk, Inc.

Chair:

Steven R. Lentz, MD, PhD, University of Iowa, Iowa City, IA

Speakers:

ALICE MA, MD, University of North Carolina, Chapel Hill. NC

Lynn Malec, MD, MSc, Versiti Blood Research Institute, Wauwatosa, WI

Contact: Kelly McGregor

Email: kmcgregor@mjhevents.com

Clinical Assessment of Gene Therapies for Hemophilia A and Hemophilia B: Key Takeaways For Your Practice

Friday 3:00 p.m. - 6:00 p.m.

Marriott Grand Ballroom 8-9 Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by CSL Behring.

Speakers:

AMY DUNN, MD, Nationwide Children's Hospital, Columbus, OH

Steven W. Pipe, MD, University of Michigan, Ann

Arbor, MI

DORIS V. QUON, MD, PhD, Orthopedic Hospital, Los Angeles, CA

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Collaboration In Chronic ITP: Improving Quality of Life and Patient Outcomes

Friday 3:00 p.m. – 6:00 p.m. Ballroom 20AB

This program is provided by touchIME and supported by an independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME. For in-person participants only

Chair:

CINDY E. NEUNERT, MD, Columbia University Irving Medical Center, New York, NY

Speakers:

David J. Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA María Eva Mingot-Castellano, MD, Hospital

María Eva Mingot-Castellano, MD, Hospital Universitario Virgen del Rocío, Sevilla, Spain

Contact: Lucienne Pratt

Email: lucienne.pratt@touchime.org

Complex Cases in the Community Clinic: Managing Diverse Hematologic Malignancies

Friday 3:00 p.m. – 6:00 p.m.

Marriott Grand Ballroom 2-4 Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by Sanofi and Incyte Corporation.

Chair:

Matthew Matasar, MD, MS, Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, New York, NY

Speakers:

CHAN Y. CHEAH, MBBS, FRACP, FRCPA, DMSc, Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia

LUCIANO J. COSTA, MD, PHD, University of Alabama at Birmingham, Vestavia, AL

NISHA S. JOSEPH, MD, Winship Cancer Institute of Emory University, Atlanta, GA

CHAITRA S. UJJANI, MD, Clinical Research Division, Fred Hutch Cancer Center, Division of Oncology, University of Washington, Seattle, WA

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Friday 3:00 p.m. – 6:00 p.m. Ballroom 20CD

This program is This program is supported by MorphoSys and Protagonist Therapeutics Inc.

Chair:

 $R_{\rm AMI}$ S. Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Speakers:

Gabriela S. Hobbs, MD, Massachusetts General Hospital, Boston, MA Barbara Mora, MD, Division of Hematology, Ospedale ASST Sette Laghi, Varese, Italy

Contact: Kelly McGregor

Email: kmcgregor@mjhevents.com

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How the Experts Apply New Evidence from AYA to Adult Scenarios

Friday 3:00 p.m. – 6:00 p.m. Room 30 A-E

This program is provided by Physicians' Education Resource and supported by Amgen Inc, Autolus Limited, Syndax Pharmaceuticals, Inc. and Takeda Pharmaceuticals USA, Inc.

Chair:

ELIAS JABBOUR, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:

HAGOP M. KANTARJIAN, MD, The University of Texas MD Anderson Cancer Center, Houston, TX AARON C. LOGAN, MD, PHD, University of California, San Francisco, San Francisco, CA ROB PIETERS, MD, PHD, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands CLAIRE RODDIE, MD, PHD, University College London Hospitals, London, United Kingdom

Contact: Ronald Viggiani Email: rviggianimd@gmail.com Sharing Best Practices from the ALL/LBL Clinic: Navigating Patient-Centered Care with Asparaginase Therapies

Friday 3:00 p.m. – 6:00 p.m.

Marriott Grand Ballroom 5-6

Marriott Marquis San Diego Marina

This program is provided by Medscape and supported by Jazz Pharmaceuticals, Inc.

Chair:

IBRAHIM ALDOSS, MD, City of Hope National Medical Center, Duarte, CA

Speakers:

Sandra Kurtin, PhD, ANP, Clinical Assistant Professor of Medicine, Tucson, AZ Luke Maese, DO, University of Utah, Huntsman Cancer Institute, Primary Children's Hospital, Salt Lake City, UT

CATE O'REILLY, Senior Director Digital Partnerships, Strategic Growth, San Diego, CA

Contact: Vikki Chavis

Email: vchavis@medscapelive.com

Unleashing Emerging Therapies to Modify Myelofibrosis Pathogenesis: Shifting the Treatment Paradigm to Target Deeper Clinical and Molecular Responses

Friday 3:00 p.m. – 6:00 p.m. Room 6DE

This program is provided and supported by PRIME Education, LLC.

Chair:

Jeanne Palmer, MD, Mayo Clinic, Arizona, Scottsdale, AZ

Speakers:

Douglas Burgoyne, PharmD, FAMCP, University of Utah, Salt Lake City, UT
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY
Jeanne Palmer, MD, Mayo Clinic, Arizona, Scottsdale, AZ
Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL

Contact: Lindsey Siegel Email: *l.siegel@primeinc.org*

FRIDAY EVENING SYMPOSIA:

7:00 P.M. - 10:00 P.M.

Accelerating the Adoption of the Latest Evidence on Sequencing Therapies for Multiple Myeloma Across Practice Settings

Friday 7:00 p.m. - 10:00 p.m. Room 6DE

This program is provided and supported by PRIME Education, LLC.

Chair:

SCOTT R. GOLDSMITH, MD, City of Hope, Duarte, CA

Speakers:

Melissa Alsina, MD, Moffitt Cancer Center, Tampa, FL

BINOD DHAKAL, MBBS, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

M. SARFRAZ NAWAZ, MD, Hematology Oncology of Indiana, Carmel, IN

Contact: Ervn Litvinas

Email: e.litvinas@primeinc.org

How We Do It®: New Combinations Reshaping **Treatment Decision-Making in Newly Diagnosed Multiple Myeloma**

Friday 7:00 p.m. - 10:00 p.m. Room 30 A-E

This program is provided by Physicians' Education Resource and supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson & Johnson companies, and Sanofi.

Chair:

OLA LANDGREN, MD, University of Miami, Miami, FL

Speakers:

CRISTINA GASPARETTO, MD, Duke University Medical Center, Durham, NC

KATIA C. WEISEL, MD, Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

Contact: Elijah Anseaume Email: eanseaume@gotoper.com Show Me the Data™: How Do We Navigate the **Latest Evidence on Novel Therapies and Trials** Across GvHD Prophylaxis, Acute, and Chronic Care?

Friday 7:00 p.m. - 10:00 p.m. Room 6A

This program is provided by MIH Events and supported by Incyte Corporation and Mallinckrodt Pharmaceuticals.

Chair:

COREY S. CUTLER, MD, MPH, Dana-Farber Cancer Institute, Boston, MA

Speakers:

Amin M. Alousi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX YI-BIN CHEN, MD, MS, Harvard Medical School,

Boston, MA

CARRIE L. KITKO, MD, Vanderbilt University Medical Center, Nashville, TN

Contact: Kelly McGregor

Email: kmcgregor@mjhevents.com

Show Me the Data™: Pushing CAR T's Forward **Across Lymphoid Malignancies: Accelerating Access in the Community and Treatment** Strategies for the Road Ahead

Friday 7:00 p.m. – 10:00 p.m. **Ballroom 20CD**

This program is provided by Physicians' Education Resource and supported by Autolus Limited and Novartis Pharmaceuticals Inc.

Chair:

ALEXEY V. DANILOV, MD, PHD, City of Hope National Medical Center, Duarte, CA

Speakers:

Lori A. Leslie, MD, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NI

MAZYAR SHADMAN, MD, MPH, Fred Hutchinson Cancer Center, Seattle, WA

JASON R. WESTIN, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Elijah Anseaume Email: eanseaume@gotoper.com

PRODUCT THEATERS

PRODUCT THEATERS

Product Theaters as of October 18, 2024.

Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. The Product Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Sponsored by Incyte Corporation

A New Treatment Strategy in cGVHD from-CME)

Saturday 11:30 a.m. – 12:30 p.m. Room 5A

For in-person participants only.

Speaker:

JOHN GALVIN, MD, MPH, Incyte Corporation

Sponsored by Apellis Pharmaceuticals

Beyond the Data: Long-Term Efficacy & Safety Integrated Analyses and a Patient's Journey with Paroxysmal Nocturnal Hemoglobinuria (PNH) GODE-CALE)

Saturday 11:30 a.m. – 12:30 p.m. Room 1A

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

This session will include a patient perspective.

Speakers:

PETER HILLMEN, MB CHB, PhD, Apellis Pharmaceuticals, Inc.
PNH PATIENT

Sponsored by Bristol Myers Squibb

CAR T Cell Therapy for Second-Line (2L)
LBCL GOD-CME

Saturday 11:30 a.m. – 12:30 p.m. Room 2

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

WENDY JOHNSON, PHARMD, Bristol Myers Squibb

Sponsored by Novartis Pharmaceuticals Corporation

Choosing a Different Approach: Clinical and Nonclinical Factors for Adults with PNH on FABHALTA GOLLED

Saturday 11:30 a.m. – 12:30 p.m. Room 5B

This presentation is intended for U.S. based registered meeting attendees.

This session will include a patient perspective.

Speakers:

JINCY PAULOSE, MD, Novartis ROCIO BUENO, Person Living with PNH PERSON LIVING WITH PNH

Sponsored by Pfizer Oncology

Getting Started and Transitioning to Outpatient Care for Patients With Relapsed or Refractory Multiple Myeloma (NOTH-CME)

Saturday 11:30 a.m. – 12:30 p.m. Room 3

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

DAVID HUGHES, PHARMD, BCOP, Pfizer

Sponsored by Eli Lilly and Company

Learn About an Alternative Treatment for Certain B-Cell Malignancies Gon-CME)

Saturday 11:30 a.m. – 12:30 p.m. Room 4

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

JOHN PAGEL, MD, PHD, Eli Lilly and Company

Sponsored by AbbVie

Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL GOD-CMED

Saturday 11:30 a.m. – 12:30 p.m. Room 1B

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

WENDY SINAI, PHARMD, AbbVie

SUNDAY

Sponsored by Gamida Cell

Options When a Matched Allogeneic-HCT Source is Not Available (NON-CME)

Sunday 8:00 a.m. – 9:00 a.m. Room 5B

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

RONIT SIMANTOV, MD, Gamida Cell

Sponsored by Johnson & Johnson

Redefining Frontline Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (non-CME)

Sunday 8:00 a.m. – 9:00 a.m. Room 1B

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

Marjohn Armoon, PharmD, Johnson & Johnson

Sponsored by Pfizer

The Science Behind HYMPAVZI (Marstacimabhncq): Introducing an Innovative Treatment Option from Pfizer (FIGHT-CAME)

Sunday 8:00 a.m. – 9:00 a.m.

Room 4

For in-person participants only.

Speakers:

WILLIAM SOMERS, PhD, Pfizer TRAVIS GOULD, PhD, Pfizer ANDREW PALLADINO, MD, Pfizer JENNIFER SCHUMACHER, PhD, Pfizer

Sponsored by Sanofi

Transforming aTTP/iTTP Treatment and Management COUNCED

Sunday 8:00 a.m. – 9:00 a.m. Room 2

For in-person participants only.

Speaker:

RAHUL BOHRA, MS, PhD, Sanofi

Sponsored by Genmab & AbbVie

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL GOD-CME)

Sunday 8:00 a.m. – 9:00 a.m. Room 3

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

Felipe Marques Goncalves, MD, MBA, Genmab

Sponsored by Bristol Myers Squibb

A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS (1901-CME)

Sunday 11:30 a.m. – 12:30 p.m.

Room 5B

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

JOHN EDWARDS, MD, Bristol Myers Squibb

Sponsored by Novartis

Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP (NOTE-CME)

Sunday 11:30 a.m. – 12:30 p.m. Room 3

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speakers:

Wolfgang Janke, PhD, Novartis Shruti Kapoor, Novartis

Sponsored by Pfizer

Discover Gene Therapy as a Treatment Option for Hemophilia B Gon-CME)

Sunday 11:30 a.m. – 12:30 p.m. Room 1A

For in-person participants only.

Speakers:

LISA J WILCOX, PhD, Pfizer PRIYA PATEL, PHARMD, Pfizer OLIVER GLASS, PhD, MHSc, Pfizer

Sponsored by Johnson & Johnson

Discover the Exciting Details About a BCMA Bispecific for 4L+ RRMM GON-CMED

Sunday 11:30 a.m. – 12:30 p.m. Room 1B

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

Tonya Le Blanc, PhD, Johnson & Johnson

MONDAY

Sponsored by Johnson & Johnson

A First-In-Class Treatment for RRMM Patients GOD-CME

Monday 8:00 a.m. – 9:00 a.m.

Room 3

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

Saurabh N. Patel, MD, Johnson & Johnson

Sponsored by Geron

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS (MDC)

Monday 12:15 p.m. – 1:15 p.m.

Room 2

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

SHYAMALA NAVADA, MD, Geron

Sponsored by Johnson & Johnson

What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma? GOR-CME

Monday 12:15 p.m. – 1:15 p.m. Room 3

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

DEEPU MADDURI, MD, Johnson & Johnson

INDUSTRY THEATERS

INDUSTRY THEATERS

Industry Theaters as of October 18, 2024.

Check the mobile app for an updated list of Industry Theaters.

Industry Theater presentations are company developed presentations that highlight medical devices, medical technology, non-FDA approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. The Industry Theater sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SUNDAY

Sponsored by Syndax Pharmaceuticals

KMT2A Rearrangements in Acute Leukemia Gon-CME)

Sunday 8:00 a.m. – 9:00 a.m.

Room 5A

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

Angela Smith, MD, MS, Syndax Pharmaceuticals

Sponsored by Thermo Fisher

The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research (MOTHCARE)

Sunday 8:00 a.m. – 9:00 a.m.

Room 1A

For in-person participants only.

Speaker:

CHRIS ALLEN, PHD, Thermo Fisher

Sponsored by AstraZeneca

Exploring CLL and MCL: Disease Overview,
Latest Treatment Options and Unmet
Needs (MODI-CAME)

Sunday 11:30 a.m. – 12:30 p.m.

Room 4

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

CAROL MORENO, AstraZeneca

Sponsored by Sanofi

Innovations in Hemophilia Research: Fitusiran, An Investigational Rebalancing Agent for the Treatment of Hemophilia Con-CMED

Sunday 11:30 a.m. – 12:30 p.m.

Room 5A

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speakers:

Craig Benson, MD, Sanofi Marek Demissie, MD, PhD, Sanofi Marja Puurunen, MD, PhD, Sanofi

MONDAY

Sponsored by Agios Pharmaceuticals

Energizing Red Blood Cells: The Latest Clinical Trial Data of Mitapivat in Thalassemia Gon-CME)

Monday 12:15 p.m. – 1:15 p.m.

Room 5A

For in-person participants only.

This session will include a patient perspective.

Speakers:

SARAH GHEUENS, MD, PhD, Agios Pharmaceuticals JEREMIE H. ESTEPP, MD, Agios Pharmaceuticals RALPH COLASANTI

NDUSTRY FORUMS

INDUSTRY FORUMS

Industry Forums as of October 18, 2024.

Check the mobile app for an updated list of Industry Forums.

Industry Forums are non-CME sessions developed by sponsoring companies with interactive discussions on topics focused on educational resources for the diagnosis and treatment of hematologic diseases, improvements or quality in health care, patient support services and/or treatment resources. Discussions feature various perspectives and roles including health care providers, company representatives, patients, caretakers, and patient advocates. The Industry Forum session offered at the time listed below will be solely promotional in nature; therefore, continuing medical education credit will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Sponsored by Novartis

Nonmalignant Hematologic Disorders Forum: Deeper Dive Into PNH, aHUS, and ITP (MODICALE)

Saturday 8:00 a.m. – 9:00 a.m. Room 4

For in-person participants only. Maximum of 50 participants.

Speakers:

JINCY PAULOSE, MD, NOVARTIS LINCY GEEVARGHESE, MD, NOVARTIS NICHOLAS KUYPERS, PHD, NOVARTIS MARY LISHA PAUL, MD, NOVARTIS SOYON LEE, PHARMD, NOVARTIS

COMPANY SHOWCASES

Company Showcases as of October 18, 2024.

Check the mobile app for an updated list of Company Showcases.

Company Showcase presentations are 15-minute promotional presentations that provide an overview of the companies' services, pipeline products, clinical trials, or mission-based initiatives for a company, non-profit organization, or contract/clinical research organization. The Company Showcase sessions offered at the times listed below will be solely promotion in nature; therefore, continuing medical education credits will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Sponsored by Invivoscribe, Inc.

Invivoscribe- Partnering with Pharma to Streamline Oncological Clinical Development for CME

Saturday 1:30 p.m. – 1:45 p.m. Room 5B

For in-person participants only.

Speaker:

JASON GERHOLD, Invivoscribe, Inc.

Sponsored by Grail, Inc.

Using Multi-Cancer Early Detection Testing to Screen for Cancers That Lack Recommended Screenings (NOTH-CME)

Saturday 1:30 p.m. – 1:45 p.m. Room 4

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speaker:

MEGAN HALL, PhD, Grail, Inc.

Sponsored by 10x Genomics Inc.

10x Genomics Company Showcase GON-CME)

Saturday 1:45 p.m. – 2:00 p.m. Room 5A

For in-person participants only.

Speaker:

EGON RANGHINI, PHD, 10x Genomics Inc.

Sponsored by Galapagos

Fresh, Fit and Fast: Pioneering the Future of Cell Therapy through Decentralized Manufacturing (ADDICALE)

Saturday 1:45 p.m. – 2:00 p.m. Room 3

For in-person participants only.

Speakers:

JEEVAN SHETTY, MD, Galapagos JACQUELINE VINK-KORNDORFFER, Galapagos

Sponsored by Pixelgen Technologies

The Spatial Organization of Surface Proteins of Single Cells in Myelodysplastic Syndrome for Diagnostics and Drug Target Discovery by Molecular Pixelation (MPX)

Saturday 3:30 p.m. – 3:45 p.m. Room 5B

For in-person participants only.

Speakers:

SIMON FREDERIKSSON, Pixelgen Technologies AARON VINY, MD, Pixelgen Technologies

CLINICAL TRIAL SHOWCASES

Clinical Trial Showcases as of October 18, 2024.

Check the mobile app for an updated list of Clinical Trial Showcases.

Clinical Trial Showcase presentations are 15-minute promotional presentations that provide an overview of the clinical trials offered by the company, non-profit organization, or contract/clinical research organization. The Clinical Trial Showcase session offered at the time listed below will be solely promotion in nature; therefore, continuing medical education credit will not be offered.

All events take place in the San Diego Convention Center unless indicated otherwise. All times are in Pacific time. Duplication/recording is prohibited.

SATURDAY

Sponsored by Foresight Diagnostics

The ALPHA3 Trial: Harnessing the Potential of Combining Next-Generation "Off-the-Shelf" Investigational CAR T Product with Advanced MRD Testing to Improve Outcomes in First Line LBCL (NORTHE)

Saturday 3:30 p.m. – 3:45 p.m. Room 4

This presentation is intended for U.S. based registered meeting attendees.

For in-person participants only.

Speakers:

DAVID KURTZ, MD, PhD, Foresight Diagnostics SANDRA CLOSE, PhD, Foresight Diagnostics JOHN TRUESDELL, MBA, Foresight Diagnostics



American Society of Hematology

Helping hematologists conquer blood diseases worldwide

8th Edition ASH-SAP Self-Assessment Program

40% OFF PLUS FREE SHIPPING

PREMIER: PRINT AND ONLINE TEXTBOOK, PRINT Q & A BOOK, AND ONLINE CME/M	OC EXAM	40% OFF
Member – Active and International	\$530	\$318
Member - U.S. & International Associate	\$400	\$240
Member - Graduate/Medical Student/Resident	\$270	\$162
FHF Print Only	\$188	\$108
Non-member	\$680	\$408
DIGITAL: DIGITAL TEXTBOOK AND DIGITAL CME/M	OC EXAM	40% OFF
Member - Active and International	\$430	\$258
Member - U.S. & International Associate	\$280	\$168
Member - Graduate/Medical Student/Resident	\$180	\$108
Non-member	\$550	\$330

ORDER TODAY AT: ASH Store on-site

hematology.org/store



ROWSE BY DISEAS

BROWSE BY DISEASE

AS OF 10/24/2024

The ASH annual meeting features sessions on every area of hematology. For attendees focused on a particular disease, we have assembled an index of oral sessions that will cover the chosen disease, listed by date and time.

This Index does not represent all available sessions; not every disease is represented here, and not all sessions are disease-specific. Check the virtual meeting platform and the meeting mobile app to search for sessions by the full list of keywords.

DISEASE	PAGE
Bleeding and Clotting	155
Bone Marrow Failure Syndrome	159
Genetic Disorders	161
Hemoglobinopathies	163
Immune Disorders	165
Lymphoid Malignancies	167
Metabolic Disorders	175
Myeloid Malignancies	177

Browse by Disease 145



Progress in **Hematology**Powered by **Philanthropy**

ASH Foundation
Moving Hematology Forward

The ASH Foundation fuels the future of hematology through your generous contributions.

Every dollar you donate directly supports the groundbreaking programs and initiatives led by the American Society of Hematology.

Your donation helps to advance progress in hematology and patient care worldwide.

With 100% of your donation going to critical programs, you're helping shape a brighter future for patients and professionals.

Donate now.



११

A gift to the ASH Foundation is an investment in the continued growth of every facet of hematology, especially in translating advances to patients with blood disorders worldwide.



James LaBelle, MD, PhD, Chair, ASH Foundation Committee, 2024–2025

Visit **hematology.org/foundation** to learn more and contribute today.

Moving hematology forward

BLEEDING AND CLOTTING

BLEEDING AND CLOTTING

Day	Time	Session Title	Program	Location	CME
Friday	7:00-10:00 AM	Satellite Symposia: Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience & Innovation for More Personalized Disease Control	Interact with Industry	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives	Interact with Industry	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	CME
Friday	2:00-5:00 PM	Scientific Workshop on Interplay Between Coagulation and Malignancy	Scientific Program	Room 24	
Friday	3:00-6:00 PM	Satellite Symposia: Cases and Conversations™: The Rationale for Utilizing Non-Factor Replacement Therapies in Hemophilia Care	Interact with Industry	Room 6A	CME
Friday	3:00-6:00 PM	Satellite Symposia: Clinical assessment of gene therapies for hemophilia A and hemophilia B: Key takeaways for your practice	Interact with Industry	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	CME
Friday	3:00-6:00 PM	Satellite Symposia: Collaboration In Chronic ITP: Improving Quality Of Life And Patient Outcomes	Interact with Industry	Ballroom 20AB	CME
Saturday	8:00-9:00 AM	Industry Forums: Nonmalignant Hematologic Disorders Forum: Deeper Dive Into PNH, aHUS, and ITP	Interact with Industry	Room 4	
Saturday	9:30-10:45 AM	The Expanding Landscape of Treatment for ITP	Education Program	Room 28 A-D	CME
Saturday	9:30-10:45 AM	Understanding the Impact of Donor and Recipient Metabolic Variability on Blood Transfusion Outcomes	Scientific Program	Room 7	CME
Saturday	9:30-11:00 AM	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire	Oral Abstract Sessions	Room 24	
Saturday	9:30-11:00 AM	401. Blood Transfusion: Advancements in Transfusion Science	Oral Abstract Sessions	Room 31	
Saturday	9:30-11:00 AM	508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH	Oral Abstract Sessions	Room 11	
Saturday	9:30-11:00 AM	703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies	Oral Abstract Sessions	Ballroom 20AB	
Saturday	9:30-11:00 AM	ASH Clinical Practice Guidelines on Pediatric Venous Thromboembolism (VTE)	Special-Interest Sessions	Room 25	CME
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	12:00-1:30 PM	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease	Oral Abstract Sessions	Room 11	
Saturday	12:00-1:30 PM	322. Hemophilia A and B: Clinical and Epidemiological: Beyond Efficacy of Hemostatic Agents in Hemophilia: Exploring Pharmacokinetics, Dosing Regimens, and Special Populations	Oral Abstract Sessions	Room 29	
Saturday	12:00-1:30 PM	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Humoral Coagulation Factors: Venous Thrombosis and Beyond	Oral Abstract Sessions	Room 28 A-D	
Saturday	12:00-1:30 PM	331. Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP	Oral Abstract Sessions	Room 30	
Saturday	12:00-1:30 PM	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Optimizing Classical Hematology Care	Oral Abstract Sessions	Room 31	
Saturday	2:00-3:15 PM	Beyond TTP: "Atypical" TMAs for the Hematologist	Education Program	Room 24	CME

BLEEDING AND CLOTTING

Day	Time	Session Title	Program	Location	CME
Saturday	2:00-3:15 PM	Hematologic Challenges at the End-of-Life	Education Program	Room 6A	CME
Saturday	2:00-3:15 PM	Hematologic Management of the Patient with Heavy Menstrual Bleeding	Education Program	Room 28 A-D	CME
Saturday	2:00-3:30 PM	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets and Endothelium in Thrombotic Disorders	Oral Abstract Sessions	Room 25	
Saturday	2:00-3:30 PM	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms	Oral Abstract Sessions	Room 7	
Saturday	2:00-3:30 PM	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: It's All About the Money!	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	
Saturday	4:00-5:15 PM	HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia	Education Program	Room 28 A-D	CME
Saturday	4:00-5:15 PM	Scientific Symposia: Interface of Complement and Coagulation	Scientific Program	Room 33	CME
Saturday	4:00-5:30 PM	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis in Pregnancy and Childhood	Oral Abstract Sessions	Room 29	
Saturday	4:00-5:35 PM	JOINT SESSION: Newly Described Functions in the Vascular Space	Scientific Program	Room 25	CME
Sunday	8:00-9:00 AM	Product Theaters: The Science Behind HYMPAVZI (Marstacimab-hncq): Introducing an Innovative Treatment Option from Pfizer	Interact with Industry	Room 4	
Sunday	9:30-10:45 AM	Scientific Symposia: Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies	Scientific Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	CME
Sunday	9:30-11:00 AM	301. Platelets and Megakaryocytes: Basic and Translational: Megakarocyte and Platelet Biology: From Formation to Function	Oral Abstract Sessions	Room 28 A-D	
Sunday	9:30-11:00 AM	321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag	Oral Abstract Sessions	Room 25	
Sunday	11:30 AM-12:30 PM	Product Theaters: Discover Gene Therapy as a Treatment Option for Hemophilia B	Interact with Industry	Room 1A	
Sunday	12:00-1:30 PM	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science	Oral Abstract Sessions	Room 30	
Sunday	12:00-1:30 PM	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes	Oral Abstract Sessions	Room 29	
Sunday	12:00-1:30 PM	909. Education, Communication, and Workforce: Bridging the Gap: Enhancing Communication and Education for Hematologists and our Patients	Oral Abstract Sessions	Room 6A	
Sunday	2:00-4:00 PM	Plenary Scientific Session	Marquee Sessions	Hall B	
Sunday	4:30-5:45 PM	Challenges in Cancer-Associated Thrombosis	Education Program	Hall B	CME
Sunday	4:30-5:45 PM	Paradigm Shifts in Hemostasis: From Mechanisms to Therapies and Back	Scientific Program	Room 28 A-D	CME
Sunday	4:30-5:45 PM	Scientific Symposia: Newly Discovered Functions of Megakaryocytes and Platelets	Scientific Program	Room 29	CME
Sunday	4:30-6:00 PM	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis	Oral Abstract Sessions	Room 6CF	
Sunday	4:30-6:30 PM	Systems-Based Hematology Education and Networking Session: Anticoagulation Stewardship and AI-Assisted Management	Special-Interest Sessions	Room 25	CME
Monday	10:30-11:45 AM	Anticoagulation SOS: Navigating Monitoring Conundrums	Education Program	Room 28 A-D	CME
Monday	10:30 AM-12:00 PM	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP	Oral Abstract Sessions	Room 29	

BLEEDING AND CLOTTING

BLEEDING AND CLOTTING


Day	Time	Session Title	Program	Location	CME
Monday	10:30 AM-12:00 PM	322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term	Oral Abstract Sessions	Room 30	
Monday	10:30 AM-12:00 PM	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non- Malignant Hematologic Diseases	Oral Abstract Sessions	Room 6B	
Monday	2:45-4:00 PM	Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?	Education Program	Room 29	CME
Monday	2:45-4:00 PM	Spotlight Sessions: Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?	Education Program	Room 24	CME
Monday	2:45-4:00 PM	Spotlight Sessions: Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis	Scientific Program	Room 30	CME
Monday	2:45-4:15 PM	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis: Models, Risk Factors, and Outcomes	Oral Abstract Sessions	Room 28 A-D	
Monday	4:30-5:45 PM	Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist	Education Program	Room 25	CME
Monday	4:30-6:00 PM	801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies	Oral Abstract Sessions	Room 33	
Monday	4:30-6:00 PM	Special Symposium on the Basic Science of Hemostasis and Thrombosis	Scientific Program	Room 31	
Monday	6:00-7:30 PM	ASH Networking Reception for the Hemostasis and Thrombosis Community - Hosted by the <i>Blood</i> Vessels, Thrombosis and Hemostasis Journal	Special-Interest Sessions	East Terrace (Upper Level)	



Start your next chapter

The ASH Job Center is the premier recruiting site for the field of hematology. Employers are posting new career opportunities to reach candidates of all backgrounds, qualifications, and experience levels.

Meet employers at #ASH24 to find your next role!



XHIBITORS

EXHIBITORS

Participating Exhibitors as of October 07, 2024

Company Name	Booth Number
10x Genomics	2610
AbbVie	2105
Ablavision Inc.	3237
Acrotech Biopharma	2301
Actinium Pharmaceuticals	2033
Adaptive Biotechnologies Corporation	3219
ADC Therapeutics	1227
Agios Pharmaceuticals	105
Allucent	2653
American Association for Cancer Research	200
American Porphyria Foundation	28
American Society for Transplantation and Cellular Therapy (AST	CT) 118
American Society of Gene and Cell Therapy (ASGCT)	37
American Society of Hematology	1215, Virtual
American Society of Pediatric Hematology Oncology (ASPHO)	24
Amgen (Commercial)	533
Amyloidosis Foundation	12
Amyloidosis Support Groups	40
Aniara Diagnostica	119
Apellis Pharmaceuticals	513, 612
Aplastic Anemia and MDS International Foundation, Inc.	2043
AplusA	648
Applied Cells	3246
Aptitude Health	453
Arcellx	1615
argenx	2705
ARUP Laboratories	2455
Arvinas, Inc.	117
Ascentage Pharma	3337
Association for Value-Based Cancer Care	21
Association of Cancer Care Centers	34
Association of PAs in Oncology	17
Astellas Pharma US, Inc.	2421
Astoriom	3301

EXHIBITORS

AstraZeneca	1433
Autolus	227
AXON Communications 3	3455, 3457
Azurity Pharmaceuticals, Inc	2501
BAP Pharma	220
Bayer	848
Beam Therapeutics	1449
Beckman Coulter Life Sciences	401
BeiGene USA, Inc.	417
Best Buy Health	621
Binaytara Foundation	26
Binding Site, Inc.	1255
BioIVT	2752
BioLineRx, Inc.	243
Biomea Fusion, Inc	221
BioSkryb Genomics Inc.	3421
BioSpherix	3302
Blood Cancers Today / Mashup Media	3146
Blue Spark Technologies, Inc.	1456
bluebird bio	739, 749
Blueprint Medicines	541
BostonGene	1955
Brazilian Association of Hematology, Hemotherapy and Cell Therapy	32
Bristol Myers Squibb 26	09, Virtua
C3i Center Inc	141
Calyx	3249
Cardinal Health	3351
Caribou Biosciences, Inc.	3253
Caris Life Sciences	3340
Catalyst Oncology	2553
Cellectar Biosciences	3300
Children's Healthcare of Atlanta	Virtua
Children's Hospital of Philadelphia	3308
CIBMTR (Center for International Blood & Marrow Transplant Research	h) 116
Cincinnati Childrens Hospital Medical Center	23
Citius Oncology	3343
City of Hope Comprehensive Cancer Center	313
Cleveland Clinic Taussig Cancer Institute	2134
Clinical Education Alliance	2505
CLL Society	7, Virtua
Cogent Biosciences	2804
Conexiant	2100

Continuum Clinical	1
Cooley's Anemia Foundation	16
CRISPR Therapeutics	1049
Cryoport Systems	512
CSL Behring	625
CTI Clinical Trial & Consulting Services	3415
Cure HHT	31
Curis, Inc.	2605
Daiichi Sankyo	133
DAVA Oncology	548, 549
Devyser	3443
Diagenode, Inc.	1357
Diamond Blackfan Anemia Canada	9
Diamond Blackfan Anemia Foundation Inc.	10
DiaPharma Group, Inc.	123
Doximity	2102
Editas Medicine	136
Eli Lilly and Company	1715
Elsevier	3047
Emmes Company	145
Enable Injections	2348
Eurofins Viracor	3405
European Hematology Association	300
Fennec Pharmaceuticals	3437
Flatiron Health, Inc.	2142
Food and Drug Administration	27
Foresight Diagnostics	3423
Fortrea	1956
Foundation for Sickle Cell Disease Research	2652
Foundation for the Accreditation of Cellular Therapy	5
Foundation Medicine	2604
Fred Hutchinson Cancer Center	3205
Galapagos	3313
Gamida Cell	2247, 2346
Genentech	715
Genmab	3029
Genomic Testing Cooperative	2548
GenPath	2449
GenScript ProBio USA Inc	120
GenVault	121
Geron Inc.	2405
Gilead and Kite Oncology	1233

EXHIBITORS

Global Action Network for Sickle Cell & Other Inherited Blood Disorders	15
GRAIL	2019
GSK	1015
Harvest Integrated Research Organization Corp.	1548
Haymarket Oncology	2704
HCU Network America	36
Healgen Scientific	3439
HealthTree Foundation	19
HealthWell Foundation	29
Histiocyte Society/Histiocytosis Association	38
Ichnos Glenmark Innovation	2940
ICON plc	2101
Imaging Endpoints II, LLC	2155
Incyte Corporation	1833
Intermountain Health	751
International Myeloma Foundation	2401
International Myeloma Society	2
International Society on Thrombosis and Haemostasis (ISTH)	13
Intrinsic LifeSciences	3014
Invivoscribe, Inc.	127
INVIVYD	316
Ipsen Biopharmaceuticals	1453
IQVIA Biotech	2148
IQVIA Laboratories	2249
JAMA Network	301
Jazz Pharmaceuticals	2819
John Theurer Cancer Center	500
Johnson & Johnson	2130
Johnson & Johnson Innovative Medicine	2129
Kactus	140
Kaiser Permanente - Southern California Permanente Medical Group	3453
Kartos Therapeutics, Inc. (a Delaware corporation)	2147
Karyopharm Therapeutics Inc.	733
Kashi Clinical Laboratories	3449
Kedrion Biopharma	2118
Kura Oncology	2701
Kyowa Kirin, Inc.	2437
Labcorp Oncology	455
Legend Biotech	2805
Lunaphore	2753
Machaon Diagnostics, Inc.	449
Mallinckrodt Pharmacouticals	3///1

Mayo Clinic Laboratories	2017
MD Anderson Cancer Center	1949
Mechatronics Instruments B.V.	951
Med Learning Group	2253, 3055
MedGenome	3357
Medidata, a Dassault Systèmes company	1055
Medlive	2456
Medpace Inc.	104
Medscape Oncology & Hematology	1325
Melinta Therapeutics	1857
Menarini Silicon Biosystems	2515
Merck & Co., Inc	432
Miltenyi Biomedicine GmbH	553
Mission Bio	2112
MJH Life Sciences	649
Moffitt Cancer Center	349
myTomorrows	134
National Blood Clot Alliance	8
National Comprehensive Cancer Network (NCCN)	11
National Heart, Lung, and Blood Institute	2901
NeoGenomics	2347
NMDP	112
Northside Hospital	949
Northwell Health	2041
Notable Labs	2554
Novartis	2529
Novo Nordisk Healthcare AG	1748
NURIX	655
OHSU Knight Cancer Institute	3456
Omeros Corporation	321
Oncology Learning Network	3433
Only Orphans Cote LLC	413
ONO PHARMA	3013
Ontada	2132
OpenEvidence	3411
Orca Bio	327
Ossium Health, Inc.	217
Ozette Technologies, Inc	2357
Parexel	126
Pfizer	833
PharmaEssentia Corporation	3229
Pharming Healthcare	132


EXHIBITORS

Phase Genomics	1356
Piedmont Healthcare	3413
Pierre Fabre	1625
Pillar Biosciences, Inc.	1621
Pixelgen Technologies AB	2852
Platelet Disorder Support Association	4
Precision for Medicine	2021
Predicine	1225
Premier Research	2500
Protagonist Therapeutics, Inc	1549
Prothena	2027
PSI CRO	2037
Quest Diagnostics	3427
Rapid Novor Inc.	2841
Recordati Rare Diseases	720
Regeneron Pharmaceuticals	633
Rigel Pharmaceuticals	3005
Rocket Pharmaceuticals	3409
Roswell Park Comprehensive Cancer Center	3417
Rutgers Cancer Institute of New Jersey/RWJBarnabas Health	3304
Samsung Bioepis	1555
Sanguina, Inc.	3214
Sanofi	1415
Sarah Cannon Research Institute	1154
Scopio Labs	3447
Sebia	3209
Secura Bio Inc.	1849
Servier Pharmaceuticals	1349
Shwachman-Diamond Syndrome Foundation	14
Siemens	216
Silence Therapeutics	3241
Siteman Cancer Center	3445
SOBI, Inc	2429
Society for Immunotherapy of Cancer (SITC)	18
Society of Hematologic Oncology	35
Sophorum Consulting	222
Spark Biomedical Inc	2511
Spark Therapeutics, Inc.	849
Spherix Global Insights	1354
St. Jude Children's Research Hospital	39
St. Luke's Health System	30
Star Therapeutics	108

STEMCELL Technologies	122
Stemline Therapeutics, Inc.	2941, 3319
Sumitomo Pharma America	3305
Sutter Health	3336
Syndax Pharmaceuticals, Inc.	3019
Syneos Health	1149
Syros	3200
Taiho Oncology - Commercial	615
Taiho Oncology, Inc.	305
Takeda	2829
Team Telomere	6
Telo Genomics	400
Tempus	3400
The Leukemia & Lymphoma Society	2122
The MDS Foundation, Inc.	3
Theradex Oncology	755
ThermoFisher	1249
Triage Cancer	33
Turkish Society of Hematology	41
uBriGene Biosciences Inc.	1720
UC San Diego Health Center for Bleeding and Clotting Disorders	3338
UCI Health	20
United BioSource (UBC)	3348
United Porphyrias Association	22
Vaniam Group	1155
Vertex Pharmaceuticals Inc.	504
Veterans Health Administration	3431
VJHemOnc	3212
Voiant	2015
Wolters Kluwer	2915
Worldwide Clinical Trials	3105
Wuhan Kindstar Medical Laboratory Limited Company	142
X4 Pharmaceuticals	2106
Xspray Pharma AB	218
Y-mAbs Therapeutics, Inc.	3239

Hematology 2024

AMERICAN SOCIETY of HEMATOLOGY Education Program[™] 66th ASH[®] Annual Meeting and Exposition December 7-10, 2024



Hematology

ORDER TODAY AT

- ► ASH STORE onsite
- ► Hematology.org/store



The *Hematology* ASH Education Program 2024 provides review articles from the Education Program at the 2024 ASH Annual Meeting

NEW PRINT EDITION	
Member: Active and International	\$120
Member: U.S. & International Associate	\$100
Member: Graduate/Medical Student/Resident	\$100
Non-member	\$160

BONE MARROW FAILURE SYNDROME

BONE MARROW FAILURE SYNDROME

Day	Time	Session Title	Program	Location	CME
Friday	7:00-10:00 AM	Satellite Symposia: Advances in Paroxysmal Nocturnal Hemoglobinuria: Reshaping Management Decision- Making through Case Challenges Together with the International PNH Interest Group	Interact with Industry	Ballroom 20AB	CME
Friday	7:00-10:00 AM	Satellite Symposia: MDS 2024: Let's Overcome the Challenges	Interact with Industry	Manchester Grand Hyatt San Diego, Grand Hall B	CME
Friday	2:00-5:00 PM	Scientific Workshop on Clonal Hematopoiesis	Scientific Program	Room 8	
Friday	2:00-5:00 PM	Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure	Scientific Program	Room 6CF	
Saturday	8:00-9:00 AM	Industry Forums: Nonmalignant Hematologic Disorders Forum: Deeper Dive Into PNH, aHUS, and ITP	Interact with Industry	Room 4	
Saturday	9:30-11:00 AM	508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH	Oral Abstract Sessions	Room 11	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	11:30 AM-12:30 PM	Product Theaters: Choosing a Different Approach: Clinical and Nonclinical Factors for Adults with PNH on FABHALTA	Interact with Industry	Room 5B	
Saturday	2:00-3:30 PM	503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Saturday	2:00-3:30 PM	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms	Oral Abstract Sessions	Room 7	
Saturday	4:00-5:30 PM	508. Bone Marrow Failure: Acquired: Emerging Data in the Treatment of Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria	Oral Abstract Sessions	Room 11	
Saturday	4:00-5:30 PM	636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS	Oral Abstract Sessions	Ballroom 20CD	
Saturday	4:00-5:30 PM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Sessions	Room 6DE	
Sunday	9:30-11:00 AM	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models	Oral Abstract Sessions	Room 11	
Sunday	12:00-1:30 PM	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases	Oral Abstract Sessions	Room 11	
Monday	10:30 AM-12:00 PM	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant	Oral Abstract Sessions	Room 6A	
Monday	12:15-1:15 PM	Product Theaters: A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS	Interact with Industry	Room 2	
Monday	2:45-4:15 PM	506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease	Oral Abstract Sessions	Room 11	
Monday	4:30-6:00 PM	801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies	Oral Abstract Sessions	Room 33	
Monday	4:30-6:00 PM	904. Outcomes Research: Hemoglobinopathies: Non- Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease	Oral Abstract Sessions	Room 6DE	

blood journals

Your Home for Hematology

- **blood**
- blood advances
- **S** blood neoplasia
- **blood** VTH vessels, thrombosis & hemostasis
- **blood** global hematology NEW
- blood ICT immunology & cellular therapy
- blood RCI NEW red cells & iron

bloodjournals.org



NEW



GENETIC DISORDERS

GENETIC DISORDERS

Saturday Saturday Saturday	9:30-11:00 AM 9:30-11:00 AM 9:30-11:00 AM 9:30-11:00 AM	102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire 508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies	Abstracts Abstracts Abstracts	Room 24 Room 11	
Saturday Saturday	9:30-11:00 AM 9:30-11:00 AM	Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire 508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and	Abstracts		
Saturday	9:30-11:00 AM	Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and		Room 11	
ŕ		Basic and Translational: Novel Cell Platforms and	Abstracts		
Saturday	12:00-1:30 PM			Ballroom 20AB	
		203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease	Abstracts	Room 11	
Saturday	12:00-1:30 PM	331. Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP	Abstracts	Room 30	
Saturday	2:00-3:30 PM	101. Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche	Abstracts	Room 33	
Saturday	2:00-3:30 PM	503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation	Abstracts	Manchester Grand Hyatt San Diego, Grand Hall D	
Saturday	2:00-3:30 PM	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms	Abstracts	Room 7	
Sunday	9:30-11:00 AM	112. Thalassemia and Globin Gene Regulation: We're Going to Catch a Big One: Towards Targeted Therapies in Thalassemia	Abstracts	Room 31	
Sunday	9:30-11:00 AM	201. Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia	Abstracts	Manchester Grand Hyatt San Diego, Grand Hall D	
Sunday	9:30-11:00 AM	321. Coagulation and Fibrinolysis: Basic and Translational. A Coagulation Grab Bag	Abstracts	Room 25	
Sunday	9:30-11:00 AM	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models	Abstracts	Room 11	
Sunday	9:30-11:00 AM	801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside	Abstracts	Room 30	
Sunday	12:00-1:30 PM	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Treatments and Outcomes	Abstracts	Room 29	
Sunday	4:30-6:00 PM	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications – Lessons from Pre-clinical Models	Abstracts	Room 31	
Sunday	4:30-6:00 PM	602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology	Abstracts	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Monday	10:30 AM-12:00 PM	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases	Abstracts	Room 6B	
Monday	4:30-6:00 PM	101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease	Abstracts	Room 28 A-D	

GENETIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Monday	4:30-6:00 PM	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM	Abstracts	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Monday	4:30-6:00 PM	801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies	Abstracts	Room 33	
Monday	6:00-7:30 PM	ASH Networking Reception for the Hemostasis and Thrombosis Community - Hosted by the <i>Blood Vessels</i> , <i>Thrombosis and Hemostasis</i> Journal	Special-Interest Sessions	East Terrace (Upper Level)	

HEMOGLOBINOPATHIES

HEMOGLOBINOPATHIES

Day	Time	Session Title	Program	Location	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Evolving Treatment Paradigms for Patients with Hemoglobinopathies	Interact with Industry	Room 30 A-E	CME
Friday	12:00-5:00 PM	ASH-a-Palooza	Trainee Activities	Gaslamp Quarter	
Friday	2:00-5:00 PM	Scientific Workshop on Aging and Hematology	Scientific Program	Room 7	
Friday	2:00-5:00 PM	Scientific Workshop on Challenges and Novel Technologies in Red Blood Cell Quality Assessment	Scientific Program	Room 3	
Friday	2:00-5:00 PM	Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm with AI Strategies for 'Real World' Patient Representation	Scientific Program	Room 4	
Friday	2:00-5:00 PM	Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies	Scientific Program	Room 31	
Saturday	9:30-10:45 AM	Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology	Scientific Program	Manchester Grand Hyatt San Diego, Grand Hall D	CME
Saturday	9:30-10:45 AM	Optimizing Non-Curative Therapies for Sickle Cell Disease	Education Program	Room 33	CME
Saturday	9:30-11:00 AM	102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation	Oral Abstract Sessions	Room 29	
Saturday	9:30-11:00 AM	401. Blood Transfusion: Advancements in Transfusion Science	Oral Abstract Sessions	Room 31	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	12:00-1:30 PM	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies	Oral Abstract Sessions	Room 25	
Saturday	12:00-1:30 PM	802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies	Oral Abstract Sessions	Room 33	
Saturday	12:30-1:30 PM	2024 Ham-Wasserman Lecture	Marquee Sessions	Hall B	CME
Saturday	2:00-3:15 PM	Hematologic Challenges at the End-of-Life	Education Program	Room 6A	CME
Saturday	2:00-3:15 PM	Integrating New Therapies into the Management of Classical Heme Disorders	Education Program	Room 30	CME
Saturday	2:00-3:30 PM	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease	Oral Abstract Sessions	Room 31	
Saturday	2:00-3:30 PM	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Therapeutic Advances in Sickle Cell Disease	Oral Abstract Sessions	Hall B	
Saturday	2:00-3:30 PM	Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities	Special-Interest Sessions	Room 11	CME
Saturday	4:00-5:15 PM	Scientific Symposia: Interface of Complement and Coagulation	Scientific Program	Room 33	CME
Saturday	4:00-5:30 PM	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Tools and Biomarkers for Improving Sickle Cell Disease Treatments	Oral Abstract Sessions	Room 30	
Saturday	4:00-5:30 PM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Sessions	Room 6DE	

HEMOGLOBINOPATHIES

Day	Time	Session Title	Program	Location	CME
Saturday	4:00-5:30 PM	904. Outcomes Research: Hemoglobinopathies: Non- Malignant Conditions: Determinants of Health Equity Across the Spectrum	Oral Abstract Sessions	Room 31	
Sunday	9:30-10:45 AM	Scientific Symposia: Interrogating the Impact of the Intestinal Microbiome on Transplant and Cellular Therapies	Scientific Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	CME
Sunday	9:30-11:00 AM	112. Thalassemia and Globin Gene Regulation: We're Going to Catch a Big One: Towards Targeted Therapies in Thalassemia	Oral Abstract Sessions	Room 31	
Sunday	9:30-11:00 AM	801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside	Oral Abstract Sessions	Room 30	
Sunday	9:30-11:00 AM	900. Health Services and Quality Improvement: Hemoglobinopathies: Navigating and Optimizing Healthcare Systems	Oral Abstract Sessions	Hall B	
Sunday	9:30-11:00 AM	Sickle Cell Disease Centers Session	Special-Interest Sessions	Room 33	CME
Sunday	12:00-1:30 PM	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Improving Outcomes in Sickle Cell Disease Around the World	Oral Abstract Sessions	Room 28 A-D	
Sunday	12:00-1:30 PM	900. Health Services and Quality Improvement: Hemoglobinopathies: Empowering Choices: Navigating Shared Decision-Making for Patient- Centric Care	Oral Abstract Sessions	Room 25	
Sunday	2:00-4:00 PM	Plenary Scientific Session	Marquee Sessions	Hall B	
Sunday	4:30-5:45 PM	Spotlight Sessions: Curative Therapies for Sickle Cell Disease: Option for Some but Not Quite All	Education Program	Room 30	CME
Sunday	4:30-6:00 PM	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications – Lessons from Pre-clinical Models	Oral Abstract Sessions	Room 31	
Monday	10:30-11:45 AM	Challenges and Opportunities of Sickle Cell Care in Africa	Education Program	Room 31	CME
Monday	10:30 AM-12:00 PM	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non- Malignant Hematologic Diseases	Oral Abstract Sessions	Room 6B	
Monday	12:15-1:15 PM	Industry Theaters: Energizing Red Blood Cells: The Latest Clinical Trial Data of Mitapivat in Thalassemia	Interact with Industry	Room 5A	
Monday	1:30-2:30 PM	Ernest Beutler Lecture and Prize	Marquee Sessions	Hall B	CME
Monday	2:45-4:00 PM	Spotlight Sessions: Iron at the Crossroads Between Erythropoiesis and Megakaryopoiesis	Scientific Program	Room 30	CME
Monday	2:45-4:15 PM	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: The Effects of Sickle Cell Disease on Organ Function	Oral Abstract Sessions	Room 33	
Monday	4:30-6:00 PM	904. Outcomes Research: Hemoglobinopathies: Non- Malignant Conditions: Transforming Care: Insights into Healthcare Utilization, Outcome Measurement, and Treatment Impact in Sickle Cell Disease	Oral Abstract Sessions	Room 6DE	
Monday	4:30-6:00 PM	ASH Research Collaborative Data Hub Sickle Cell Disease Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation	Special-Interest Sessions	Room 11	
Monday	6:00-8:00 PM	Center for Sickle Cell Disease Initiatives: Advancing Progress in Sickle Cell Disease Update and Reception: hosted by ASH and ASH Research Collaborative	Special-Interest Sessions	Room 11 & West Terrace	
Tuesday	9:45-11:15 AM	2024 Presidential Symposium	Marquee Sessions	Hall B	CME

IMMUNE DISORDERS

IMMUNE DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: A Violent Graft in a Vulnerable Host: The Future of aGVHD Management	Interact with Industry	Room 29	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Advances in the Management of Myeloproliferative Neoplasms and Systemic Mastocytosis: Diagnosis/Classification, Risk Stratification, and Optimal Therapeutic Selection	Interact with Industry	Manchester Grand Hyatt San Diego, Grand Hall B	CME
Friday	2:00-5:00 PM	Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies	Scientific Program	Room 31	
Friday	3:00-6:00 PM	Satellite Symposia: Collaboration In Chronic ITP: Improving Quality Of Life And Patient Outcomes	Interact with Industry	Ballroom 20AB	CME
Saturday	8:00-9:00 AM	Industry Forums: Nonmalignant Hematologic Disorders Forum: Deeper Dive Into PNH, aHUS, and ITP	Interact with Industry	Room 4	
Saturday	9:30-10:45 AM	ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease	Education Program	Room 6CF	CME
Saturday	9:30-10:45 AM	Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation	Education Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	CME
Saturday	9:30-11:00 AM	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD	Oral Abstract Sessions	Ballroom 20CD	
Saturday	9:30-11:00 AM	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies	Oral Abstract Sessions	Room 30	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	12:00-1:30 PM	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease	Oral Abstract Sessions	Room 11	
Saturday	12:00-1:30 PM	331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: A Brave New World: Novel Tools, Targets and Treatments in TTP	Oral Abstract Sessions	Room 30	
Saturday	12:00-1:30 PM	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies	Oral Abstract Sessions	Room 25	
Saturday	2:00-3:30 PM	101. Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche	Oral Abstract Sessions	Room 33	
Saturday	2:00-3:30 PM	503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Saturday	2:00-3:30 PM	701. Experimental Transplantation: Basic and Translational: GVHD, Mucosal Immunology and the Microbiome	Oral Abstract Sessions	Room 6B	
Saturday	4:00-5:15 PM	HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia	Education Program	Room 28 A-D	CME
Saturday	4:00-5:30 PM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Sessions	Room 6DE	
Sunday	9:30-11:00 AM	201. Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Sunday	9:30-11:00 AM	301. Platelets and Megakaryocytes: Basic and Translational: Megakarocyte and Platelet Biology: From Formation to Function	Oral Abstract Sessions	Room 28 A-D	
Sunday	12:00-1:30 PM	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science	Oral Abstract Sessions	Room 30	
Sunday	2:00-4:00 PM	Plenary Scientific Session	Marquee Sessions	Hall B	

IMMUNE DISORDERS

Day	Time	Session Title	Program	Location	CME
Sunday	4:30-6:00 PM	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	
Sunday	4:30-6:00 PM	907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	
Monday	10:30 AM-12:00 PM	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Clinical Evidence in ITP	Oral Abstract Sessions	Room 29	
Monday	10:30 AM-12:00 PM	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Innovative Approaches to Improve Care for Understudied Non-Malignant Hematologic Diseases	Oral Abstract Sessions	Room 6B	
Monday	2:45-4:15 PM	201. Granulocytes, Monocytes, and Macrophages: From Inflammation to Hemophagocytic Lymphohistiocytosis	Oral Abstract Sessions	Room 6DE	
Monday	4:30-6:00 PM	101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease	Oral Abstract Sessions	Room 28 A-D	
Monday	4:30-6:00 PM	801. Gene Therapies: Gene Therapies for Hemophilia, Cancer and Immunodeficiencies	Oral Abstract Sessions	Room 33	

Day	Time	Session Title	Program	Location	CME
Friday	7:00-10:00 AM	Satellite Symposia: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know	Interact with Industry	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	CME
Friday	7:00-10:00 AM	Satellite Symposia: An Interactive Case-based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates	Interact with Industry	Manchester Grand Hyatt San Diego, Grand Hall C	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-free Treatment Paradigm	Interact with Industry	Manchester Grand Hyatt San Diego, Grand Hall C	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know	Interact with Industry	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors	Interact with Industry	Manchester Grand Hyatt San Diego, Grand Hall D	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms	Interact with Industry	Marriott Marquis San Diego Marina, San Diego Ballroom AB	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR-Ts	Interact with Industry	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME
Friday	12:00-5:00 PM	ASH-a-Palooza	Trainee Activities	Gaslamp Quarter	
Friday	2:00-5:00 PM	Scientific Workshop on Aging and Hematology	Scientific Program	Room 7	
Friday	2:00-5:00 PM	Scientific Workshop on Clonal Hematopoiesis	Scientific Program	Room 8	
Friday	2:00-5:00 PM	Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm with AI Strategies for 'Real World' Patient Representation	Scientific Program	Room 4	
Friday	2:00-5:00 PM	Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies	Scientific Program	Room 31	
Friday	2:00-5:00 PM	Scientific Workshop on Interplay Between Coagulation and Malignancy	Scientific Program	Room 24	
Friday	2:00-5:00 PM	Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients	Scientific Program	Room 2	
Friday	2:00-5:00 PM	Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies	Scientific Program	Room 33	
Friday	2:00-5:00 PM	Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies	Scientific Program	Room 28 A-D	
Friday	3:00-6:00 PM	Satellite Symposia: Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma	Interact with Industry	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	CME
Friday	3:00-6:00 PM	Satellite Symposia: Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios	Interact with Industry	Room 30 A-E	CME
Friday	7:00-10:00 PM	Satellite Symposia: How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma	Interact with Industry	Room 30 A-E	CME
Friday	7:00-10:00 PM	Satellite Symposia: Show Me the Data™: Pushing CAR T's Forward Across Lymphoid Malignancies Accelerating Access in the Community and Treatment Strategies for the Road Ahead	Interact with Industry	Ballroom 20CD	CME
Saturday	9:30-10:45 AM	A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma	Education Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME

Day	Time	Session Title	Program	Location	CME
Saturday	9:30-10:45 AM	ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease	Education Program	Room 6CF	CME
Saturday	9:30-10:45 AM	Moving the Needle in Hodgkin Lymphoma	Education Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	CME
Saturday	9:30-10:45 AM	Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation	Education Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	CME
Saturday	9:30-10:45 AM	Proteo-Genomics to Better Study Multiple Myeloma Biology and Evolution	Scientific Program	Marriott Marquis San Diego Marina, San Diego Ballroom AB	CME
Saturday	9:30-11:00 AM	603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Saturday	9:30-11:00 AM	628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	
Saturday	9:30-11:00 AM	641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Saturday	9:30-11:00 AM	653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma?	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Saturday	9:30-11:00 AM	703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies	Oral Abstract Sessions	Ballroom 20AB	
Saturday	9:30-11:00 AM	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	
Saturday	9:30-11:00 AM	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies	Oral Abstract Sessions	Room 6B	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	11:30 AM-12:30 PM	Product Theaters: CAR T Cell Therapy for Second-line (2L) LBCL	Interact with Industry	Room 2	
Saturday	11:30 AM-12:30 PM	Product Theaters: Learn About an Alternative Treatment for Certain B-Cell Malignancies.	Interact with Industry	Room 4	
Saturday	11:30 AM-12:30 PM	Product Theaters: Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL	Interact with Industry	Room 1B	
Saturday	12:00-1:30 PM	802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies	Oral Abstract Sessions	Room 33	
Saturday	1:30-1:45 PM	Company Showcases: Invivoscribe – Partnering with Pharma to Streamline Oncological Clinical Development	Interact with Industry	Room 5B	
Saturday	2:00-3:15 PM	Host Factors Driving Anti-Leukemia Immunotherapy Outcomes	Scientific Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	CME
Saturday	2:00-3:15 PM	Newly Diagnosed Multiple Myeloma: Many Choices and More Questions	Education Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	CME
Saturday	2:00-3:30 PM	603. Lymphoid Oncogenesis: Basic: Molecular Insights into Acute Lymphoblastic Leukemias	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Saturday	2:00-3:30 PM	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML	Oral Abstract Sessions	Ballroom 20CD	

Day	Time	Session Title	Program	Location	CME
Saturday	2:00-3:30 PM	621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Targets in Aggressive Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	
Saturday	2:00-3:30 PM	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Therapies for Mantle Cell Lymphoma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	
Saturday	2:00-3:30 PM	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	
Saturday	2:00-3:30 PM	653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Saturday	2:00-3:30 PM	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: AI Approaches to Drug Development, Classification and Outcomes	Oral Abstract Sessions	Room 6DE	
Saturday	2:00-3:30 PM	907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple Myeloma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Saturday	2:00-3:30 PM	Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities	Special-Interest Sessions	Room 11	CME
Saturday	3:30-3:45 PM	Clinical Trial Showcases: The ALPHA3 Trial: Harnessing the Potential of Combining Next- Generation "Off-the-Shelf" Investigational CAR T Product with Advanced MRD Testing to Improve Outcomes in First Line LBCL	Interact with Industry	Room 4	
Saturday	4:00-5:30 PM	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Saturday	4:00-5:30 PM	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Saturday	4:00-5:30 PM	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Saturday	4:00-5:30 PM	622. Lymphomas: Translational – Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	
Saturday	4:00-5:30 PM	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	
Saturday	4:00-5:30 PM	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	
Saturday	4:00-5:30 PM	653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	
Saturday	4:00-5:30 PM	702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Saturday	4:00-5:30 PM	902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments	Oral Abstract Sessions	Room 6B	
Saturday	4:00-5:30 PM	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations	Oral Abstract Sessions	Room 6A	

Day	Time	Session Title	Program	Location	CME
Saturday	4:00-5:30 PM	ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation	Special-Interest Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Saturday	4:00-5:35 PM	JOINT SESSION: Molecular Characterization of Lymphomas in Children, Adolescents, and Young Adults	Scientific Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME
Sunday	8:00-9:00 AM	Industry Theaters: The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research	Interact with Industry	Room 1A	
Sunday	8:00-9:00 AM	Product Theaters: Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL	Interact with Industry	Room 3	
Sunday	9:30-10:45 AM	Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies.	Scientific Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	CME
Sunday	9:30-11:00 AM	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions- Impact on AML Outcomes	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Sunday	9:30-11:00 AM	621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Sunday	9:30-11:00 AM	624. Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma	Oral Abstract Sessions	Ballroom 20AB	
Sunday	9:30-11:00 AM	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas	Oral Abstract Sessions	Ballroom 20CD	
Sunday	9:30-11:00 AM	626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Sunday	9:30-11:00 AM	653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Sunday	9:30-11:00 AM	654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	
Sunday	9:30-11:00 AM	702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing	Oral Abstract Sessions	Room 6A	
Sunday	9:30-11:00 AM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation	Oral Abstract Sessions	Room 6B	
Sunday	9:30-11:00 AM	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Sunday	9:30-11:00 AM	ASH Clinical Practice Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults	Special-Interest Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME
Sunday	12:00-1:30 PM	624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy	Oral Abstract Sessions	Ballroom 20CD	
Sunday	12:00-1:30 PM	626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Sunday	12:00-1:30 PM	627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL	Oral Abstract Sessions	Ballroom 20AB	
Sunday	12:00-1:30 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Sunday	12:00-1:30 PM	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	


Day	Time	Session Title	Program	Location	CME
Sunday	12:00-1:30 PM	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases	Oral Abstract Sessions	Room 11	
Sunday	12:00-1:30 PM	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	
Sunday	2:00-4:00 PM	Plenary Scientific Session	Marquee Sessions	Hall B	
Sunday	4:30-5:45 PM	Follicular Lymphoma: Playing the Long Game	Education Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	CME
Sunday	4:30-5:45 PM	Spotlight Sessions: Biology Underlying Disparities in Lymphoid Malignancies	Scientific Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	CME
Sunday	4:30-6:00 PM	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Sunday	4:30-6:00 PM	622. Lymphomas: Translational – Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	
Sunday	4:30-6:00 PM	626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Sunday	4:30-6:00 PM	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Sunday	4:30-6:00 PM	654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Sunday	4:30-6:00 PM	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	
Sunday	4:30-6:00 PM	907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	
Monday	7:30-8:30 AM	ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by <i>Blood Immunology & Cellular</i> <i>Therapy</i> (For In-person Participants)	Scientific Program	Halls G-H - Blood Journals Studio	
Monday	10:30-11:45 AM	A Shifting Landscape: Treatment of MCL	Education Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME
Monday	10:30-11:45 AM	It's a Different World: CLL 2024	Education Program	Hall B	CME
Monday	10:30-11:45 AM	Spotlight Sessions: Smoldering Myeloma: A Case for Early Intervention?	Education Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	CME
Monday	10:30 AM-12:00 PM	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	
Monday	10:30 AM-12:00 PM	621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Monday	10:30 AM-12:00 PM	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Monday	10:30 AM-12:00 PM	641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	

Day	Time	Session Title	Program	Location	CME
Monday	10:30 AM-12:00 PM	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Monday	10:30 AM-12:00 PM	654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Monday	10:30 AM-12:00 PM	902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	
Monday	2:45-4:00 PM	Adult ALL Advancements: Optimizing Cure in 2024	Education Program	Ballroom 20AB	CME
Monday	2:45-4:15 PM	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma	Oral Abstract Sessions	Ballroom 20CD	
Monday	2:45-4:15 PM	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell diseases	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	
Monday	2:45-4:15 PM	621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	
Monday	2:45-4:15 PM	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	
Monday	2:45-4:15 PM	627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	
Monday	2:45-4:15 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	
Monday	2:45-4:15 PM	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Monday	2:45-4:15 PM	653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Monday	2:45-4:15 PM	701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity	Oral Abstract Sessions	Room 6B	
Monday	2:45-4:15 PM	702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy	Oral Abstract Sessions	Room 6CF	
Monday	2:45-4:15 PM	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies	Oral Abstract Sessions	Hall B	
Monday	2:45-4:15 PM	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival	Oral Abstract Sessions	Room 6A	
Monday	2:45-4:15 PM	907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies	Oral Abstract Sessions	Marriott Marquis San Diego Marina, San Diego Ballroom AB	
Monday	4:30-5:45 PM	Addressing Unmet Needs in T Cell Lymphomas	Education Program	Ballroom 20AB	CME
Monday	4:30-6:00 PM	503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Monday	4:30-6:00 PM	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma	Oral Abstract Sessions	Ballroom 20CD	
Monday	4:30-6:00 PM	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6	

Day	Time	Session Title	Program	Location	CME
Monday	4:30-6:00 PM	622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	
Monday	4:30-6:00 PM	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	
Monday	4:30-6:00 PM	627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19	
Monday	4:30-6:00 PM	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Monday	4:30-6:00 PM	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 21-22	
Monday	4:30-6:00 PM	654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma	Oral Abstract Sessions	Hall B	
Monday	4:30-6:00 PM	655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	
Monday	4:30-6:00 PM	702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells	Oral Abstract Sessions	Room 6CF	
Monday	4:30-6:00 PM	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse	Oral Abstract Sessions	Room 6A	
Monday	4:30-6:00 PM	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	

Hematology 2024

AMERICAN SOCIETY of HEMATOLOGY Education Program[™] 66th ASH[®] Annual Meeting and Exposition December 7-10, 2024



Hematology 2024 CME/MOC Tests

EARN UP TO 40 CME CREDITS/ABIM MOC POINTS* by completing two 20-credit exams, one classical hematology and one malignant hematology.



Purchase the CME/MOC test at ashpublications.org/hematology

Hematology 2024 content is at ashpublications.org/hematology

*Accreditation and Credit Designation
The American Society of Hematology (ASH)
is accredited by the Accreditation Council
for Continuing Medical Education (ACCME)
to provide continuing medical education for
physicians

ASH designates this journal-based CME activity for a maximum of 40 AMA PRA Category 1 Credits**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*ABIM Maintenance of Certification
Successful completion of this CME activity enables
the participant to earn up to 40 MOC points in
the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent
to the amount of CME credits claimed. It is the
CME activity provider's responsibility to submit
participant completion information to ACCME for
the purpose of granting ABIM MOC credit.

METABOLIC DISORDERS


METABOLIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	2:00-5:00 PM	Scientific Workshop on Challenges and Novel Technologies in Red Blood Cell Quality Assessment	Scientific Program	Room 3	
Saturday	9:30-11:00 AM	102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation	Oral Abstract Sessions	Room 29	
Saturday	9:30-11:00 AM	401. Blood Transfusion: Advancements in Transfusion Science	Oral Abstract Sessions	Room 31	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	2:00-3:15 PM	Integrating New Therapies into the Management of Classical Heme Disorders	Education Program	Room 30	CME
Saturday	2:00-3:15 PM	Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios	Education Program	Room 29	CME
Saturday	2:00-3:30 PM	101. Red Cells and Erythropoiesis, Excluding Iron: Effects of Inflammation on Erythropoiesis and the Niche	Oral Abstract Sessions	Room 33	
Saturday	2:00-3:30 PM	Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities	Special-Interest Sessions	Room 11	CME
Sunday	9:30-11:05 AM	JOINT SESSION: Emerging Therapeutic Strategies Targeting Epigenetic, Transcriptomic, and Metabolic Mechanisms	Scientific Program	Room 24	CME
Monday	4:30-5:45 PM	Crosstalk Between Iron Homeostasis and Metabolism	Scientific Program	Room 29	CME
Monday	4:30-6:00 PM	101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis in Disease	Oral Abstract Sessions	Room 28 A-D	





A Compendium for the Practicing Hematologist



A collection of top "How I Treat" articles from *Blood*, many of which are updated to reflect the most recent scientific and clinically relevant information.

Featuring 20 articles with clinical updates in the following areas:

- Cellular Therapy
- Myeloid Neoplasms
- Acute Lymphoblastic Leukemia
- Lymphoma
- General Classical Hematology
- Platelets
- Hemostasis and Thrombosis
- Plasma Cell Dyscrasias

ORDER TODAY AT:

- ► ASH Store on-site
- hematology.org/store



SPECIAL PRICING

ASH Member	\$50	\$45
Associate Member	\$40	\$36
Non-member	-\$70-	\$63

Day	Time	Session Title	Program	Location	CME
Friday	7:00-10:00 AM	Satellite Symposia: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia - What Clinicians Want to Know	Interact with Industry	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	CME
Friday	7:00-10:00 AM	Satellite Symposia: MDS 2024: Let's Overcome the Interact with Industry Challenges		Manchester Grand Hyatt San Diego, Grand Hall B	CME
Friday	7:00-10:00 AM	Satellite Symposia: Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease	Interact with Industry	Marriott Marquis San Diego Marina, San Diego Ballroom AB	CME
Friday	11:00 AM-2:00 PM	Satellite Symposia: Medical Crossfire®: Bridging Evidence to Practice in AML Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials	Interact with Industry	Ballroom 20CD	CME
Friday	12:00-5:00 PM	ASH-a-Palooza	Trainee Activities	Gaslamp Quarter	
Friday	2:00-5:00 PM	Scientific Workshop on Aging and Hematology	Scientific Program	Room 7	
Friday	2:00-5:00 PM	Scientific Workshop on Clonal Hematopoiesis	Scientific Program	Room 8	
Friday	2:00-5:00 PM	Scientific Workshop on Decentralized Clinical Trials in Hematology: Reshaping the Traditional Clinical Trial Paradigm with AI Strategies for 'Real World' Patient Representation	Scientific Program	Room 4	
Friday	2:00-5:00 PM	Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies	Scientific Program	Room 31	
Friday	2:00-5:00 PM	Scientific Workshop on Interplay Between Coagulation and Malignancy	Scientific Program	Room 24	
Friday	2:00-5:00 PM	Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients	Scientific Program	Room 2	
Friday	2:00-5:00 PM	Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies	Scientific Program	Room 33	
Friday	3:00-6:00 PM	Satellite Symposia: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia - What Clinicians Want to Know	Interact with Industry	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	CME
Saturday	9:30-10:45 AM	A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma	Education Program	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	CME
Saturday	9:30-10:45 AM	AML M&Ms: How to Integrate Mutations and MRD Data	Education Program	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	CME
Saturday	9:30-10:45 AM	Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology	Scientific Program	Manchester Grand Hyatt San Diego, Grand Hall D	CME
Saturday	9:30-11:00 AM	102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation	Oral Abstract Sessions	Room 29	
Saturday	9:30-11:00 AM	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire	Oral Abstract Sessions	Room 24	
Saturday	9:30-11:00 AM	508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH	Oral Abstract Sessions	Room 11	
Saturday	9:30-11:00 AM	602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies	Oral Abstract Sessions	Room 6A	
Saturday	9:30-11:00 AM	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Determinants of Venetoclax Resistance and Response	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Saturday	9:30-11:00 AM	617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies	Oral Abstract Sessions	Hall B	

Day	Time	Session Title	Program	Location	CME
Saturday	9:30-11:00 AM	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Multi- omic Applications for Disease Evolution and Response to Therapy	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Saturday	9:30-11:00 AM	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD	Oral Abstract Sessions	Ballroom 20CD	
Saturday	9:30-11:00 AM	908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Saturday	12:00-1:30 PM	802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies	Oral Abstract Sessions	Room 33	
Saturday	11:15 AM-12:15 PM	Career Development Lunch	Trainee Activities	Manchester Grand Hyatt San Diego, Coronado Ballroom	
Saturday	1:30-1:45 PM	Company Showcases: Invivoscribe – Partnering with Pharma to Streamline Oncological Clinical Development	Interact with Industry	Room 5B	
Saturday	2:00-3:15 PM	Chasing Zebras: Navigating Rare Myeloid Neoplasms	Education Program	Manchester Grand Hyatt San Diego, Grand Hall C	CME
Saturday	2:00-3:15 PM	Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios	Education Program	Room 29	CME
Saturday	2:00-3:30 PM	503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Saturday	2:00-3:30 PM	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Saturday	2:00-3:30 PM	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML	Oral Abstract Sessions	Ballroom 20CD	
Saturday	2:00-3:30 PM	617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Saturday	2:00-3:30 PM	619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Saturday	2:00-3:30 PM	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Personalized and Molecular Approaches in Myeloproliferative Neoplasms: Risk Stratification and Therapeutic Implications	Oral Abstract Sessions	Ballroom 20AB	
Saturday	2:00-3:30 PM	Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities	Special-Interest Sessions	Room 11	CME
Saturday	4:00-5:15 PM	Handling Bad News: How to Best Manage TP53 Myeloid Disease	Education Program	Manchester Grand Hyatt San Diego, Grand Hall D	CME
Saturday	4:00-5:30 PM	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Saturday	4:00-5:30 PM	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Saturday	4:00-5:30 PM	636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS	Oral Abstract Sessions	Ballroom 20CD	
Saturday	4:00-5:30 PM	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS	Oral Abstract Sessions	Ballroom 20AB	
Saturday	4:00-5:30 PM	702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Saturday	4:00-5:30 PM	908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	

Day	Time	Session Title	Program	Location	CME
Sunday	8:00-9:00 AM	ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal Function to Malignancy Hosted by <i>Blood Neoplasia</i> (For In-person Participants)	Scientific Program	Halls G-H - Blood Journals Studio	
Sunday	8:00-9:00 AM	Industry Theaters: KMT2A rearrangements in acute leukemia	Interact with Industry	Room 5A	
Sunday	8:00-9:00 AM	Industry Theaters: The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research	Interact with Industry	Room 1A	
Sunday	9:30-10:45 AM	Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies.	Scientific Program	Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17	CME
Sunday	9:30-10:45 AM	MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy	Education Program	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	CME
Sunday	9:30-11:00 AM	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models	Oral Abstract Sessions	Room 11	
Sunday	9:30-11:00 AM	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Sunday	9:30-11:00 AM	632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG	
Sunday	9:30-11:00 AM	634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Sunday	9:30-11:00 AM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation	Oral Abstract Sessions	Room 6B	
Sunday	9:30-11:00 AM	908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Sunday	11:30 AM-12:30 PM	Product Theaters: A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS	Interact with Industry	Room 5B	
Sunday	11:30 AM-12:30 PM	Product Theaters: Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP	Interact with Industry	Room 3	
Sunday	12:30-1:30 PM	ASH-EHA Joint Symposium	Marquee Sessions	Hall B	CME
Sunday	2:00-4:00 PM	Plenary Scientific Session	Marquee Sessions	Hall B	
Sunday	4:30-5:45 PM	Race and Ancestry in Precision Medicine	Special-Interest Sessions	Room 6DE	CME
Sunday	4:30-5:45 PM	Spotlight Sessions: The Clone Wars: Myeloid Neoplasia Risk in Clonal Hematopoiesis	Education Program	Manchester Grand Hyatt San Diego, Grand Hall C	CME
Sunday	4:30-6:00 PM	602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Sunday	4:30-6:00 PM	618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Sunday	4:30-6:00 PM	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Sunday	4:30-6:00 PM	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG	
Sunday	4:30-6:00 PM	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities	Oral Abstract Sessions	Room 6B	

Day	Time	Session Title	Program	Location	CME
Sunday	4:30-6:00 PM	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis	Oral Abstract Sessions	Room 6CF	
Sunday	4:30-6:00 PM	ASH Clinical Practice Guidelines on Amyloidosis	Special-Interest Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	CME
Monday	7:30-8:30 AM	ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by <i>Blood Immunology & Cellular</i> <i>Therapy</i> (For In-person Participants)	Scientific Program	Halls G-H - Blood Journals Studio	
Monday	10:30 AM-12:00 PM	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Monday	10:30 AM-12:00 PM	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Monday	10:30 AM-12:00 PM	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Monday	10:30 AM-12:00 PM	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant	Oral Abstract Sessions	Room 6A	
Monday	10:30 AM-12:00 PM	903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Monday	12:15-1:15 PM	Product Theaters: A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS	Interact with Industry	Room 2	
Monday	2:45-4:15 PM	506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease	Oral Abstract Sessions	Room 11	
Monday	2:45-4:15 PM	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Monday	2:45-4:15 PM	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Monday	2:45-4:15 PM	618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Monday	2:45-4:15 PM	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	
Monday	2:45-4:15 PM	636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Monday	2:45-4:15 PM	701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity	Oral Abstract Sessions	Room 6B	
Monday	2:45-4:15 PM	703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	
Monday	2:45-4:15 PM	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival	Oral Abstract Sessions	Room 6A	
Monday	4:30-6:00 PM	503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall C	
Monday	4:30-6:00 PM	602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD	
Monday	4:30-6:00 PM	617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall B	
Monday	4:30-6:00 PM	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH	

Day	Time	Session Title	Program	Location	CME
Monday	4:30-6:00 PM	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Harbor Ballroom DEFG	
Monday	4:30-6:00 PM	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia	Oral Abstract Sessions	Manchester Grand Hyatt San Diego, Grand Hall D	
Monday	4:30-6:00 PM	723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse	Oral Abstract Sessions	Room 6A	
Monday	4:30-6:00 PM	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs	Oral Abstract Sessions	Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	
Tuesday	9:45-11:15 AM	2024 Presidential Symposium	Marquee Sessions	Hall B	CME

Notes:		

Notes:	
	_
	_

VISIT US AT BOOTH 633

to learn about our commitment to our patients and their communities



2024 ASH Annual Meeting Dec 7-10, San Diego, CA



TAKE YOUR MARK

Visit Booth #1433 to gear up with the latest data



SCAN TO LEARN MORE





CALQUENCE is a registered trademark of the AstraZeneca group of companies. ©2024 AstraZeneca. All rights reserved. US-93847 9/24